Indole compounds and method of use

Indole compounds targeting GSPT1 through molecular glue degraders provide a potent and selective approach to degrade GSPT1, addressing the need for effective cancer therapy by enhancing degradation activity and reducing side effects.

WO2026234142A1PCT designated stage Publication Date: 2026-11-12F HOFFMANN LA ROCHE & CO AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063187
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-04-02
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current therapies lack effective molecular glue degraders that can selectively target and degrade GSPT1 protein, which is overexpressed in various cancers, to disrupt cancer cell proliferation and restore normal cellular function.

Method used

Development of indole compounds that induce proximity between GSPT1 and an E3 ubiquitin ligase, leading to ubiquitination and proteasomal degradation of GSPT1, thereby inhibiting cancer cell growth.

Benefits of technology

The indole compounds demonstrate superior GSPT1 degradation activity, broad-spectrum anti-proliferative efficacy, and improved pharmacological profiles, including enhanced solubility, metabolic stability, and reduced cardiotoxicity, effectively targeting multiple cancer cell lines with minimal off-target toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026063187_12112026_PF_FP_ABST
    Figure EP2026063187_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to compounds of formula (I), ( )m ( )n (I), wherein R1 to R6, L1, L2, m and n are as described herein, and their pharmaceutically acceptable salts, enantiomers and diastereomers thereof, and compositions including the compounds and methods of using the compounds.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Docket No. P60153

[0002] INDOLE COMPOUNDS AND METHOD OF USE

[0003] TECHNICAL FIELD

[0004] The present invention relates to organic compounds useful for therapy and / or prophylaxis in a mammal, and in particular to degradation of GSPT1 useful for treatment or prophylaxis of cancer.

[0005] BACKGROUND

[0006] The G1 to S phase transition 1 (GSPT1) protein, also known as eukaryotic release factor 3a (eRF3a), is crucial for cell cycle progression and acts as a eukaryotic translation termination factor, recognizing stop codons during protein synthesis. Cancer cells, with their rapid proliferation and high protein synthesis demands, may be particularly dependent on GSPT1, making it a strategic therapeutic target. Overexpression of GSPT1 has been implicated in a variety of cancers, including acute myeloid leukemia (AML) (Joshua D. Hansen et al, 2021), gastric cancer (J. Malta-Vacas et al, 2005), colon cancer (R. Xiao et al, 2015), lung cancer (S. Nair et al, 2014) and breast cancer (J. Malta-Vacas et al, 2009). This makes GSPT1 a valuable target for therapeutic intervention, as modulating its activity can disrupt the proliferation of cancer cells dependent on accelerated translation machinery.

[0007] Recent advancements have introduced the concept of molecular glue degraders as potent small molecule therapeutics that specifically target GSPT1. These compounds operate by inducing the proximity of GSPT1 to an E3 ubiquitin ligase, triggering ubiquitination and subsequent proteasomal degradation of the protein (Mary E. Matyskiela et al, 2016). Unlike conventional inhibitors, molecular glues leverage the body's natural protein degradation pathways to eliminate proteins that contribute to disease progression.

[0008] The application of GSPT1 -targeting molecular glue degraders offers a promising strategy for the treatment of cancers linked to aberrant expression of this protein. By selectively degrading GSPT1, these small molecules aim to restore normal cellular function and impede cancer cell growth, presenting a novel approach to cancer therapy.

[0009] Therefore, there is unmet medical needs to discover molecular glue degraders to selectively target and degrade GSPT1, offering potential benefits in the management of various malignancies.

[0010] SUMMARY OF INVENTIONDocket No. P60153

[0011] The present invention relates to a compound of formula (I),

[0012]

[0013] wherein

[0014] R1is H or deuterium;

[0015] each R2is independently H, halogen, hydroxy, amino or C1-6alkyl;

[0016] each R3is independently H, halogen, hydroxy or C1-6alkyl;

[0017] R4is R4aor R4acarbonyl, wherein R4ais a 6-10 membered aryl, 5-10 membered heteroaryl or 3-12 membered heterocyclyl, any one of which is unsubstituted or substituted by one to three substituents independently selected from the group consisting of

[0018] (C1-6alkyl)2amino,

[0019] (hydroxyC1-6alkoxy)C1-6alkoxy,

[0020] amino,

[0021] C1-6alkoxy,

[0022] C1-6alkoxycarbonyl,

[0023] C1-6alkyl,

[0024] C1-6alkylamino,

[0025] C1-6alkylsulfanyl,

[0026] haloC1-6alkyl,

[0027] halogen,

[0028] hydroxy,

[0029] hydroxyC1-6alkoxy,

[0030] hydroxyC1-6alkyl,

[0031] hydroxyC1-6alkyl(C1-6alkyl)amino,

[0032] hydroxyC1-6alkylsulfanyl,

[0033] hydroxyhaloC1-6alkoxy,Docket No. P60153

[0034] 6-10 membered aryl unsubstituted or substituted by one to three substituents independently selected from the group consisting of (((hydroxyCi-6alkyl)carbonyl)(C1-6alkyl)amino)Ci- ealkyl, ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((C1-6alkyl)2amino)Ci-6alkyl, ((hydroxyCi- 6alkyl)carbonylamino)Ci-6alkyl, (C1-6alkoxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkoxy)Ci- ealkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyhaloC1-6alkyl)C1-6alkyl, amino, aminoCi- ealkyl, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(Ci- 6alkoxy)Ci-6alkyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl, hydroxyhaloC1-6alkyl, Ci- ealkylsulfinyl, C1-6alkyl sulfanyl and carbamoyl,

[0035] 5-10 membered heteroaryl unsubstituted or substituted by one to three substituents independently selected from the group consisting of (((hydroxyC1-6alkyl)carbonyl)(Ci- 6alkyl)amino)Ci-6alkyl, ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((C1-6alkyl)2amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (C1-6alkoxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyhaloC1-6alkyl)Ci- ealkyl, amino, aminoC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl, hydroxyhaloC1-6alkyl, C1-6alkylsulfinyl, C1-6alkylsulfanyl and carbamoyl, and 3-12 membered heterocyclyl unsubstituted or substituted by one to three substituents independently selected from the group consisting of (((hydroxyC1-6alkyl)carbonyl)(Ci- 6alkyl)amino)Ci-6alkyl, ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((C1-6alkyl)2amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (C1-6alkoxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyhaloC1-6alkyl)Ci- ealkyl, amino, aminoC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl, hydroxyhaloC1-6alkyl, C1-6alkylsulfinyl, C1-6alkylsulfanyl and carbamoyl,

[0036] R5is H, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or (R5aCi-6alkoxy)C1-6alkyl, wherein R5ais H or phenyl unsubstituted or substituted by amino or nitro;

[0037] R6is H or C1-6alkyl;

[0038] L1is C1-6alkylene;

[0039] L2is a bond or C1-6alkylene;

[0040] m is 0, 1, 2 or 3;

[0041] n is 0, 1, 2, 3 or 4;

[0042] or a pharmaceutically acceptable salt thereof.Docket No. P60153

[0043] The compounds of formula (I) according to the present invention exhibit several unexpected technical advantages over existing reference compounds:

[0044] • Superior Potency and Degradation Efficiency: The compounds demonstrate exceptional GSPT1 degradation activity, with many examples achieving DC50 values in the sub-nanomolar range (e.g., Examples 107, 134, 185, and 197 reaching ≤0.1nM). This represents a significant increase in potency compared to reference compounds Ref- 1 and Ref-2.

[0045] • Broad-Spectrum Anti-Proliferative Efficacy: Biological evaluations across diverse human cancer cell lines confirm that the compounds are highly effective against multiple tumor models, including:

[0046] o Small Cell Lung Cancer (SCLC): Demonstrated by potent inhibition of NCI-H446 cell growth.

[0047] o Non-Small Cell Lung Cancer (NSCLC): Shown by high activity in Calu-6 cell models.

[0048] o Hematological Malignancies: Exceptional potency against Multiple Myeloma (MM1s) and Acute Myeloid Leukemia (MV-4-11) cell lines.

[0049] o Solid Tumors: Significant anti-proliferative activity in Pancreatic (KP4), Colorectal (SW48), Ovarian (OVCAR-3), Hepatocellular (HuH-7), and Breast cancer (MDA-MB-468) models.

[0050] • Strict CRBN-Dependency: Anti-proliferation assays using CRBN knock-out models (KP4-CRBN-KO) confirm that the compounds' therapeutic activity is specifically mediated through the cereblon E3 ligase pathway, reducing the likelihood of off-target toxicity.

[0051] • Optimized Drug-Like Properties: Beyond cytotoxicity, the compounds of this invention exhibit an improved pharmacological profile, including enhanced solubility, superior metabolic stability, and a reduced risk of cardiotoxicity (hERG profile).

[0052] • Enhanced Safety Profile: The compounds show improved phototoxicity and low CYP inhibition, suggesting a reduced potential for drug-drug interactions and side effects during clinical administration.

[0053] TERMS AND DEFINITIONSDocket No. P60153

[0054] The term "acid" refers to a compound capable of donating a proton (Brønsted acid), dissociating into proton and counter ion in water at 25°C and giving a solution having neutral pH or below. Concrete examples of the acid are phosphoric acid (orthophosphoric acid), sulfuric acid, nitric acid, phosphinic acid, phosphonic acid, diphosphonic acid, hydrochloric acid, pyrophosphoric acid, metaphosphoric acid and nitrous acid. These acids may be used in the form of metal salts, ammonium salts or the like; in particular, the acid is hydrochloric acid.

[0055] The term “aryl” refers to a monovalent aromatic carbocyclic mono- or bicyclic ring system comprising 6 to 10 carbon ring atoms. Examples of aryl moi eties include phenyl and naphthyl.

[0056] The term “C1-6alkyl” refers to a saturated linear (i.e., unbranched) or branched univalent hydrocarbon chain or combination thereof, having the number of carbon atoms designated (i.e., Ci-6 means one to six carbon atoms). Particular C1-6alkyl groups are those having 1 to 6 carbon atoms, having 2 to 6 carbon atoms (a “C2-ealkyl”), or having 1 to 4 carbon atoms (a “Cn 4alkyl”). Examples of C1-6alkyl group include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, homologs and isomers of, for example, n-pentyl, n-hexyl, and the like.

[0057] The term “C1-6alkylene” refers to a linear or branched saturated divalent hydrocarbon group of 1 to 6 carbon atoms or a divalent branched saturated divalent hydrocarbon group of 3 to 6 carbon atoms. Examples of C1-6alkylene groups include methylene, ethylene, propylene, 2-methylpropylene, butylene, 2-ethylbutylene, pentylene, hexylene.

[0058] The term “C1-6alkoxy” refers to C1-6alkyl-O-.

[0059] The term “C3-7cycloalkyl” refers to a monovalent saturated monocyclic or bicyclic hydrocarbon group of 3 to 7 ring carbon atoms. Bicyclic means consisting of two saturated carbocycles having one or more carbon atoms in common. Examples for monocyclic C3-7cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

[0060] Examples for bicyclic C3-?cycloalkyl include bicyclofl.1.0]butyl, bicyclo[2.2. l]heptanyl, bicyclo[l.l.l]pentanyl and bicyclo[2.2.2]octanyl.

[0061] The term “C3-7cycloalkylene” refers to a divalent C3-?cycloalkyl, wherein the two valence bonds may be attached to the same carbon atom or to different carbon atoms of the cycloalkyl group.

[0062] The term “C3-7cycloalkoxy” refers to C3-7cycloalkyl-O-.Docket No. P60153

[0063] The term “Cs-iocycloalkyl” refers to a monovalent saturated monocyclic, bicyclic or tricyclic hydrocarbon group of 3 to 10 ring carbon atoms.

[0064] The term “carbonyl” denotes a -C(O)- group.

[0065] The term “cyano”, alone or in combination with other groups, refers to CN (i.e., nitrile). The term “deuterio” or “deuterium” refers to the Isotope of hydrogen that has a single neutron as well as a proton in the nucleus.

[0066] The term “oxo”, alone or in combination with other groups, refers to =0.

[0067] The term “halo”, “halogen”, and “halide” are used interchangeably herein and denote fluoro, chloro, bromo, or iodo.

[0068] The term “haloC1-6alkyl” refers to a C1-6alkyl group wherein at least one of the hydrogen atoms of the Cl-6alkyl group has been replaced by same or different halogen atoms, particularly fluoro atoms. Examples of haloC1-6alkyl include monofluoro-, difluoro- or trifluoro-methyl, -ethyl or -propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, or trifluoromethyl.

[0069] The term “haloC1-6alkoxy” refers to haloC1-6alkyl-O-. Examples of a haloalkoxy group are difluoromethoxy (-OCHF2), trifluoromethoxy (-OCF3).

[0070] The term “hydroxy”, alone or in combination with other groups, refers to -OH.

[0071] The term "hydroxyC1-6alkyl" refers to a C1-6alkyl group wherein one or more of the hydrogen atoms of the C1-6alkyl group have been replaced by a hydroxy moiety. Examples include alcohols and diols.

[0072] The term "hydroxyC1-6alkoxy" refers to a C1-6alkoxy group wherein one or more of the hydrogen atoms of the C1-6alkoxy group have been replaced by a hydroxy moiety. Examples include alcohols and diols.

[0073] The term “hydroxyC1-6alkyl(C1-6alkyl)amino” refers to amino group substituted by C1-6alkyl and hydroxyC1-6alkyl.

[0074] The term “C1-6alkylsulfanyl” refers to C1-6alkyl-S-.

[0075] The term “C1-6alkylsulfinyl” refers to Ci-6alkyl-S(0)-.

[0076] The term “hydroxyC1-6alkylsulfanyl” refers to hydroxyC1-6alkyl-S-.

[0077] The term “hydroxyhaloC1-6alkoxy” refers to a haloC1-6alkoxy group wherein one or more of the hydrogen atoms of the haloC1-6alkoxy group have been replaced by a hydroxy moiety.Docket No. P60153

[0078] The term “hydroxyhaloC1-6alkyl” refers to a haloC1-6alkyl group wherein one or more of the hydrogen atoms of the haloC1-6alkyl group have been replaced by a hydroxy moiety.

[0079] The term “(aminophenyl)Ci-6alkoxyCi-6alkyl” refers to (aminophenyl)Ci-6alkoxy-C1-6alkyl- group.

[0080] The term “(nitrophenyl)Ci-6alkoxyCi-6alkyl” refers to (nitrophenyl)Ci-6alkoxy-Ci-6alkyl-group.

[0081] The term “ethane- 1,1 -diyl” refers to -CH(CH3)-.

[0082] The term “Carbamoyl” refers to -C(0)NH2.

[0083] The term “cyanoC1-6alkyl” refers to a C1-6alkyl substituted by cyano.

[0084] The term “benzoyl” refers to phenylcarbonyl.

[0085] The symbol “ / ” denotes the substitution site.

[0086] The term “heteroaryl” refers to an aromatic heterocyclic mono-, bi- or tricyclic ring system of 5 to 14 ring atoms, more particularly from 5 to 10 ring atoms, more particularly from 8 to 10 ring atoms, more particularly from 5 to 6 ring atoms, comprising 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon. In some aspects, monocyclic heteroaryl rings may be 5-6 membered. Bicyclic heteroaryl ring systems may be 8-10 membered, including fused bicyclics having two fused five-membered heteroaryl rings (denoted as 5-5), having a fivemembered heteroaryl ring and a fused six-membered heteroaryl ring (denoted as 5-6 and 6-5), and having two fused six-membered heteroaryl rings (denoted as 6-6). The heteroaryl group can be optionally substituted as defined herein. Examples of heteroaryl moi eties include indazolyl, indolyl, isoindolinyl, triazolopyridinyl, imidazopyridinyl, imidazopyrazinyl, indolinyl, pyridyl, triazolopyridazinyl, isoquinolinyl, pyridazinyl, triazolopyrazinyl, pyrrolotriazinyl, spirocyclopropaneindolinyl, pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, isoxazolyl, benzofuranyl, isothiazolyl, benzothienyl, aza-indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzooxadi azolyl, benzothiadiazolyl, benzotri azolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, pyrrolopyridinyl, furopyridinyl, thienopyridinyl, pyrrolopyridazinyl, pyrrolopyrimidinyl, pyrrolopyrazinyl, thienopyridazinyl, thienopyrimidinyl, thienopyrazinyl, furopyridazinyl, furopyrimidinyl, furopyrazinyl, furotriazinyl, thienotriazinyl, imidazopyridazinyl, imidazopyrimidinyl, imidazotriazinyl, pyrazolopyridinyl, pyrazolopyridazinyl, pyrazolopyrimidinyl, pyrazolopyrazinyl, pyrazolotriazinyl, isoxazolopyridinyl, isoxazolopyridazinyl, isoxazolopyrazinyl,Docket No. P60153

[0087] isoxazolopyrimidinyl, isoxazolotriazinyl, oxazolopyridinyl, oxazolopyridazinyl, oxazolopyrazinyl, oxazolopyrimidinyl, oxazolotriazinyl, isothiazolopyridinyl, isothiazolopyridazinyl, isothiazolopyrazinyl, isothiazolopyrimidinyl, isothiazolotriazinyl, thiazolopyridinyl, thiazolopyridazinyl, thiazolopyrazinyl, thiazolopyrimidinyl, thiazolotriazinyl, triazolopyrimidinyl, triazolotriazinyl, oxadiazolopyridinyl, oxadiazolopyridazinyl, oxadiazolopyrimidinyl, oxadiazolopyrazinyl, oxadiazolotriazinyl, thiadi azol opyridinyl, thiadiazolopyridazinyl, thiadiazolopyrimidinyl, thiadiazolopyrazinyl, thiadiazolotriazinyl, pyrrolopyridinonyl, pyrrolopyrazinonyl, pyrrolopyridazinonyl, pyrrolopyrimidinonyl, pyrrolotriazinonyl, furopyridinonyl, furopyrimidinonyl, furopyridazinonyl, furopyrazinonyl, furotriazinonyl, thienopyridinonyl, thienopyrimidinonyl, thienopyridazinonyl, thienopyrazinonyl, thienotriazinonyl, imidazopyridinonyl, imidazopyrazinonyl, imidazopyridazinonyl, purinonyl, imidazotriazinonyl, pyrazolopyridinonyl, pyrazolopyridazinonyl, pyrazolopyrimidinonyl, pyrazolopyrazinonyl, pyrazolotriazinonyl, isoxazolopyridinonyl, isoxazolopyridazinonyl, isoxazolopyrazinonyl, isoxazolopyrimidinonyl, isoxazolotriazinonyl, oxazolopyridinonyl, oxazolopyridazinonyl, oxazolopyrazinonyl, oxazolopyrimidinonyl, oxazolotriazinonyl, isothiazolopyridinonyl, isothiazolopyridazinonyl, isothiazolopyrazinonyl, isothiazolopyrimidinonyl, isothiazolotriazinonyl, thiazolopyridinonyl, thiazolopyridazinonyl, thiazolopyrazinonyl, thiazolopyrimidinonyl, thiazolotriazinonyl, tri azol opyri dinonyl, triazolopyridazinonyl, triazolopyrimidinonyl,

[0088] triazol opyrazinonyl. triazol otriazinonyl, oxadiazol opyri dinonyl, oxadi azol opyri dazinonyl, oxadiazolopyrimidinonyl, oxadiazolopyrazinonyl, oxadiazolotriazinonyl, thiadiazolopyridinonyl, thiadiazolopyridazinonyl, thiadiazolopyrimidinonyl, thiadiazolopyrazinonyl, thiadiazolotriazinonyl, naphthyridinyl, pyridopyridazinyl, pyridopyrimidinyl, pyridopyrazinyl, pyridazinopyridazinyl, pyrimidopyridazinyl, pyrazinopyridazinyl, pyrimidopyrimidinyl, pteridinyl, pyrazinopyrazinyl, naphthyridinonyl, pyridazinopyridonyl, pyrimidinopyridonyl, pyrazinopyridonyl, pyridopyridazinonyl, pyridazinopyridazinonyl, pyrimidopyridazinonyl, pyrazinopyridazinonyl, pyridopyrimidinonyl, pyrimidopyridazinonyl, pyrimidopyrimidinonyl, pteridinonyl, pyridopyrazinonyl, pyrazinopyrazinonyl, pyrazinopyridazinonyl, and pteridinonyl. More particular heteroaryl are pyridyl, triazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[2,3-d]pyridazinyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[4,3-b]pyridinyl and thieno[3,4-d]pyrimidinyl.

[0089] The term "heterocycle" or "heterocyclyl" refers to a 3, 4, 5, 6, 7, 8, 9, 10-membered monocyclic, 7, 8, 9 and 10-membered bicyclic (including fused, bridged and spiro bicyclic), orDocket No. P60153

[0090] 10, 11, 12, 13, 14 and 15-membered bicyclic (including fused, bridged and spiro bicyclic) or 10, 11, 12, 13, 14, 15 and 16-membered tricyclic (including fused, bridged and spiro tricyclic) heterocyclic moiety that is saturated or partially unsaturated, and has one or more (e.g., 1, 2, 3 or 4) heteroatoms selected from oxygen, nitrogen and sulfur in the ring with the remaining ring atoms being carbon. In some aspects, the heterocycle is a heterocycloalkyl. In particular aspects heterocycle or heterocyclyl refers to a 4, 5, 6 or 7-membered Heterocycle. When used in reference to the ring atom of a heterocycle, a nitrogen or sulfur may also be in an oxidized form, and a nitrogen may be substituted with one or more C1-6alkyl or other groups.

[0091] The heterocycle can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. Any of the heterocycle ring atoms can be optionally substituted with one or more substituents described herein. In one example, the heterocyclyl group includes 0 to 3 double bonds. Any nitrogen or sulfur heteroatom may optionally be oxidized (e.g., NO, SO, SO2), and any nitrogen heteroatom may optionally be quaternized (e.g., [NR.4]+C1’, [NR.4]+OH'). Examples of such saturated or partially unsaturated heterocycles include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, pyrrolidine 1 -oxide, N-hydroxypiperidine, 1-methylpyrrolidine N-oxide, diazirinyl and quinuclidinyl. The term heterocycle also includes groups in which a heterocycle is fused to one or more aryl, heteroaryl, or cycloalkyl rings, such as indolinyl, 3H-indolyl, chromanyl, azabicyclo[2.2. l]heptanyl, azabicyclo[3.1.0]hexanyl, azabicyclo[3.1.1]heptanyl, octahydroindolyl, or tetrahydroquinolinyl. Particular heterocyclyl includes 2,3-dihydropyrazolo[5,l-b]oxazolyl, 5,7-dihydrothieno[3,4-d]pyrimidinyl, 2-oxooxazolyl, 2-oxo-imidazolyl, 7-oxo-pyrrolo[2,3-c]pyridinyl, 6-oxo-4H-pyrrolo[3,4-b]pyrrolyl and 5-oxo-6H-pyrrolo[3,2-b]pyrrolyl, 2,3-dihydropyrazolo[5,l-b]oxazolyl, isoindolinyl, and 5,7-dihydropyrrolo[3,4-d]pyrimidinyl.

[0092] The term “optional” or “optionally” denotes that a subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.

[0093] The term “optionally substituted” unless otherwise specified means that a group may be unsubstituted or substituted by one or more (e.g., 0, 1, 2, 3, 4, or 5 or more, or any range derivable therein) of the substituents listed for that group in which said substituents may be theDocket No. P60153

[0094] same or different. In an embodiment, an optionally substituted group has 1 substituent. In another embodiment an optionally substituted group has 2 substituents. In another embodiment an optionally substituted group has 3 substituents. In another embodiment an optionally substituted group has 4 substituents. In another embodiment an optionally substituted group has 5 substituents.

[0095] The term “di substituted” refers to that a group is substituted twice.

[0096] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed 'isomers.' Isomers that differ in the arrangement of their atoms in space are termed 'stereoisomers.' Stereoisomers that are not mirror images of one another are termed 'diastereomers,' and those that are non-superimposable mirror images of each other are termed 'enantiomers'. When a compound has an asymmetric center, for example, if a carbon atom is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn, Ingold, and Prelog, or by the manner in which the molecule rotates the plane of polarized light and is designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers, respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a 'racemic mixture'.

[0097] The compounds disclosed herein, including formula (I), can possess one or more asymmetric centers or axes. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers, atropisomers, and mixtures, racemic or otherwise, thereof, as well as individual epimers, atropisomers, and mixtures thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of 'Advanced Organic Chemistry', 4th edition J. March, John Wiley and Sons, New York, 1992).

[0098] Certain compounds may exhibit tautomerism. Tautomeric compounds can exist as two or more interconvertible species. Prototropic tautomers result from the migration of a covalently bonded hydrogen atom between two atoms. Tautomers exist in equilibrium and attempt to isolate an individual tautomer usually produce a mixture whose chemical and physical properties are consistent with a mixture of compounds. The position of the equilibrium is dependent on chemical features within the molecule. For example, in many aliphatic aldehydes and ketones, such as acetaldehyde, the keto form predominates, while in phenols, the enol formDocket No. P60153

[0099] predominates. Common prototropic tautomers include keto / enol (-C(=O)-CH- -C(- OH)=CH-), amide / imidic acid (-C(=O)-NH- -C(-OH)=N-) and amidine (-C(=NR)-NH- - C(-NHR)=N-) tautomers. The latter two are particularly common in heteroaryl and heterocyclic rings and the present invention encompasses all tautomeric forms of the compounds.

[0100] The term “Atropisomers” refers to stereoisomers resulting from hindered rotation about a single bond where the energy barrier to rotation is high enough to allow for the isolation of individual conformers.

[0101] The term " Bond" when used in reference to a linker (e.g., L2) refers to that the two moieties connected by the bond are linked directly to each other without any intervening atoms.

[0102] The term “pharmaceutically acceptable excipient” denotes any ingredient having no therapeutic activity and being non-toxic such as disintegrators, binders, fillers, solvents, buffers, tonicity agents, stabilizers, antioxidants, surfactants or lubricants used in formulating pharmaceutical products.

[0103] The term “pharmaceutical composition” refers to a mixture or solution comprising a therapeutically effective amount of an active pharmaceutical ingredient together with pharmaceutically acceptable Excipients to be administered to a mammal, e.g., a human in need thereof.

[0104] The term “pharmaceutically acceptable acid addition salt” refers to those pharmaceutically acceptable salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and organic acids selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicyclic acid.

[0105] The term “pharmaceutically acceptable base addition salt” refers to those pharmaceutically acceptable salts formed with an organic or inorganic base. Examples of acceptable inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Salts derived from pharmaceutically acceptable organic nontoxic bases includes salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchangeDocket No. P60153

[0106] resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethylamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, and polyamine resins.

[0107] The term “pharmaceutically acceptable salts” refers to salts which are not biologically or otherwise undesirable. Pharmaceutically acceptable salts include both acid and base addition salts.

[0108] The term “pharmaceutically active metabolite” refers to a pharmacologically active product produced through metabolism in the body of a specified compound or salt thereof. After entry into the body, most drugs are substrates for chemical reactions that may change their physical properties and biologic effects. These metabolic conversions, which usually affect the polarity of the compounds of the invention, alter the way in which drugs are distributed in and excreted from the body. However, in some cases, metabolism of a drug is required for therapeutic effect.

[0109] The term "protecting group" refers to the group which selectively blocks a reactive site in a multifunctional compound such that a chemical reaction can be conducted selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry. Protective groups can be removed at the appropriate point. Exemplary protective groups are Amino-protective groups, carboxy-protective groups or hydroxy-protective groups. Particular protective groups are the tert-butoxy carbonyl (Boc), benzyloxycarbonyl (Cbz), fluorenylmethoxycarbonyl (Fmoc) and benzyl (Bn). Further particular protective groups are the tert-butoxy carbonyl (Boc) and the fluorenylmethoxycarbonyl (Fmoc). More particular protective group is the tert-butoxycarbonyl (Boc). Exemplary protective groups and their application in organic synthesis are described, for example, in “Protective Groups in Organic Chemistry” by T. W. Greene and P. G. M. Wutts, 5th Ed., 2014, John Wiley & Sons, N. Y.

[0110] The term “subject” denotes a vertebrate. In certain embodiments, the vertebrate is a mammal. Mammals include humans, non-human primates such as chimpanzees and other apes and monkey species, farm animals such as cattle, horses, sheep, goats, and swine, domestic animals such as rabbits, dogs, and cats, laboratory animals including rodents, such as rats, mice, and guinea pigs. In certain embodiments, a mammal is a human. The term subject does not denote a particular age or sex.Docket No. P60153

[0111] The term “substituent” refers to an atom or group of chemically bonded atoms that is attached to another atom or molecule by one or more chemical bonds thereby forming part of a molecule. When indicating the number of substituents, the term “one or more” refers to the range from one substituent to the highest possible number of substitution, i.e. replacement of one hydrogen up to replacement of all hydrogens by substituents, in particular wherein “one or more” refers to one, two or three, most particularly “one or more” refers to one or two.

[0112] The term “therapeutically effective amount” refers to an amount of a compound or molecule of the present invention that, when administered to a subject, (i) treats or prevents the particular disease, condition or disorder, (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition or disorder described herein. The therapeutically effective amount will vary depending on the compound, the disease state being treated, the severity of the disease treated, the age and relative health of the Subject, the route and form of administration, the judgement of the attending medical or veterinary practitioner, and other factors.

[0113] The term “treatment” or "treating" and grammatical variations thereof as used herein refers to therapeutic therapy. In reference to a particular condition, treating means: (1) to ameliorate the condition or one or more of the biological manifestations of the condition, (2) to interfere with (a) one or more points in the biological cascade that leads to or is responsible for the condition or (b) one or more of the biological manifestations of the condition, (3) to alleviate one or more of the symptoms, effects or side effects associated with the condition or treatment thereof, or (4) to slow the progression of the condition or one or more of the biological manifestations of the condition. Prophylactic therapy using the methods and / or compositions of the invention is also contemplated. The skilled artisan will appreciate that "prevention" is not an absolute term. In medicine, "prevention" is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or severity of a condition or biological manifestation thereof, or to delay the onset of such condition or biological manifestation thereof.

[0114] DESCRIPTION OF EMBODIMENTS

[0115] Embodiment lb: A compound of formula (I),Docket No. P60153

[0116]

[0117] wherein

[0118] R1is H or deuterium;

[0119] each R2is independently H, halogen, hydroxy, amino or C1-6alkyl;

[0120] each R3is independently H, halogen, hydroxy or C1-6alkyl;

[0121] R4is R4aor R4acarbonyl, wherein R4ais a 6-10 membered aryl, 5-10 membered heteroaryl or 3-12 membered heterocyclyl, any one of which is unsubstituted or substituted by one to three substituents independently selected from the group consisting of

[0122] (C1-6alkyl)2amino,

[0123] (hydroxyC1-6alkoxy)C1-6alkoxy,

[0124] amino,

[0125] C1-6alkoxy,

[0126] C1-6alkoxycarbonyl,

[0127] C1-6alkyl,

[0128] C1-6alkylamino,

[0129] C1-6alkylsulfanyl,

[0130] haloC1-6alkyl,

[0131] halogen,

[0132] hydroxy,

[0133] hydroxyC1-6alkoxy,

[0134] hydroxyC1-6alkyl,

[0135] hydroxyC1-6alkyl(C1-6alkyl)amino,

[0136] hydroxyC1-6alkylsulfanyl,

[0137] hydroxyhaloC1-6alkoxy,

[0138] 6-10 membered aryl unsubstituted or substituted by one to three substituents independently selected from the group consisting of (((hydroxyCi-6alkyl)carbonyl)(Ci-6alkyl)amino)Ci-Docket No. P60153

[0139] ealkyl, ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((C1-6alkyl)2amino)Ci-6alkyl, ((hydroxyCi- 6alkyl)carbonylamino)Ci-6alkyl, (C1-6alkoxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkoxy)Ci- ealkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyhaloC1-6alkyl)C1-6alkyl, amino, aminoCi- ealkyl, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(Ci- 6alkoxy)Ci-6alkyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl, hydroxyhaloC1-6alkyl, Ci- ealkylsulfinyl, C1-6alkyl sulfanyl and carbamoyl,

[0140] 5-10 membered heteroaryl unsubstituted or substituted by one to three substituents independently selected from the group consisting of (((hydroxyC1-6alkyl)carbonyl)(Ci- 6alkyl)amino)Ci-6alkyl, ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((C1-6alkyl)2amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (C1-6alkoxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyhaloC1-6alkyl)Ci- ealkyl, amino, aminoC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl, hydroxyhaloC1-6alkyl, C1-6alkylsulfinyl, C1-6alkylsulfanyl and carbamoyl, and 3-12 membered heterocyclyl unsubstituted or substituted by one to three substituents independently selected from the group consisting of (((hydroxyC1-6alkyl)carbonyl)(Ci- 6alkyl)amino)Ci-6alkyl, ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((C1-6alkyl)2amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (C1-6alkoxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyhaloC1-6alkyl)Ci- ealkyl, amino, aminoC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl, hydroxyhaloC1-6alkyl, C1-6alkylsulfinyl, C1-6alkylsulfanyl and carbamoyl,

[0141] R5is H, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or (R5aCi-6alkoxy)C1-6alkyl, wherein R5ais H or phenyl unsubstituted or substituted by amino or nitro;

[0142] R6is H or C1-6alkyl;

[0143] L1is C1-6alkylene;

[0144] L2is a bond or C1-6alkylene;

[0145] m is 0, 1, 2 or 3;

[0146] n is 0, 1, 2, 3 or 4;

[0147] or a pharmaceutically acceptable salt thereof.

[0148] Embodiment 2b: The compound of embodiment lb, or a pharmaceutically acceptable salt thereof, wherein

[0149] R1is H or deuterium;Docket No. P60153

[0150] each R2is independently H, halogen, hydroxy, amino or C1-6alkyl;

[0151] each R3is independently H, halogen, hydroxy or C1-6alkyl;

[0152] R4is R4aor R4acarbonyl,

[0153] wherein R4ais 1,2-benzoxazolyl, 1,3-benzodioxolyl, 1,3 -benzothiazolyl, 2, 3 -dihydro- 1,4- benzodioxinyl, benzimidazolyl, benzothiophenyl, imidazo[1,2-a]pyridinyl, indazolyl, indolyl, isoindolinyl, phenyl, pyrazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[4,3-b]pyridinyl, pyridyl or pyrimidinyl, any one of which is unsubstituted or substituted by one to three substituents independently selected from the group consisting of (C1-6alkyl)2amino,

[0154] (hydroxyC1-6alkoxy)C1-6alkoxy,

[0155] 1.2.4-triazolyl substituted by C1-6alkyl,

[0156] 1.3.4-oxadiazolyl substituted by C1-6alkyl,

[0157] 1.3.4-thiadiazolyl unsubstituted or substituted by C1-6alkyl,

[0158] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0159] 5.7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi-6alkyl)carbonyl, 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0160] 6,6-dioxo-5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0161] 6.7-dihydro-4H-pyrazolo[1,5-a]pyrazinyl substituted by C1-6alkyl,

[0162] 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl,

[0163] 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazinyl,

[0164] 6-oxo-5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0165] amino,

[0166] C1-6alkoxy,

[0167] C1-6alkoxycarbonyl,

[0168] C1-6alkyl,

[0169] C1-6alkylamino,

[0170] C1-6alkylsulfanyl,

[0171] haloC1-6alkyl,

[0172] halogen,

[0173] hydroxy,

[0174] hydroxyC1-6alkoxy,

[0175] hydroxyC1-6alkyl,

[0176] hydroxyC1-6alkyl(C1-6alkyl)amino,Docket No. P60153

[0177] hydroxyC1-6alkylsulfanyl,

[0178] hydroxyhaloC1-6alkoxy,

[0179] imidazolyl substituted by C1-6alkyl,

[0180] isoxazolyl,

[0181] oxazolyl unsubstituted or substituted by C1-6alkyl,

[0182] phenyl unsubstituted or substituted by aminoC1-6alkyl or ((Ci-6alkoxycarbonyl)amino)Ci- ealkyl,

[0183] piperidyl disubstituted with C1-6alkyl and hydroxyC1-6alkyl,

[0184] pyrazinyl,

[0185] pyrazolyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of

[0186] (((hydroxyC1-6alkyl)carbonyl)(C1-6alkyl)amino)C1-6alkyl,

[0187] ((C1-6alkoxycarbonyl)amino)C1-6alkyl,

[0188] ((C1-6alkyl)2amino)Ci-6alkyl,

[0189] ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl,

[0190] (C1-6alkoxyC1-6alkoxy)C1-6alkyl,

[0191] (hydroxyC1-6alkoxy)C1-6alkyl,

[0192] (hydroxyC1-6alkyl)C1-6alkyl,

[0193] (hydroxyhaloC1-6alkyl)C1-6alkyl,

[0194] amino,

[0195] C1-6alkoxyC1-6alkyl,

[0196] C1-6alkoxycarbonyl,

[0197] C1-6alkyl,

[0198] cyanoC1-6alkyl,

[0199] halogen,

[0200] hydroxy(C1-6alkoxy)C1-6alkyl,

[0201] hydroxyC1-6alkyl,

[0202] hydroxyhaloC1-6alkyl, and

[0203] tetrahydrothiophenyl,

[0204] pyridazinyl,

[0205] pyridyl,

[0206] pyrimidinyl unsubstituted or substituted by C1-6alkylsulfinyl, C1-6alkylsulfanyl, carbamoyl or C1-6alkoxycarbonyl,Docket No. P60153

[0207] pyrrolidinyl unsubstituted or substituted by hydroxy,

[0208] pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,

[0209] tetrazolyl unsubstituted or substituted by C1-6alkyl,

[0210] thiazolyl,

[0211] thieno[3,4-d]pyrimidinyl, and

[0212] triazolyl unsubstituted or substituted by C1-6alkyl,

[0213] R5is H, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or (R5aCi-6alkoxy)Ci-6alkyl, wherein R5ais H or phenyl unsubstituted or substituted by amino or nitro;

[0214] R6is H or C1-6alkyl;

[0215] L1is C1-6alkylene;

[0216] L2is a bond or C1-6alkylene;

[0217] m is 0 or 1;

[0218] n is 1 or 2;

[0219] or a pharmaceutically acceptable salt thereof.

[0220] Embodiment 3b: The compound of any one of embodiments lb-2b, or a pharmaceutically acceptable salt thereof, wherein R1is H.

[0221] Embodiment 4b: The compound of any one of embodiments lb-3b, or a pharmaceutically acceptable salt thereof, wherein each R2is independently H, halogen, amino or hydroxy.

[0222] Embodiment 5b: The compound of any one of embodiments lb-4b, or a pharmaceutically acceptable salt thereof, wherein each R2is independently H, fluoro, amino or hydroxy.

[0223] Embodiment 6b: The compound of any one of embodiments lb-5b, or a pharmaceutically acceptable salt thereof, wherein each R2is independently H or hydroxy.

[0224] Embodiment 7b: The compound of any one of embodiments lb-6b, or a pharmaceutically acceptable salt thereof, wherein each R3is independently H, fluoro, chloro, hydroxy, methyl or ethyl.

[0225] Embodiment 8b: The compound of any one of embodiments lb-7b, or a pharmaceutically acceptable salt thereof, wherein each R3is independently H, halogen or C1-6alkyl.

[0226] Embodiment 9b: The compound of any one of embodiments lb-8b, or a pharmaceutically acceptable salt thereof, wherein each R3is independently H, fluoro, chloro or ethyl.

[0227] Embodiment 10b: The compound of any one of embodiments lb-9b, or a pharmaceutically acceptable salt thereof, wherein

[0228] R4is 1,2-benzoxazolyl,

[0229] 1,3-benzodioxolyl,Docket No. P60153

[0230] 1,3-benzothiazolyl,

[0231] 2,3-dihydro-1,4-benzodioxinyl,

[0232] benzimidazolyl substituted by C1-6alkyl,

[0233] benzothiophenyl,

[0234] benzoyl,

[0235] imidazo[1,2-a]pyridinyl,

[0236] indazolyl unsubstituted or substituted by halogen or C1-6alkyl,

[0237] indolyl substituted by C1-6alkyl,

[0238] isoindolinyl substituted by C1-6alkoxycarbonyl,

[0239] phenyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of

[0240] (hydroxyC1-6alkoxy)C1-6alkoxy,

[0241] 1,2,4-triazolyl,

[0242] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0243] 5,7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi- ealkyl)carbonyl,

[0244] amino,

[0245] C1-6alkoxy,

[0246] C1-6alkoxycarbonyl,

[0247] C1-6alkyl,

[0248] C1-6alkylamino,

[0249] C1-6alkylsulfanyl,

[0250] halogen,

[0251] hydroxy,

[0252] hydroxyC1-6alkoxy,

[0253] hydroxyC1-6alkyl,

[0254] hydroxyC1-6alkyl(C1-6alkyl)amino,

[0255] hydroxyC1-6alkylsulfanyl,

[0256] hydroxyhaloC1-6alkoxy,

[0257] imidazolyl substituted by C1-6alkyl,

[0258] pyrazolyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of (((hydroxyCi-6alkyl)carbonyl)(Ci-6alkyl)amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (Ci-6alkoxyCi-6alkoxy)Ci-Docket No. P60153

[0259] ealkyl, (hydroxyCi-6alkyl)C1-6alkyl, (hydroxyCi-6alkoxy)C1-6alkyl, (hydroxyhaloCi- 6alkyl)C1-6alkyl, amino, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, cyanoC1-6alkyl, halogen, hydroxy(Ci-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl and hydroxyhaloC1-6alkyl,

[0260] pyrimidinyl unsubstituted or substituted by carbamoyl or C1-6alkoxycarbonyl, pyrrolidinyl substituted by hydroxy,

[0261] pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,

[0262] tetrazolyl,

[0263] thieno[3,4-d]pyrimidinyl, and

[0264] triazolyl unsubstituted or substituted by C1-6alkyl,

[0265] pyrazinyl disubstituted with amino and C1-6alkylpyrazolyl,

[0266] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino or C1-6alkylamino, pyrazolo[4,3-b]pyridinyl substituted by C1-6alkyl,

[0267] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0268] (C1-6alkyl)2amino,

[0269] 1.2.4-triazolyl substituted by C1-6alkyl,

[0270] 1.3.4-oxadiazolyl substituted by C1-6alkyl,

[0271] 1.3.4-thiadiazolyl unsubstituted or substituted by C1-6alkyl,

[0272] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0273] 5.7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,

[0274] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0275] 6,6-dioxo-5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0276] 6.7-dihydro-4H-pyrazolo[1,5-a]pyrazinyl substituted by C1-6alkyl,

[0277] 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl,

[0278] 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazinyl,

[0279] 6-oxo-5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0280] amino,

[0281] C1-6alkoxy,

[0282] C1-6alkoxycarbonyl,

[0283] C1-6alkyl,

[0284] C1-6alkylamino,

[0285] haloC1-6alkyl,Docket No. P60153

[0286] hydroxyC1-6alkoxy,

[0287] isoxazolyl,

[0288] oxazolyl unsubstituted or substituted by C1-6alkyl,

[0289] phenyl substituted by aminoC1-6alkyl or ((C1-6alkoxycarbonyl)amino)C1-6alkyl, piperidyl disubstituted with C1-6alkyl and hydroxyC1-6alkyl,

[0290] pyrazinyl,

[0291] pyrazolyl unsubstituted or substituted by ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((Ci- 6alkyl)2amino)Ci-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, amino, C1-6alkyl or tetrahydrothiophenyl,

[0292] pyridazinyl,

[0293] pyridyl,

[0294] pyrimidinyl unsubstituted or substituted by C1-6alkyl sulfinyl or C1-6alkylsulfanyl, pyrrolidinyl,

[0295] tetrazolyl unsubstituted or substituted by C1-6alkyl,

[0296] thiazolyl,

[0297] thieno[3,4-d]pyrimidinyl, and

[0298] triazolyl,

[0299] or pyrimidinyl substituted by one or two substituents independently selected from the group consisting of amino, C1-6alkylpyrazolyl and pyrimidinyl.

[0300] Embodiment 1 lb: The compound of any one of embodiments lb- 10b, or a pharmaceutically acceptable salt thereof, wherein

[0301] R4is 1,3-benzodioxolyl,

[0302] phenyl substituted by one or two substituents independently selected from the group consisting of

[0303] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0304] 5,7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi- ealkyl)carbonyl,

[0305] amino,

[0306] C1-6alkoxycarbonyl,

[0307] C1-6alkylamino,

[0308] C1-6alkylsulfanyl,

[0309] hydroxy,

[0310] hydroxyC1-6alkoxy,Docket No. P60153

[0311] pyrazolyl substituted by (hydroxyC1-6alkoxy)C1-6alkyl, C1-6alkyl or hydroxyC1-6alkyl, pyrimidinyl,

[0312] pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,

[0313] thieno[3,4-d]pyrimidinyl, and

[0314] triazolyl,

[0315] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[0316] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0317] 1,3,4-thiadiazolyl,

[0318] 2,3-dihydropyrazolo[5,1-b]oxazolyl,

[0319] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0320] amino,

[0321] C1-6alkoxy,

[0322] C1-6alkoxycarbonyl,

[0323] phenyl substituted by aminoC1-6alkyl,

[0324] pyrazolyl substituted by amino or C1-6alkyl,

[0325] pyrimidinyl, and

[0326] thieno[3,4-d]pyrimidinyl,

[0327] or pyrimidinyl substituted by C1-6alkylpyrazolyl.

[0328] Embodiment 12b: The compound of any one of embodiments lb- 1 lb, or a pharmaceutically acceptable salt thereof, wherein

[0329] R4is l,3-benzodioxol-5-yl,

[0330] phenyl substituted by one or two substituents independently selected from the group consisting of

[0331] 2,3-dihydropyrazolo[5,1-b]oxazol-7-yl,

[0332] 5,7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by methyl or 2-hydroxyacetyl, amino,

[0333] methoxycarbonyl,

[0334] methylamino,

[0335] methylsulfanyl,

[0336] hydroxy,

[0337] 2-hydroxyethoxy,

[0338] pyrazolyl substituted by 2-(2-hydroxyethoxy)ethyl, methyl or 2-hydroxyethyl,Docket No. P60153

[0339] pyrimidinyl,

[0340] pyrrolo[3,4-d]pyrimidinyl substituted by methyl,

[0341] thieno[3,4-d]pyrimidinyl, and

[0342] triazolyl,

[0343] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[0344] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0345] 1,3,4-thiadiazolyl,

[0346] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0347] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0348] amino,

[0349] C1-6alkoxy,

[0350] C1-6alkoxycarbonyl,

[0351] phenyl substituted by aminomethyl,

[0352] pyrazolyl substituted by amino or methyl,

[0353] pyrimidinyl, and

[0354] thieno[3,4-d]pyrimidinyl,

[0355] or pyrimidinyl substituted by 1-methylpyrazol-4-yl.

[0356] Embodiment 13b: The compound of any one of embodiments lb- 12b, or a pharmaceutically acceptable salt thereof, wherein R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2-amino-4-(l-methylpyrazol-3-yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 3-amino-4-(l-methylpyrazol-3-yl)phenyl, 3-amino-4-(l-methylpyrazol-4-yl)phenyl, 3-amino-4-(6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl)phenyl, 3-amino-4-(triazol-2-yl)phenyl, 3-amino-4-[6-(2-hydroxyacetyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]phenyl, 3-amino-4-methoxycarbonyl-phenyl, 3-amino-4-methylsulfanyl-phenyl, 3-amino-4-pyrimidin-2-yl-phenyl, 3-amino-4-thieno[3,4-d]pyrimidin-2-yl-phenyl, 3-hydroxy-4-(l-methylpyrazol-3-yl)phenyl, 3-hydroxy-4-(6-methylpyrrolo[3,4-d]pyrimidin-2-yl)phenyl, 3 -hydroxy -4-methoxycarbonyl-phenyl, 3 -hydroxy -4-pyrimidin-2-yl-phenyl, 4-(l-methylpyrazol-4-yl)phenyl, 4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl, 4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2-pyridyl, 5-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl, 5-(3-aminopyrazol-l-yl)-6-methoxy-2-pyridyl, 5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl, 6-amino-5-(l,3,4-thiadiazol-2-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-amino-5-(5,7-dihydrothieno[3,4-Docket No. P60153

[0357] d]pyrimidin-2-yl)-2-pyridyl, 6-amino-5-pyrimidin-2-yl-2-pyridyl, 6-amino-5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl, 6-methoxy-5-methoxycarbonyl-2-pyridyl, 7-aminopyrazolo[l,5-a]pyridin-6-yl or pyrazolo[l,5-a]pyridin-6-yl.

[0358] Embodiment 14b: The compound of any one of embodiments lb- 13b, or a pharmaceutically acceptable salt thereof, wherein R5is H, (3 -aminophenyl)m ethoxymethyl, (3-nitrophenyl)methoxymethyl, 2-hydroxyethyl, benzyloxymethyl, ethyl, hydroxy, hydroxymethyl, methyl or propyl.

[0359] Embodiment 15b: The compound of any one of embodiments lb- 14b, or a pharmaceutically acceptable salt thereof, wherein R5is H, C1-6alkyl, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl.

[0360] Embodiment 16b: The compound of any one of embodiments lb- 15b, or a pharmaceutically acceptable salt thereof, wherein R5is H, benzyloxymethyl, ethyl, hydroxymethyl or methyl.

[0361] Embodiment 17b: The compound of any one of embodiments lb- 16b, or a pharmaceutically acceptable salt thereof, wherein R6is H.

[0362] Embodiment 18b: The compound of any one of embodiments lb- 17b, or a pharmaceutically acceptable salt thereof, wherein L1is methylene or ethane- 1,1 -diyl.

[0363] Embodiment 19b: The compound of any one of embodiments lb- 18b, or a pharmaceutically acceptable salt thereof, wherein L2is a bond or methylene.

[0364] Embodiment 20b: The compound of any one of embodiments lb- 19b, or a pharmaceutically acceptable salt thereof, wherein m is 1.

[0365] Embodiment 21b: The compound of any one of embodiments lb-20b, or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2.

[0366] Embodiment 22b: The compound of any one of embodiments lb-2 lb, or a pharmaceutically acceptable salt thereof, wherein

[0367] R1is H;

[0368] each R2is independently H or hydroxy;

[0369] each R3is independently H, halogen or C1-6alkyl;

[0370] R4is 1,3-benzodioxolyl,

[0371] phenyl substituted by one or two substituents independently selected from the group consisting of

[0372] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0373] 5,7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi- ealkyl)carbonyl,

[0374] amino,Docket No. P60153

[0375] C1-6alkoxycarbonyl,

[0376] C1-6alkylamino,

[0377] C1-6alkylsulfanyl,

[0378] hydroxy,

[0379] hydroxyC1-6alkoxy,

[0380] pyrazolyl substituted by (hydroxyC1-6alkoxy)C1-6alkyl, C1-6alkyl or hydroxyC1-6alkyl, pyrimidinyl,

[0381] pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,

[0382] thieno[3,4-d]pyrimidinyl, and

[0383] triazolyl,

[0384] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[0385] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0386] 1,3,4-thiadiazolyl,

[0387] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0388] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0389] amino,

[0390] C1-6alkoxy,

[0391] C1-6alkoxycarbonyl,

[0392] phenyl substituted by aminoC1-6alkyl,

[0393] pyrazolyl substituted by amino or C1-6alkyl,

[0394] pyrimidinyl, and

[0395] thieno[3,4-d]pyrimidinyl,

[0396] or pyrimidinyl substituted by C1-6alkylpyrazolyl;

[0397] R5is H, C1-6alkyl, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl;

[0398] R6is H;

[0399] L1is C1-6alkylene;

[0400] L2is a bond or C1-6alkylene;

[0401] m is 1;

[0402] n is 1 or 2;

[0403] or a pharmaceutically acceptable salt thereof.

[0404] Embodiment 23b: The compound of any one of embodiments lb-22b, or a pharmaceutically acceptable salt thereof, whereinDocket No. P60153

[0405] R1is H;

[0406] each R2is independently H or hydroxy;

[0407] each R3is independently H, fluoro, chloro or ethyl;

[0408] R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2-amino-4-(l-methylpyrazol-3- yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 3- amino-4-( 1 -methylpyrazol-3 -yl)phenyl, 3 -amino-4-( 1 -methylpyrazol-4-yl)phenyl, 3 -amino-4- (6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimi din-2 -yl)phenyl, 3-amino-4-(triazol-2-yl)phenyl, 3- amino-4-[6-(2-hydroxyacetyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]phenyl, 3-amino-4- methoxycarbonyl-phenyl, 3-amino-4-methylsulfanyl-phenyl, 3-amino-4-pyrimidin-2-yl- phenyl, 3-amino-4-thieno[3,4-d]pyrimidin-2-yl-phenyl, 3-hydroxy-4-(l-methylpyrazol-3- yl)phenyl, 3-hydroxy-4-(6-methylpyrrolo[3,4-d]pyrimidin-2-yl)phenyl, 3-hydroxy-4- methoxycarbonyl-phenyl, 3-hydroxy-4-pyrimidin-2-yl-phenyl, 4-(l-methylpyrazol-4- yl)phenyl, 4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl, 4-[l-(2-hydroxyethyl)pyrazol-4- yl]phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2- pyridyl, 5-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl, 5-(3-aminopyrazol- l-yl)-6-methoxy-2-pyridyl, 5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl, 6-amino-5- (l,3,4-thiadiazol-2-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-amino-5- (5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl, 6-amino-5-pyrimidin-2-yl-2-pyridyl, 6- amino-5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2- pyridyl, 6-methoxy-5-methoxycarbonyl-2-pyridyl, 7-aminopyrazolo[l,5-a]pyridin-6-yl or pyrazolo[l,5-a]pyridin-6-yl;

[0409] R5is H, benzyloxymethyl, ethyl, hydroxymethyl or methyl;

[0410] R6is H;

[0411] L1is methylene or ethane- 1,1 -diyl;

[0412] L2is a bond or methylene;

[0413] m is 1;

[0414] n is 1 or 2;

[0415] or a pharmaceutically acceptable salt thereof.

[0416] Embodiment 24b: A compound of formula (la),Docket No. P60153

[0417]

[0418] Wherein

[0419] R1is H;

[0420] R2ais H, halogen, amino or hydroxy;

[0421] R2bis H or halogen;

[0422] R2cis H;

[0423] R3ais halogen, hydroxy or C1-6alkyl;

[0424] R3bis H;

[0425] R3cis H or halogen;

[0426] R3dis H, halogen or C1-6alkyl;

[0427] R4is 1,2-benzoxazolyl,

[0428] 1,3-benzodioxolyl,

[0429] 1,3-benzothiazolyl,

[0430] 2,3-dihydro-1,4-benzodioxinyl,

[0431] benzimidazolyl substituted by C1-6alkyl,

[0432] benzothiophenyl,

[0433] benzoyl,

[0434] imidazo[1,2-a]pyridinyl,

[0435] indazolyl unsubstituted or substituted by halogen or C1-6alkyl,

[0436] indolyl substituted by C1-6alkyl,

[0437] isoindolinyl substituted by C1-6alkoxycarbonyl,

[0438] phenyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of

[0439] (hydroxyC1-6alkoxy)C1-6alkoxy,

[0440] 1,2,4-triazolyl,Docket No. P60153

[0441] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0442] 5,7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi- 6alkyl)carbonyl,

[0443] amino,

[0444] C1-6alkoxy,

[0445] C1-6alkoxycarbonyl,

[0446] C1-6alkyl,

[0447] C1-6alkylamino,

[0448] C1-6alkylsulfanyl,

[0449] halogen,

[0450] hydroxy,

[0451] hydroxyC1-6alkoxy,

[0452] hydroxyC1-6alkyl,

[0453] hydroxyC1-6alkyl(C1-6alkyl)amino,

[0454] hydroxyC1-6alkylsulfanyl,

[0455] hydroxyhaloC1-6alkoxy,

[0456] imidazolyl substituted by C1-6alkyl,

[0457] pyrazolyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of (((hydroxyCi-6alkyl)carbonyl)(Ci-6alkyl)amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (Ci-6alkoxyCi-6alkoxy)Ci- ealkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyhaloCi- 6alkyl)Ci-6alkyl, amino, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, cyanoC1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl and hydroxyhaloC1-6alkyl,

[0458] pyrimidinyl unsubstituted or substituted by carbamoyl or C1-6alkoxycarbonyl, pyrrolidinyl substituted by hydroxy,

[0459] pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,

[0460] tetrazolyl,

[0461] thieno[3,4-d]pyrimidinyl, and

[0462] triazolyl unsubstituted or substituted by C1-6alkyl,

[0463] pyrazinyl disubstituted with amino and C1-6alkylpyrazolyl,

[0464] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino or C1-6alkylamino, pyrazolo[4,3-b]pyridinyl substituted by C1-6alkyl,Docket No. P60153

[0465] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0466] (C1-6alkyl)2amino,

[0467] 1.2.4-triazolyl substituted by C1-6alkyl,

[0468] 1.3.4-oxadiazolyl substituted by C1-6alkyl,

[0469] 1.3.4-thiadiazolyl unsubstituted or substituted by C1-6alkyl,

[0470] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0471] 5.7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,

[0472] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0473] 6,6-dioxo-5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0474] 6.7-dihydro-4H-pyrazolo[1,5-a]pyrazinyl substituted by C1-6alkyl,

[0475] 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl,

[0476] 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazinyl,

[0477] 6-oxo-5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0478] amino,

[0479] C1-6alkoxy,

[0480] C1-6alkoxycarbonyl,

[0481] C1-6alkyl,

[0482] C1-6alkylamino,

[0483] haloC1-6alkyl,

[0484] hydroxyC1-6alkoxy,

[0485] isoxazolyl,

[0486] oxazolyl unsubstituted or substituted by C1-6alkyl,

[0487] phenyl substituted by aminoC1-6alkyl or ((C1-6alkoxycarbonyl)amino)C1-6alkyl, piperidyl disubstituted with C1-6alkyl and hydroxyC1-6alkyl,

[0488] pyrazinyl,

[0489] pyrazolyl unsubstituted or substituted by ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((Ci- 6alkyl)2amino)Ci-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, amino, C1-6alkyl or tetrahydrothiophenyl,

[0490] pyridazinyl,

[0491] pyridyl,

[0492] pyrimidinyl unsubstituted or substituted by C1-6alkyl sulfinyl or C1-6alkylsulfanyl, pyrrolidinyl,Docket No. P60153

[0493] tetrazolyl unsubstituted or substituted by C1-6alkyl,

[0494] thiazolyl,

[0495] thieno[3,4-d]pyrimidinyl, and

[0496] triazolyl,

[0497] or pyrimidinyl substituted by one or two substituents independently selected from the group consisting of amino, C1-6alkylpyrazolyl and pyrimidinyl;

[0498] R5is H, (aminophenyl)Ci-6alkoxyCi-6alkyl, (nitrophenyl)Ci-6alkoxyCi-6alkyl, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl;

[0499] R6is H;

[0500] L1is C1-6alkylene;

[0501] L2is a bond or C1-6alkylene;

[0502] or a pharmaceutically acceptable salt thereof.

[0503] Embodiment 25b: The compound of any one of embodiments lb-24b, or a pharmaceutically acceptable salt thereof, wherein R2ais H or hydroxy.

[0504] Embodiment 26b: The compound of any one of embodiments lb-25b, or a pharmaceutically acceptable salt thereof, wherein R2bis H.

[0505] Embodiment 27b: The compound of any one of embodiments lb-26b, or a pharmaceutically acceptable salt thereof, wherein R3ais halogen.

[0506] Embodiment 28b: The compound of any one of embodiments lb-27b, or a pharmaceutically acceptable salt thereof, wherein R3ais fluoro or chloro.

[0507] Embodiment 29b: The compound of any one of embodiments lb-28b, or a pharmaceutically acceptable salt thereof, wherein R3cis H.

[0508] Embodiment 30b: The compound of any one of embodiments lb-29b, or a pharmaceutically acceptable salt thereof, wherein R3dis H or C1-6alkyl.

[0509] Embodiment 31b: The compound of any one of embodiments lb-30b, or a pharmaceutically acceptable salt thereof, wherein R3dis H or ethyl.

[0510] Embodiment 32b: The compound of any one of embodiments lb-3 lb, or a pharmaceutically acceptable salt thereof, wherein

[0511] R4is 1,3-benzodioxolyl,

[0512] phenyl substituted by one or two substituents independently selected from the group consisting of

[0513] 2,3-dihydropyrazolo[5,l-b]oxazolyl,Docket No. P60153

[0514] 5.7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi- 6alkyl)carbonyl,

[0515] amino,

[0516] C1-6alkoxycarbonyl,

[0517] C1-6alkylamino,

[0518] C1-6alkylsulfanyl,

[0519] hydroxy,

[0520] hydroxyC1-6alkoxy,

[0521] pyrazolyl substituted by (hydroxyC1-6alkoxy)C1-6alkyl, C1-6alkyl or hydroxyC1-6alkyl, pyrimidinyl,

[0522] pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,

[0523] thieno[3,4-d]pyrimidinyl, and

[0524] triazolyl,

[0525] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[0526] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0527] 1,3,4-thiadiazolyl,

[0528] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0529] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0530] amino,

[0531] C1-6alkoxy,

[0532] C1-6alkoxycarbonyl,

[0533] phenyl substituted by aminoC1-6alkyl,

[0534] pyrazolyl substituted by amino or C1-6alkyl,

[0535] pyrimidinyl, and

[0536] thieno[3,4-d]pyrimidinyl,

[0537] or pyrimidinyl substituted by C1-6alkylpyrazolyl.

[0538] Embodiment 33b: The compound of any one of embodiments lb-32b, or a pharmaceutically acceptable salt thereof, wherein

[0539] R4is l,3-benzodioxol-5-yl,

[0540] phenyl substituted by one or two substituents independently selected from the group consisting of

[0541] 2,3-dihydropyrazolo[5,l-b]oxazol-7-yl,Docket No. P60153

[0542] 5,7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by methyl or 2-hydroxyacetyl, amino,

[0543] methoxycarbonyl,

[0544] methylamino,

[0545] methylsulfanyl,

[0546] hydroxy,

[0547] 2-hydroxyethoxy,

[0548] pyrazolyl substituted by 2-(2-hydroxyethoxy)ethyl, methyl or 2-hydroxyethyl, pyrimidinyl,

[0549] pyrrolo[3,4-d]pyrimidinyl substituted by methyl,

[0550] thieno[3,4-d]pyrimidinyl, and

[0551] triazolyl,

[0552] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[0553] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0554] 1,3,4-thiadiazolyl,

[0555] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0556] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0557] amino,

[0558] C1-6alkoxy,

[0559] C1-6alkoxycarbonyl,

[0560] phenyl substituted by aminomethyl,

[0561] pyrazolyl substituted by amino or methyl,

[0562] pyrimidinyl, and

[0563] thieno[3,4-d]pyrimidinyl,

[0564] or pyrimidinyl substituted by 1-methylpyrazol-4-yl.

[0565] Embodiment 34b: The compound of any one of embodiments lb-33b, or a pharmaceutically acceptable salt thereof, wherein R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2-amino-4-(l-methylpyrazol-3-yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 3-amino-4-(l-methylpyrazol-3-yl)phenyl, 3-amino-4-(l-methylpyrazol-4-yl)phenyl, 3-amino-4-(6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl)phenyl, 3-amino-4-(triazol-2-yl)phenyl, 3-amino-4-[6-(2-hydroxyacetyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]phenyl, 3-amino-4-methoxycarbonyl-phenyl, 3-amino-4-methylsulfanyl-phenyl, 3-amino-4-Docket No. P60153

[0566] pyrimidin-2-yl-phenyl, 3-amino-4-thieno[3,4-d]pyrimidin-2-yl-phenyl, 3-hydroxy-4-(l-methylpyrazol-3-yl)phenyl, 3-hydroxy-4-(6-methylpyrrolo[3,4-d]pyrimidin-2-yl)phenyl, 3 -hydroxy -4-methoxycarbonyl-phenyl, 3 -hydroxy -4-pyrimidin-2-yl-phenyl, 4-(l-methylpyrazol-4-yl)phenyl, 4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl, 4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2-pyridyl, 5-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl, 5-(3-aminopyrazol-l-yl)-6-methoxy-2-pyridyl, 5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl, 6-amino-5-(l,3,4-thiadiazol-2-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-amino-5-(5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl, 6-amino-5-pyrimidin-2-yl-2-pyridyl, 6-amino-5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl, 6-methoxy-5-methoxycarbonyl-2-pyridyl, 7-aminopyrazolo[l,5-a]pyridin-6-yl or pyrazolo[l,5-a]pyridin-6-yl.

[0567] Embodiment 35b: The compound of any one of embodiments lb-34b, or a pharmaceutically acceptable salt thereof, wherein R5is H, (3 -aminophenyl)m ethoxymethyl, (3-nitrophenyl)methoxymethyl, 2-hydroxyethyl, benzyloxymethyl, ethyl, hydroxy, hydroxymethyl, methyl or propyl.

[0568] Embodiment 36b: The compound of any one of embodiments lb-35b, or a pharmaceutically acceptable salt thereof, wherein R5is H, C1-6alkyl, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl.

[0569] Embodiment 37b: The compound of any one of embodiments lb-36b, or a pharmaceutically acceptable salt thereof, wherein R5is H, benzyloxymethyl, ethyl, hydroxymethyl or methyl.

[0570] Embodiment 38b: The compound of any one of embodiments lb-37b, or a pharmaceutically acceptable salt thereof, wherein R6is H.

[0571] Embodiment 39b: The compound of any one of embodiments lb-38b, or a pharmaceutically acceptable salt thereof, wherein L1is methylene or ethane- 1,1 -diyl.

[0572] Embodiment 40b: The compound of any one of embodiments lb-39b, or a pharmaceutically acceptable salt thereof, wherein L2is a bond or methylene.

[0573] Embodiment 41b: The compound of any one of embodiments lb-40b, or a pharmaceutically acceptable salt thereof, wherein

[0574] R1is H;

[0575] R2ais H or hydroxy;

[0576] R2bis H;

[0577] R2cis H;

[0578] R3ais halogen;

[0579] R3bis H;Docket No. P60153

[0580] R3cis H;

[0581] R3dis H or C1-6alkyl;

[0582] R4is 1,3-benzodioxolyl,

[0583] phenyl substituted by one or two substituents independently selected from the group consisting of

[0584] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0585] 5.7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi- ealkyl)carbonyl,

[0586] amino,

[0587] C1-6alkoxycarbonyl,

[0588] C1-6alkylamino,

[0589] C1-6alkylsulfanyl,

[0590] hydroxy,

[0591] hydroxyC1-6alkoxy,

[0592] pyrazolyl substituted by (hydroxyC1-6alkoxy)C1-6alkyl, C1-6alkyl or hydroxyC1-6alkyl, pyrimidinyl,

[0593] pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,

[0594] thieno[3,4-d]pyrimidinyl, and

[0595] triazolyl,

[0596] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[0597] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0598] 1,3,4-thiadiazolyl,

[0599] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0600] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0601] amino,

[0602] C1-6alkoxy,

[0603] C1-6alkoxycarbonyl,

[0604] phenyl substituted by aminoC1-6alkyl,

[0605] pyrazolyl substituted by amino or C1-6alkyl,

[0606] pyrimidinyl, and

[0607] thieno[3,4-d]pyrimidinyl,

[0608] or pyrimidinyl substituted by C1-6alkylpyrazolyl;Docket No. P60153

[0609] R5is H, C1-6alkyl, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl;

[0610] R6is H;

[0611] L1is C1-6alkylene;

[0612] L2is a bond or C1-6alkylene;

[0613] or a pharmaceutically acceptable salt thereof.

[0614] Embodiment 42b: The compound of any one of embodiments lb-4 lb, or a pharmaceutically acceptable salt thereof, wherein

[0615] R1is H;

[0616] R2ais H or hydroxy;

[0617] R2bis H;

[0618] R2cis H;

[0619] R3ais fluoro or chloro;

[0620] R3bis H;

[0621] R3cis H;

[0622] R3dis H or ethyl;

[0623] R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2-amino-4-(l-methylpyrazol-3- yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 3- amino-4-( 1 -methylpyrazol-3 -yl)phenyl, 3 -amino-4-( 1 -methylpyrazol-4-yl)phenyl, 3 -amino-4- (6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimi din-2 -yl)phenyl, 3-amino-4-(triazol-2-yl)phenyl, 3- amino-4-[6-(2-hydroxyacetyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]phenyl, 3-amino-4- methoxycarbonyl-phenyl, 3-amino-4-methylsulfanyl-phenyl, 3-amino-4-pyrimidin-2-yl- phenyl, 3-amino-4-thieno[3,4-d]pyrimidin-2-yl-phenyl, 3-hydroxy-4-(l-methylpyrazol-3- yl)phenyl, 3-hydroxy-4-(6-methylpyrrolo[3,4-d]pyrimidin-2-yl)phenyl, 3-hydroxy-4- methoxycarbonyl-phenyl, 3-hydroxy-4-pyrimidin-2-yl-phenyl, 4-(l-methylpyrazol-4- yl)phenyl, 4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl, 4-[l-(2-hydroxyethyl)pyrazol-4- yl]phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2- pyridyl, 5-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl, 5-(3-aminopyrazol- l-yl)-6-methoxy-2-pyridyl, 5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl, 6-amino-5- (l,3,4-thiadiazol-2-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-amino-5- (5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl, 6-amino-5-pyrimidin-2-yl-2-pyridyl, 6- amino-5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2- pyridyl, 6-methoxy-5-methoxycarbonyl-2-pyridyl, 7-aminopyrazolo[l,5-a]pyridin-6-yl or pyrazolo[l,5-a]pyridin-6-yl;Docket No. P60153

[0624] R5is H, benzyloxymethyl, ethyl, hydroxymethyl or methyl;

[0625] R6is H;

[0626] L1is methylene or ethane- 1,1 -diyl;

[0627] L2is a bond or methylene;

[0628] or a pharmaceutically acceptable salt thereof.

[0629] Embodiment 48b: The use of a compound according to any one of embodiments lb-42b or 41a, or a pharmaceutically acceptable salt thereof, for the treatment or prophylaxis of cancer, wherein the cancer is hematological malignancies, gastric cancer, esophageal cancer, colorectal cancer, pancreatic ductal adenocarcinoma, lung cancer, ovarian cancer, breast cancer, prostate cancer, liver cancer or glioblastoma.

[0630] Embodiment 49b: The use of a compound according to any one of embodiments lb-42b or 41a, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prophylaxis of cancer, wherein the cancer is hematological malignancies, gastric cancer, esophageal cancer, colorectal cancer, pancreatic ductal adenocarcinoma, lung cancer, ovarian cancer, breast cancer, prostate cancer, liver cancer or glioblastoma.

[0631] Embodiment 50b: The use according to embodiment 48b or 49b, wherein the cancer is lung cancer, hematological malignancies, prostate cancer or breast cancer.

[0632] Embodiment 51b: The use according to any one of embodiments 48b-50b, wherein the lung cancer is non-small cell lung cancer or small cell lung cancer.

[0633] Embodiment 52b: The use according to any one of embodiments 48b-51b, wherein the hematological malignancies is multiple myeloma or acute myeloid leukemia.

[0634] Embodiment 53b: A compound according to any one of embodiments lb-42b or 41a, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancer, wherein the cancer is lung cancer, hematological malignancies, prostate cancer or breast cancer.

[0635] Embodiment 54b: A method of treating cancer in a subject in need thereof, wherein the cancer is lung cancer, hematological malignancies, prostate cancer or breast cancer, and wherein the method comprises administering a therapeutically effective amount of a compound according to any one of embodiments lb-42b or 41a, or a pharmaceutically acceptable salt thereof, to the subject.

[0636] Embodiment la: A compound of formula (I),Docket No. P60153

[0637]

[0638] wherein

[0639] R1is H or deuterium;

[0640] each R2is independently H, halogen, hydroxy, amino or C1-6alkyl;

[0641] each R3is independently H, halogen, hydroxy or C1-6alkyl;

[0642] R4is R4aor R4acarbonyl, wherein R4ais a 6-10 membered aryl, 5-10 membered heteroaryl or 3-12 membered heterocyclyl, any one of which is unsubstituted or substituted by one to three substituents independently selected from the group consisting of

[0643] (C1-6alkyl)2amino,

[0644] (hydroxyC1-6alkoxy)C1-6alkoxy,

[0645] amino,

[0646] C1-6alkoxy,

[0647] C1-6alkoxycarbonyl,

[0648] C1-6alkyl,

[0649] C1-6alkylamino,

[0650] C1-6alkylsulfanyl,

[0651] haloC1-6alkyl,

[0652] halogen,

[0653] hydroxy,

[0654] hydroxyC1-6alkoxy,

[0655] hydroxyC1-6alkyl,

[0656] hydroxyC1-6alkyl(C1-6alkyl)amino,

[0657] hydroxyC1-6alkylsulfanyl,

[0658] hydroxyhaloC1-6alkoxy,

[0659] 6-10 membered aryl unsubstituted or substituted by one to three substituents independently selected from the group consisting of (((hydroxyCi-6alkyl)carbonyl)(Ci-6alkyl)amino)Ci-Docket No. P60153

[0660] ealkyl, ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((C1-6alkyl)2amino)Ci-6alkyl, ((hydroxyCi- 6alkyl)carbonylamino)Ci-6alkyl, (C1-6alkoxyC1-6alkoxy)C1-6alkyl, (hydroxyCi-6alkoxy)Ci- ealkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyhaloC1-6alkyl)C1-6alkyl, amino, aminoCi- ealkyl, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(Ci- 6alkoxy)Ci-6alkyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl and hydroxyhaloC1-6alkyl, 5-10 membered heteroaryl unsubstituted or substituted by one to three substituents independently selected from the group consisting of (((hydroxyC1-6alkyl)carbonyl)(Ci- 6alkyl)amino)Ci-6alkyl, ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((C1-6alkyl)2amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (C1-6alkoxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyhaloC1-6alkyl)Ci- ealkyl, amino, aminoC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl and hydroxyhaloC1-6alkyl, and

[0661] 3-12 membered heterocyclyl unsubstituted or substituted by one to three substituents independently selected from the group consisting of (((hydroxyC1-6alkyl)carbonyl)(Ci- 6alkyl)amino)Ci-6alkyl, ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((C1-6alkyl)2amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (C1-6alkoxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyhaloC1-6alkyl)Ci- ealkyl, amino, aminoC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl and hydroxyhaloC1-6alkyl;

[0662] R5is H, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or (R5aCi-6alkoxy)Ci-6alkyl, wherein R5ais H or phenyl unsubstituted or substituted by amino or nitro;

[0663] R6is H or C1-6alkyl;

[0664] L1is C1-6alkylene;

[0665] L2is a bond or C1-6alkylene;

[0666] m is 0, 1, 2 or 3;

[0667] n is 0, 1, 2, 3 or 4;

[0668] or a pharmaceutically acceptable salt thereof.

[0669] In one embodiment, the compound of formula (I) or (la), wherein R4is R4a.

[0670] Embodiment 2a: The compound of embodiment la, wherein

[0671] R1is H or deuterium;

[0672] each R2is independently H, halogen, hydroxy, amino or C1-6alkyl;Docket No. P60153

[0673] each R3is independently H, halogen, hydroxy or C1-6alkyl;

[0674] R4is R4aor R4acarbonyl,

[0675] wherein R4ais a 1,2-benzoxazolyl, 1,3 -benzodi oxolyl, 1,3 -benzothiazolyl, 2, 3 -dihydro- 1,4- benzodioxinyl, benzimidazolyl, benzothiophenyl, imidazo[1,2-a]pyridinyl, indazolyl, indolyl, isoindolinyl, phenyl, pyrazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[4,3-b]pyridinyl, pyridyl or pyrimidinyl, any one of which is unsubstituted or substituted by one to three substituents independently selected from the group consisting of (C1-6alkyl)2amino,

[0676] (hydroxyCi-6alkoxy)Ci-6alkoxy,

[0677] 1,3,4-thiadiazolyl,

[0678] 2, 3 -dihy dropy razol o [5, 1 -b ] oxazoly 1,

[0679] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0680] amino,

[0681] C1-6alkoxy,

[0682] C1-6alkoxycarbonyl,

[0683] C1-6alkyl,

[0684] C1-6alkylamino,

[0685] C1-6alkylsulfanyl,

[0686] haloC1-6alkyl,

[0687] halogen,

[0688] hydroxy,

[0689] hy droxy C i-ealkoxy,

[0690] hydroxyC1-6alkyl,

[0691] hydroxyC1-6alkyl(C1-6alkyl)amino,

[0692] hydroxyC1-6alkylsulfanyl,

[0693] hydroxyhaloC1-6alkoxy,

[0694] imidazolyl substituted by C1-6alkyl,

[0695] phenyl substituted by aminoC1-6alkyl or ((C1-6alkoxycarbonyl)amino)C1-6alkyl, piperidyl substituted by C1-6alkyl and hydroxyC1-6alkyl,

[0696] pyrazolyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of (((hydroxyCi-6alkyl)carbonyl)(Ci-6alkyl)amino)Ci- ealkyl, ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((C1-6alkyl)2amino)Ci-6alkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (C1-6alkoxyC1-6alkoxy)C1-6alkyl,Docket No. P60153

[0697] (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyhaloCi- 6alkyl)Ci-6alkyl, amino, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl and hydroxyhaloC1-6alkyl,

[0698] pyridazinyl,

[0699] pyrimidinyl,

[0700] pyrrolidinyl unsubstituted or substituted by hydroxy,

[0701] tetrazolyl,

[0702] thieno[3,4-d]pyrimidinyl, and

[0703] triazolyl unsubstituted or substituted by C1-6alkyl;

[0704] R5is H, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or (R5aCi-6alkoxy)Ci-6alkyl, wherein R5ais H or phenyl unsubstituted or substituted by amino or nitro;

[0705] R6is H or C1-6alkyl;

[0706] L1is C1-6alkylene;

[0707] L2is a bond or C1-6alkylene;

[0708] m is 0 or 1;

[0709] n is 1 or 2;

[0710] or a pharmaceutically acceptable salt thereof.

[0711] Embodiment 3a: The compound of any one of embodiments la-2a, or a pharmaceutically acceptable salt thereof, wherein R1is H.

[0712] Embodiment 4a: The compound of any one of embodiments la-3 a, or a pharmaceutically acceptable salt thereof, wherein R2is independently H, halogen, amino or hydroxy.

[0713] Embodiment 5a: The compound of any one of embodiments la-4a, or a pharmaceutically acceptable salt thereof, wherein each R2is independently H, fluoro, amino or hydroxy.

[0714] Embodiment 6a: The compound of any one of embodiments la-5a, or a pharmaceutically acceptable salt thereof, wherein each R2is independently H or hydroxy.

[0715] Embodiment 7a: The compound of any one of embodiments la-6a, or a pharmaceutically acceptable salt thereof, wherein each R3is independently H, fluoro, chloro, hydroxy, methyl or ethyl.

[0716] Embodiment 8a: The compound of any one of embodiments la-7a, or a pharmaceutically acceptable salt thereof, wherein each R3is independently H or halogen.Docket No. P60153

[0717] Embodiment 9a: The compound of any one of embodiments la-8a, or a pharmaceutically acceptable salt thereof, wherein each R3is independently H, fluoro or chloro.

[0718] Embodiment 10a: The compound of any one of embodiments la-9a, or a pharmaceutically acceptable salt thereof, wherein

[0719] R4is 1,2-benzoxazolyl,

[0720] 1,3-benzodioxolyl,

[0721] 1,3-benzothiazolyl,

[0722] 2,3-dihydro-1,4-benzodioxinyl,

[0723] benzimidazolyl substituted by C1-6alkyl,

[0724] benzothiophenyl,

[0725] benzoyl,

[0726] imidazo[1,2-a]pyridinyl,

[0727] indazolyl unsubstituted or substituted by halogen or C1-6alkyl,

[0728] indolyl substituted by C1-6alkyl,

[0729] isoindolinyl substituted by C1-6alkoxycarbonyl,

[0730] phenyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of

[0731] (hydroxyC1-6alkoxy)C1-6alkoxy,

[0732] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0733] amino,

[0734] C1-6alkoxy,

[0735] C1-6alkyl,

[0736] C1-6alkylamino,

[0737] C1-6alkylsulfanyl,

[0738] halogen,

[0739] hydroxy,

[0740] hydroxyC1-6alkoxy,

[0741] hydroxyC1-6alkyl,

[0742] hydroxyC1-6alkyl(C1-6alkyl)amino,

[0743] hydroxyC1-6alkylsulfanyl,

[0744] hydroxyhaloC1-6alkoxy,

[0745] imidazolyl substituted by C1-6alkyl,Docket No. P60153

[0746] pyrazolyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of (((hydroxyCi-6alkyl)carbonyl)(Ci-6alkyl)amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (Ci-6alkoxyCi-6alkoxy)Ci- ealkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyhaloCi- 6alkyl)Ci-6alkyl, amino, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl and hydroxyhaloC1-6alkyl,

[0747] pyrimidinyl,

[0748] pyrrolidinyl substituted by hydroxy,

[0749] tetrazolyl, and

[0750] triazolyl unsubstituted or substituted by C1-6alkyl,

[0751] pyrazinyl substituted by two substituents of amino and C1-6alkylpyrazolyl,

[0752] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino or C1-6alkylamino, pyrazolo[4,3-b]pyridinyl substituted by C1-6alkyl,

[0753] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0754] (C1-6alkyl)2amino,

[0755] 1,3,4-thiadiazolyl,

[0756] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0757] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0758] amino,

[0759] C1-6alkoxy,

[0760] C1-6alkoxycarbonyl,

[0761] C1-6alkyl,

[0762] C1-6alkylamino,

[0763] haloC1-6alkyl,

[0764] hydroxyC1-6alkoxy,

[0765] phenyl substituted by aminoC1-6alkyl or ((C1-6alkoxycarbonyl)amino)C1-6alkyl, piperidyl substituted by C1-6alkyl and hydroxyC1-6alkyl,

[0766] pyrazolyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((Ci- 6alkyl)2amino)Ci-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, amino and C1-6alkyl, pyridazinyl,Docket No. P60153

[0767] pyrimidinyl,

[0768] pyrrolidinyl,

[0769] tetrazolyl,

[0770] thieno[3,4-d]pyrimidinyl, and

[0771] triazolyl,

[0772] or pyrimidinyl substituted by one or two substituents independently selected from the group consisting of amino, C1-6alkylpyrazolyl and pyrimidinyl.

[0773] In one embodiment, the compound of any one of embodiments la-9a, or a pharmaceutically acceptable salt thereof, wherein

[0774] R4is 1,2-benzoxazolyl,

[0775] 1,3-benzodioxolyl,

[0776] 1,3-benzothiazolyl,

[0777] 2,3-dihydro-1,4-benzodioxinyl,

[0778] benzimidazolyl substituted by methyl,

[0779] benzothiophenyl,

[0780] benzoyl,

[0781] imidazo[1,2-a]pyridinyl,

[0782] indazolyl unsubstituted or substituted by fluoro or methyl,

[0783] indolyl substituted by methyl,

[0784] isoindolinyl substituted by 2-tert-butoxycarbonyl,

[0785] phenyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of

[0786] 2-(2-hydroxyethoxy)ethoxy,

[0787] 2,3-dihydropyrazolo[5,l-b]oxazol-7-yl,

[0788] amino,

[0789] methoxy,

[0790] methyl,

[0791] methylamino,

[0792] methylsulfanyl,

[0793] fluoro,

[0794] chloro,

[0795] hydroxy,

[0796] 2-hydroxyethoxy,Docket No. P60153

[0797] 2-hydroxyethyl,

[0798] 2-hydroxyethyl(methyl)amino,

[0799] 2-hydroxyethylsulfanyl,

[0800] 1, 1 -difluoro-2-hydroxy-ethoxy,

[0801] imidazolyl substituted by methyl,

[0802] pyrazolyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of 2-(l,l-difluoro-2-hydroxy-ethoxy)ethyl, 2-(2- hydroxyethoxy)ethyl, 2-(2-m ethoxy ethoxy)ethyl, 2, 2-difluoro-3 -hydroxy-propyl, 2- [(2-hydroxyacetyl)amino]ethyl, 2-[(2-hydroxyacetyl)-methyl-amino]ethyl, 2- hydroxy ethyl, 2-methoxyethyl, 3-hydroxy-2-methoxy-propyl, amino,

[0803] ethoxycarbonyl, fluoro and methyl,

[0804] pyrimidinyl,

[0805] pyrrolidinyl substituted by hydroxy,

[0806] tetrazolyl, and

[0807] triazolyl unsubstituted or substituted by methyl,

[0808] pyrazinyl substituted by two substituents of amino and l-methylpyrazol-3-yl, pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino or methylamino, pyrazolo[4,3-b]pyridinyl substituted by methyl,

[0809] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0810] dimethylamino,

[0811] 1,3,4-thiadiazolyl,

[0812] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0813] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0814] amino,

[0815] methoxy,

[0816] methoxycarbonyl,

[0817] methyl,

[0818] methylamino,

[0819] trifluoromethyl,

[0820] 2-hydroxyethoxy,

[0821] phenyl substituted by aminomethyl or (tert-butoxycarbonylamino)methyl,

[0822] piperidyl substituted by methyl and hydroxymethyl,Docket No. P60153

[0823] pyrazolyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of (tert-butoxycarbonylamino)methyl, 2- (dimethylamino)ethyl, 2-(2-hydroxyethoxy)ethyl, amino and methyl, pyridazinyl,

[0824] pyrimidinyl,

[0825] pyrrolidinyl,

[0826] tetrazolyl,

[0827] thieno[3,4-d]pyrimidinyl, and

[0828] triazolyl,

[0829] or pyrimidinyl substituted by one or two substituents independently selected from the group consisting of amino, l-methylpyrazol-4-yl and pyrimidin-2-yl.

[0830] In one embodiment, the compound of any one of embodiments la-9a, or a pharmaceutically acceptable salt thereof, wherein R4is l,2-benzoxazol-3-yl, 1,3 -benzodi oxol- 4-yl, l,3-benzodioxol-5-yl, l,3-benzothiazol-5-yl, l-methylbenzimidazol-2-yl, 1-methylindazol-3-yl, l-methylindazol-5-yl, l-methylindol-4-yl, l-methylpyrazolo[4,3-b]pyridin- 5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2-(2-hydroxyethoxy)-4-(l-methylpyrazol-3-yl)phenyl, 2-(2-hydroxyethoxy)-4-(l-methylpyrazol-4-yl)phenyl, 2-(2-hydroxyethoxy)-6-(l-methylpyrazol-3-yl)-3 -pyridyl, 2-(methylamino)-4-(l-methylimidazol-4-yl)phenyl, 2-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 2-(methylamino)-5-(l-methylimidazol-4-yl)phenyl, 2,3-dihydro-l,4-benzodioxin-6-yl, 2-amino-4-(l-methylpyrazol-3-yl)phenyl, 2-fluoro-4-(l-methylpyrazol-4-yl)phenyl, 2-methoxy-6-(l-methylpyrazol-4-yl)-3 -pyridyl, 2-tert-butoxycarbonylisoindolin-5-yl, 3-(l,l-difluoro-2-hydroxy-ethoxy)phenyl, 3-(2-hydroxyethoxy)-4-methyl-phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(2-hydroxyethyl)-4-methyl-phenyl, 3-(2-hydroxyethylsulfanyl)phenyl, 3-(methylamino)-4-(l-methylimidazol-4-yl)phenyl, 3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 3-(methylamino)-4-(l-methylpyrazol-4-yl)phenyl, 3-(methylamino)-5-(l-methylimidazol-4-yl)phenyl, 3-(methylamino)-5-(l-methylpyrazol-3-yl)phenyl, 3-[2-(2-hydroxyethoxy)ethoxy]phenyl, 3-[2-hydroxyethyl(methyl)amino]phenyl, 3-amino-4-(l-methylpyrazol-3-yl)phenyl, 3-amino-4-(l-methylpyrazol-4-yl)phenyl, 3-amino-4-(l-methyltriazol-4-yl)phenyl, 3-amino-4-(tetrazol-2-yl)phenyl, 3-amino-4-(triazol-2-yl)phenyl, 3-amino-4-[l-(2-hydroxyethyl)pyrazol-3-yl]phenyl, 3-amino-4-[l-(2-methoxyethyl)pyrazol-3-yl]phenyl, 3-amino-4-chloro-phenyl, 3-amino-4-fluoro-phenyl, 3-amino-4-pyrazol-l-yl-phenyl, 3-amino-4-pyrimidin-2-yl-phenyl, 3-hydroxy-4-Docket No. P60153

[0831] (l-methylpyrazol-3-yl)phenyl, 3-hydroxy-4-pyrimidin-2-yl-phenyl, 3 -hydroxyphenyl, 4-(l-ethoxycarbonylpyrazol-4-yl)phenyl, 4-(lH-pyrazol-4-yl)phenyl, 4-(l-methylimidazol-4-yl)phenyl, 4-(l-methylpyrazol-4-yl)phenyl, 4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl, 4-(2-hydroxyethoxy)phenyl, 4-(3-aminopyrazol-l-yl)phenyl, 4-(3-hydroxypyrrolidin-l-yl)phenyl, 4-(methylamino)-3-(l-methylimidazol-4-yl)phenyl, 4-(methylamino)pyrazolo[l,5-a]pyridin-6-yl, 4-[l-(2,2-difluoro-3-hydroxy-propyl)pyrazol-4-yl]phenyl, 4-[l-(2-hydroxyethyl)pyrazol-4-yl]-3-methyl-phenyl, 4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl, 4-[ 1 -(2-methoxyethyl)pyrazol-3-yl]-3-(methylamino)phenyl, 4-[l-(2-methoxyethyl)pyrazol-4-yl]phenyl, 4-[l-(3-hydroxy-2-methoxy-propyl)pyrazol-4-yl]phenyl, 4-[l-[2-(l,l-difluoro-2-hydroxy-ethoxy)ethyl]pyrazol-4-yl]phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]-2-methoxy-phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]-3 -methoxy-phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 4-[1-[2-(2-methoxyethoxy)ethyl]pyrazol-4-yl]phenyl, 4-[l-[2-[(2-hydroxyacetyl)amino]ethyl]pyrazol-4-yl]phenyl, 4-[l-[2-[(2-hydroxyacetyl)-methyl-amino]ethyl]pyrazol-4-yl]phenyl, 4-[3 -fluoro- 1 -(2-hydroxyethyl)pyrazol-4-yl]phenyl, 4-[3-fluoro-l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 4-[5-fluoro-l-(2-hydroxyethyl)pyrazol-4-yl]phenyl, 4-amino-5-pyrimidin-2-yl-pyrimidin-2-yl, 4-aminopyrazolo[l,5-a]pyridin-6-yl, 4-chloro-3-(2-hydroxyethoxy)phenyl, 4-chloro-3-(2-hydroxyethyl)phenyl, 4-chl oro-3 -(methylamino)phenyl, 4-chlorophenyl, 4-fluoro- 3-(2-hydroxyethoxy)phenyl, 4-fluoro-3-(methylamino)phenyl, 4-fluoro-3 -hydroxy-phenyl, 4-pyrazol- 1 -ylphenyl, 5-( 1 -methylpyrazol-4-yl)-2-pyridyl, 5-(2,3 -dihydropyrazolo[5, 1 -b]oxazol-7-yl)-6-methoxy-2-pyridyl, 5-(3-aminopyrazol-l-yl)-6-methoxy-2-pyridyl, 5-(methylamino)-3-pyridyl, 5-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]-6-methoxy-2-pyridyl, 5-[l-[2-(dimethylamino)ethyl]pyrazol-4-yl]-6-methoxy-2-pyridyl, 5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl, 5-[4-[(tert-butoxycarbonylamino)methyl]phenyl]-6-methoxy-2-pyridyl, 5-[4-[(tert-butoxycarbonylamino)methyl]pyrazol-l-yl]-6-methoxy-2-pyridyl, 6-(l-methylpyrazol- 4-yl)-3 -pyridyl, 6-(2-hydroxyethoxy)-5-methyl-2-pyridyl, 6-(dimethylamino)-3 -pyridyl, 6-(methylamino)-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-(trifluoromethyl)-3 -pyridyl, 6-[4-(hydroxymethyl)-4-methyl-l-piperidyl]-3-pyridyl, 6-amino-5-(l,3,4-thiadiazol-2-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)pyrazin-2-yl, 6-amino-5-(tetrazol-2-yl)-2-pyridyl, 6-amino-5-(triazol-2-yl)-2-pyridyl, 6-amino-5-pyrazol-l-yl-2-pyridyl, 6-amino-5-pyridazin-3-yl-2-pyridyl, 6-amino-5-pyrimidin-2-yl-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl, 6-methoxy-5-pyrazol-l-yl-2-pyridyl, 6-pyrrolidin-l-yl-3 -pyridyl, 7-(methylamino)pyrazolo[l,5-a]pyridin-6-yl, 7-aminopyrazolo[l,5-Docket No. P60153

[0832] a]pyridin-6-yl, 7-fluoro-lH-indazol-4-yl, 7-fluoro-lH-indazol-5-yl, benzothiophen-2-yl, benzoyl, imidazo[l,2-a]pyridin-6-yl, indazol-4-yl, indazol-5-yl, phenyl, pyrazolo[l,5-a]pyridin-6-yl, 3-amino-4-methylsulfanyl-phenyl, 6-amino-5-(5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl, 6-amino-5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl or 6-methoxy-5-methoxycarbonyl-2-pyridyl.

[0833] Embodiment 11a: The compound of any one of embodiments la- 10a, or a pharmaceutically acceptable salt thereof, wherein

[0834] R4is 1,3-benzodioxolyl,

[0835] phenyl substituted by one or two substituents independently selected from the group consisting of

[0836] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0837] amino,

[0838] C1-6alkylamino,

[0839] C1-6alkylsulfanyl,

[0840] hydroxy,

[0841] hydroxyC1-6alkoxy,

[0842] pyrazolyl substituted by (hydroxyC1-6alkoxy)C1-6alkyl, C1-6alkyl or hydroxyC1-6alkyl, pyrimidinyl, and

[0843] triazolyl,

[0844] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[0845] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0846] 1,3,4-thiadiazolyl,

[0847] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0848] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0849] C1-6alkoxy,

[0850] C1-6alkoxycarbonyl,

[0851] phenyl substituted by aminoC1-6alkyl,

[0852] pyrazolyl substituted by one or two substituents independently selected from the group consisting of amino and C1-6alkyl,

[0853] pyrimidinyl, and

[0854] thieno[3,4-d]pyrimidinyl,

[0855] or pyrimidinyl substituted by C1-6alkylpyrazolyl.Docket No. P60153

[0856] Embodiment 12a: The compound of any one of embodiments la-1 la, or a pharmaceutically acceptable salt thereof, wherein

[0857] R4is 1,3-benzodioxolyl,

[0858] phenyl substituted by one or two substituents independently selected from the group consisting of

[0859] 2,3-dihydropyrazolo[5,l-b]oxazol-7-yl,

[0860] amino,

[0861] methylamino,

[0862] methylsulfanyl,

[0863] hydroxy,

[0864] 2-hydroxyethoxy,

[0865] pyrazolyl substituted by 2-(2-hydroxyethoxy)ethyl, methyl or 2-hydroxyethyl, pyrimidin-2-yl, and

[0866] triazol-2-yl,

[0867] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[0868] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0869] l,3,4-thiadiazol-2-yl,

[0870] 2,3-dihydropyrazolo[5,l-b]oxazol-7-yl,

[0871] 5,7-dihydrothieno[3,4-d]pyrimidin-2-yl,

[0872] methoxy,

[0873] methoxycarbonyl,

[0874] phenyl substituted by aminomethyl,

[0875] pyrazolyl substituted by one or two substituents independently selected from the group consisting of amino and methyl,

[0876] pyrimidin-2-yl, and

[0877] thieno[3,4-d]pyrimidin-2-yl,

[0878] or pyrimidinyl substituted by 1-methylpyrazol-4-yl.

[0879] Embodiment 13a: The compound of any one of embodiments la- 12a, or a pharmaceutically acceptable salt thereof, wherein R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2-amino-4-(l-methylpyrazol-3-yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 3-amino-4-(l-methylpyrazol-3-yl)phenyl, 3-amino-4-(l-methylpyrazol-4-yl)phenyl, 3-amino-4-(triazol-2-Docket No. P60153

[0880] yl)phenyl, 3-amino-4-pyrimidin-2-yl-phenyl, 3-hydroxy-4-(l-methylpyrazol-3-yl)phenyl, 3-hydroxy-4-pyrimidin-2-yl-phenyl, 4-(l-methylpyrazol-4-yl)phenyl, 4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl, 4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2-pyridyl, 5-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl, 5-(3-aminopyrazol-l-yl)-6-methoxy-2-pyridyl, 5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl, 6-amino-5-(l,3,4-thiadiazol-2-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-amino-5-pyrimidin-2-yl-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl, 7-aminopyrazolo[l,5-a]pyridin-6-yl, pyrazolo[l,5-a]pyridin-6-yl, 3-amino-4-methylsulfanyl-phenyl, 6-amino-5-(5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl, 6-amino-5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl or 6-methoxy-5-methoxycarbonyl-2-pyridyl.

[0881] Embodiment 14a: The compound of any one of embodiments la- 13 a, or a pharmaceutically acceptable salt thereof, wherein R5is H, (3-aminophenyl)methoxymethyl, (3-nitrophenyl)methoxymethyl, 2-hydroxyethyl, benzyloxymethyl, ethyl, hydroxy, hydroxymethyl, methyl or propyl.

[0882] Embodiment 15a: The compound of any one of embodiments la-14a, or a pharmaceutically acceptable salt thereof, wherein R5is H, C1-6alkyl, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl.

[0883] Embodiment 16a: The compound of any one of embodiments la- 15a, or a pharmaceutically acceptable salt thereof, wherein R5is H, benzyloxymethyl, ethyl, hydroxymethyl or methyl.

[0884] Embodiment 17a: The compound of any one of embodiments la-14a, or a pharmaceutically acceptable salt thereof, wherein R6is H.

[0885] Embodiment 18a: The compound of any one of embodiments la- 17a, or a pharmaceutically acceptable salt thereof, wherein L1is methylene.

[0886] In one embodiment, The compound of any one of embodiments la-17a, or a pharmaceutically acceptable salt thereof, wherein L1is ethylene or methylene.

[0887] Embodiment 19a: The compound of any one of embodiments la- 18a, or a pharmaceutically acceptable salt thereof, wherein L2is a bond or methylene.

[0888] Embodiment 20a: The compound of any one of embodiments la- 19a, or a pharmaceutically acceptable salt thereof, wherein m is 1.

[0889] In one embodiment, m is 2. In one embodiment, m is 3.Docket No. P60153

[0890] Embodiment 21a: The compound of any one of embodiments l-20a, or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2.

[0891] In one embodiment, n is 1, 2 or 3. In one embodiment, m is 1, 2, 3 or 4.

[0892] Embodiment 22a: The compound of any one of embodiments la-2 la, wherein

[0893] R1is H;

[0894] each R2is independently H or hydroxy;

[0895] each R3is independently H or halogen;

[0896] R4is 1,3-benzodioxolyl,

[0897] phenyl substituted by one or two substituents independently selected from the group consisting of

[0898] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0899] amino,

[0900] C1-6alkylamino,

[0901] C1-6alkylsulfanyl,

[0902] hydroxy,

[0903] hydroxyC1-6alkoxy,

[0904] pyrazolyl substituted by (hydroxyC1-6alkoxy)C1-6alkyl, C1-6alkyl or hydroxyC1-6alkyl, pyrimidinyl, and

[0905] triazolyl,

[0906] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[0907] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0908] 1,3,4-thiadiazolyl,

[0909] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[0910] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[0911] C1-6alkoxy,

[0912] C1-6alkoxycarbonyl,

[0913] phenyl substituted by aminoC1-6alkyl,

[0914] pyrazolyl substituted by one or two substituents independently selected from the group consisting of amino and C1-6alkyl,

[0915] pyrimidinyl, and

[0916] thieno[3,4-d]pyrimidinyl,

[0917] or pyrimidinyl substituted by C1-6alkylpyrazolyl;Docket No. P60153

[0918] R5is H, C1-6alkyl, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl;

[0919] R6is H;

[0920] L1is C1-6alkylene;

[0921] L2is a bond or C1-6alkylene;

[0922] m is 1;

[0923] n is 1 or 2;

[0924] or a pharmaceutically acceptable salt thereof.

[0925] Embodiment 23a: The compound of any one of embodiments la-22a, wherein

[0926] R1is H;

[0927] each R2is independently H or hydroxy;

[0928] each R3is independently H, fluoro or chloro;

[0929] R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2-amino-4-(l-methylpyrazol-3- yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 3- amino-4-( 1 -methylpyrazol-3 -yl)phenyl, 3 -amino-4-( 1 -methylpyrazol-4-yl)phenyl, 3 -amino-4- (triazol-2-yl)phenyl, 3-amino-4-pyrimidin-2-yl-phenyl, 3-hydroxy-4-(l-methylpyrazol-3- yl)phenyl, 3-hydroxy-4-pyrimidin-2-yl-phenyl, 4-(l-methylpyrazol-4-yl)phenyl, 4-(2,3- dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl, 4-[l -(2-hydroxy ethyl)pyrazol-4-yl]phenyl, 4-[l- [2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2-pyridyl, 5-(2,3- dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl, 5-(3-aminopyrazol-l-yl)-6- methoxy-2-pyridyl, 5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl, 6-amino-5-(l,3,4- thiadiazol-2-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-amino-5-pyrimidin- 2-yl-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl, 7-aminopyrazolo[l,5- a]pyridin-6-yl, pyrazolo[l,5-a]pyridin-6-yl, 3-amino-4-methylsulfanyl-phenyl, 6-amino-5- (5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl, 6-amino-5-thieno[3,4-d]pyrimidin-2-yl-2- pyridyl or 6-methoxy-5-methoxycarbonyl-2-pyridyl;

[0930] R5is H, benzyloxymethyl, ethyl, hydroxymethyl or methyl;

[0931] R6is H;

[0932] L1is methylene;

[0933] L2is a bond or methylene;

[0934] m is 1;

[0935] n is 1 or 2;

[0936] or a pharmaceutically acceptable salt thereof.

[0937] Embodiment 24a: A compound of formula (la),Docket No. P60153

[0938]

[0939] wherein

[0940] R1is H;

[0941] R2ais H, halogen, amino or hydroxy;

[0942] R2bis H or halogen;

[0943] R2cis H;

[0944] R3ais halogen, hydroxy or C1-6alkyl;

[0945] R3bis H;

[0946] R3cis H;

[0947] R3dis H or halogen;

[0948] R4is 1,2-benzoxazolyl,

[0949] 1,3-benzodioxolyl,

[0950] 1,3-benzothiazolyl,

[0951] 2,3-dihydro-1,4-benzodioxinyl,

[0952] benzimidazolyl substituted by C1-6alkyl,

[0953] benzothiophenyl,

[0954] benzoyl,

[0955] imidazo[1,2-a]pyridinyl,

[0956] indazolyl unsubstituted or substituted by halogen or C1-6alkyl,

[0957] indolyl substituted by C1-6alkyl,

[0958] isoindolinyl substituted by C1-6alkoxycarbonyl,

[0959] phenyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of

[0960] (hydroxyC1-6alkoxy)C1-6alkoxy,

[0961] 2,3-dihydropyrazolo[5,1-b]oxazolyl,Docket No. P60153

[0962] amino,

[0963] C1-6alkoxy,

[0964] C1-6alkyl,

[0965] C1-6alkylamino,

[0966] C1-6alkylsulfanyl,

[0967] halogen,

[0968] hydroxy,

[0969] hydroxyC1-6alkoxy,

[0970] hydroxyC1-6alkyl,

[0971] hydroxyC1-6alkyl(C1-6alkyl)amino,

[0972] hydroxyC1-6alkylsulfanyl,

[0973] hydroxyhaloC1-6alkoxy,

[0974] imidazolyl substituted by C1-6alkyl,

[0975] pyrazolyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of (((hydroxyCi-6alkyl)carbonyl)(Ci-6alkyl)amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (Ci-6alkoxyCi-6alkoxy)Ci- ealkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyhaloCi- 6alkyl)Ci-6alkyl, amino, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl and hydroxyhaloC1-6alkyl,

[0976] pyrimidinyl,

[0977] pyrrolidinyl substituted by hydroxy,

[0978] tetrazolyl, and

[0979] triazolyl unsubstituted or substituted by C1-6alkyl,

[0980] pyrazinyl substituted by two substituents of amino and C1-6alkylpyrazolyl,

[0981] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino or C1-6alkylamino, pyrazolo[4,3-b]pyridinyl substituted by C1-6alkyl,

[0982] pyridyl substituted by one or two substituents independently selected from the group consisting of

[0983] (C1-6alkyl)2amino,

[0984] 1,3,4-thiadiazolyl,

[0985] 2,3-dihydropyrazolo[5,1-b]oxazolyl,

[0986] 5,7-dihydrothieno[3,4-d]pyrimidinyl,Docket No. P60153

[0987] amino,

[0988] C1-6alkoxy,

[0989] C1-6alkoxycarbonyl,

[0990] C1-6alkyl,

[0991] C1-6alkylamino,

[0992] haloC1-6alkyl,

[0993] hydroxyC1-6alkoxy,

[0994] phenyl substituted by aminoC1-6alkyl or ((C1-6alkoxycarbonyl)amino)C1-6alkyl, piperidyl substituted by C1-6alkyl and hydroxyC1-6alkyl,

[0995] pyrazolyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((Ci- 6alkyl)2amino)Ci-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, amino and C1-6alkyl, pyridazinyl,

[0996] pyrimidinyl,

[0997] pyrrolidinyl,

[0998] tetrazolyl, and

[0999] triazolyl,

[1000] or pyrimidinyl substituted by one or two substituents independently selected from the group consisting of amino, C1-6alkylpyrazolyl and pyrimidinyl;

[1001] R5is H, (aminophenyl)Ci-6alkoxyCi-6alkyl, (nitrophenyl)Ci-6alkoxyCi-6alkyl, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl;

[1002] R6is H;

[1003] L1is C1-6alkylene;

[1004] L2is a bond or C1-6alkylene;

[1005] or a pharmaceutically acceptable salt thereof.

[1006] Embodiment 25a: The compound of embodiment 24a, or a pharmaceutically acceptable salt thereof, wherein R2ais H or hydroxy.

[1007] Embodiment 26a: The compound of embodiment 24a or 25a, or a pharmaceutically acceptable salt thereof, wherein R2bis H.

[1008] Embodiment 27a: The compound of embodiment 24a or 26a, or a pharmaceutically acceptable salt thereof, wherein R3ais halogen.

[1009] Embodiment 28a: The compound of any one of embodiments 24a-27a, or a pharmaceutically acceptable salt thereof, wherein R3ais fluoro or chloro.Docket No. P60153

[1010] Embodiment 29a: The compound of any one of embodiments 24a-28a, or a pharmaceutically acceptable salt thereof, wherein R3dis H.

[1011] Embodiment 30a: The compound of any one of embodiments 24a-29a, or a pharmaceutically acceptable salt thereof, wherein

[1012] R4is 1,3-benzodioxolyl,

[1013] phenyl substituted by one or two substituents independently selected from the group consisting of

[1014] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[1015] amino,

[1016] C1-6alkylamino,

[1017] C1-6alkylsulfanyl,

[1018] hydroxy,

[1019] hydroxyC1-6alkoxy,

[1020] pyrazolyl substituted by (hydroxyC1-6alkoxy)C1-6alkyl, C1-6alkyl or hydroxyC1-6alkyl, pyrimidinyl, and

[1021] triazolyl,

[1022] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[1023] pyridyl substituted by one or two substituents independently selected from the group consisting of

[1024] 1,3,4-thiadiazolyl,

[1025] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[1026] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[1027] C1-6alkoxy,

[1028] C1-6alkoxycarbonyl,

[1029] phenyl substituted by aminoC1-6alkyl,

[1030] pyrazolyl substituted by one or two substituents independently selected from the group consisting of amino and C1-6alkyl,

[1031] pyrimidinyl, and

[1032] thieno[3,4-d]pyrimidinyl,

[1033] or pyrimidinyl substituted by C1-6alkylpyrazolyl.

[1034] Embodiment 31a: The compound of any one of embodiments 24a-30a, or a pharmaceutically acceptable salt thereof, wherein

[1035] R4is 1,3-benzodioxolyl,Docket No. P60153

[1036] phenyl substituted by one or two substituents independently selected from the group consisting of

[1037] 2,3-dihydropyrazolo[5,l-b]oxazol-7-yl,

[1038] amino,

[1039] methylamino,

[1040] methylsulfanyl,

[1041] hydroxy,

[1042] 2-hydroxyethoxy,

[1043] pyrazolyl substituted by 2-(2-hydroxyethoxy)ethyl, methyl or 2-hydroxyethyl, pyrimidin-2-yl, and

[1044] triazol-2-yl,

[1045] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[1046] pyridyl substituted by one or two substituents independently selected from the group consisting of

[1047] l,3,4-thiadiazol-2-yl,

[1048] 2,3-dihydropyrazolo[5,l-b]oxazol-7-yl,

[1049] 5,7-dihydrothieno[3,4-d]pyrimidin-2-yl,

[1050] methoxy,

[1051] methoxycarbonyl,

[1052] phenyl substituted by aminomethyl,

[1053] pyrazolyl substituted by one or two substituents independently selected from the group consisting of amino and methyl,

[1054] pyrimidin-2-yl, and

[1055] thieno[3,4-d]pyrimidin-2-yl,

[1056] or pyrimidinyl substituted by 1-methylpyrazol-4-yl.

[1057] Embodiment 32a: The compound of any one of embodiments 24a-31a, or a pharmaceutically acceptable salt thereof, wherein R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2-amino-4-(l-methylpyrazol-3-yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 3-amino-4-(l-methylpyrazol-3-yl)phenyl, 3-amino-4-(l-methylpyrazol-4-yl)phenyl, 3-amino-4-(triazol-2-yl)phenyl, 3-amino-4-pyrimidin-2-yl-phenyl, 3-hydroxy-4-(l-methylpyrazol-3-yl)phenyl, 3-hydroxy-4-pyrimidin-2-yl-phenyl, 4-(l-methylpyrazol-4-yl)phenyl, 4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl, 4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl, 4-[l-[2-Docket No. P60153

[1058] (2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2-pyridyl, 5-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl, 5-(3-aminopyrazol-l-yl)-6-methoxy-2-pyridyl, 5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl, 6-amino-5-(l,3,4-thiadiazol-2-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-amino-5-pyrimidin-2-yl-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl, 7-aminopyrazolo[l,5-a]pyridin-6-yl, pyrazolo[l,5-a]pyridin-6-yl, 3-amino-4-methylsulfanyl-phenyl, 6-amino-5-(5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl, 6-amino-5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl or 6-methoxy-5-methoxycarbonyl-2-pyridyl.

[1059] Embodiment 33a: The compound of any one of embodiments 24a-32a, or a pharmaceutically acceptable salt thereof, wherein R5is H, (3-aminophenyl)methoxymethyl, (3-nitrophenyl)methoxymethyl, 2-hydroxyethyl, benzyloxymethyl, ethyl, hydroxy, hydroxymethyl, methyl or propyl.

[1060] Embodiment 34a: The compound of any one of embodiments 24a-33a, or a pharmaceutically acceptable salt thereof, wherein R5is H, C1-6alkyl, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl.

[1061] Embodiment 35a: The compound of any one of embodiments 24a-34a, or a pharmaceutically acceptable salt thereof, wherein R5is H, benzyloxymethyl, ethyl, hydroxymethyl or methyl.

[1062] Embodiment 36a: The compound of any one of embodiments 24a-35a, or a pharmaceutically acceptable salt thereof, wherein R6is H.

[1063] Embodiment 37a: The compound of any one of embodiments 24a-36a, or a pharmaceutically acceptable salt thereof, wherein L1is methylene.

[1064] Embodiment 38a: The compound of any one of embodiments 24a-37a, or a pharmaceutically acceptable salt thereof, wherein L2is a bond or methylene.

[1065] Embodiment 39a: The compound of embodiment 24a, wherein

[1066] R1is H;

[1067] R2ais H or hydroxy;

[1068] R2bis H;

[1069] R2cis H;

[1070] R3ais halogen;

[1071] R3bis H;

[1072] R3cis H;

[1073] R3dis H;Docket No. P60153

[1074] R4is 1,3-benzodioxolyl,

[1075] phenyl substituted by one or two substituents independently selected from the group consisting of

[1076] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[1077] amino,

[1078] C1-6alkylamino,

[1079] C1-6alkylsulfanyl,

[1080] hydroxy,

[1081] hydroxyC1-6alkoxy,

[1082] pyrazolyl substituted by (hydroxyC1-6alkoxy)C1-6alkyl, C1-6alkyl or hydroxyC1-6alkyl, pyrimidinyl, and

[1083] triazolyl,

[1084] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[1085] pyridyl substituted by one or two substituents independently selected from the group consisting of

[1086] 1,3,4-thiadiazolyl,

[1087] 2,3-dihydropyrazolo[5,l-b]oxazolyl,

[1088] 5,7-dihydrothieno[3,4-d]pyrimidinyl,

[1089] C1-6alkoxy,

[1090] C1-6alkoxycarbonyl,

[1091] phenyl substituted by aminoC1-6alkyl,

[1092] pyrazolyl substituted by one or two substituents independently selected from the group consisting of amino and C1-6alkyl,

[1093] pyrimidinyl, and

[1094] thieno[3,4-d]pyrimidinyl, or

[1095] pyrimidinyl substituted by C1-6alkylpyrazolyl;

[1096] R5is H, C1-6alkyl, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl;

[1097] R6is H;

[1098] L1is C1-6alkylene;

[1099] L2is a bond or C1-6alkylene;

[1100] or a pharmaceutically acceptable salt thereof.

[1101] Embodiment 40a: The compound of embodiment 39a, wherein

[1102] R1is H;Docket No. P60153

[1103] R2ais H or hydroxy;

[1104] R2bis H;

[1105] R2cis H;

[1106] R3ais fluoro or chloro;

[1107] R3bis H;

[1108] R3cis H;

[1109] R3dis H;

[1110] R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2-amino-4-(l-methylpyrazol-3- yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 3- amino-4-( 1 -methylpyrazol-3 -yl)phenyl, 3 -amino-4-( 1 -methylpyrazol-4-yl)phenyl, 3 -amino-4- (triazol-2-yl)phenyl, 3-amino-4-pyrimidin-2-yl-phenyl, 3-hydroxy-4-(l-methylpyrazol-3- yl)phenyl, 3-hydroxy-4-pyrimidin-2-yl-phenyl, 4-(l-methylpyrazol-4-yl)phenyl, 4-(2,3- dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl, 4-[l -(2-hydroxy ethyl)pyrazol-4-yl]phenyl, 4-[l- [2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2-pyridyl, 5-(2,3- dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl, 5-(3-aminopyrazol-l-yl)-6- methoxy-2-pyridyl, 5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl, 6-amino-5-(l,3,4- thiadiazol-2-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-amino-5-pyrimidin- 2-yl-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl, 7-aminopyrazolo[l,5- a]pyridin-6-yl, pyrazolo[l,5-a]pyridin-6-yl, 3-amino-4-methylsulfanyl-phenyl, 6-amino-5- (5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl, 6-amino-5-thieno[3,4-d]pyrimidin-2-yl-2- pyridyl or 6-methoxy-5-methoxycarbonyl-2-pyridyl;

[1111] R5is H, benzyloxymethyl, ethyl, hydroxymethyl or methyl;

[1112] R6is H;

[1113] L1is methylene;

[1114] L2is a bond or methylene;

[1115] or a pharmaceutically acceptable salt thereof.

[1116] Embodiment 1: A compound of formula (I),Docket No. P60153

[1117]

[1118] wherein

[1119] R1is H or deuterium;

[1120] each R2is independently H, halogen, hydroxy, amino or C1-6alkyl;

[1121] each R3is independently H, halogen, hydroxy or C1-6alkyl;

[1122] R4is R4a, R4acarbonyl or R4aC1-6alkyl, wherein R4ais a 6-10 membered aryl, 5-10 membered heteroaryl or 3-12 membered heterocyclyl, any one of which is unsubstituted or substituted by one or two substituents independently selected from the group consisting of Ci- ealkoxycarbonyl, ((hydroxyC1-6alkoxy)C1-6alkyl)pyrazolyl, (Ci-6alkoxycarbonyl)pyrazolyl, (Ci-6alkyl)halopyrazolyl, (hydroxyCi-6alkoxy)Ci-6alkoxy, (hydroxyCi-6alkyl)imidazolyl, (hydroxyCi-6alkyl)pyrazolyl, amino, C1-6alkyl, C1-6alkoxy, C1-6alkylamino, Ci- ealkylimidazolyl, C1-6alkylpyrazolyl, C3-7cycloalkylamino, halogen, haloC1-6alkyl, hydroxy, hydroxyC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkylsulfanyl, pyrazolyl and pyrrolidinyl; R5is H, C1-6alkyl, hydroxy, hydroxyC1-6alkyl, R5aCi-6alkoxyCi-6alkyl, wherein R5ais H or phenyl unsubstituted or substituted by amino or nitro;

[1123] R6is H or C1-6alkyl;

[1124] L1is C1-6alkylene;

[1125] L2is a bond or C1-6alkylene;

[1126] m is 0, 1, 2 or 3;

[1127] n is 0, 1, 2, 3 or 4;

[1128] or a pharmaceutically acceptable salt thereof.

[1129] In one embodiment, R4is R4a.

[1130] In a further embodiment, R4is R4a, wherein R4ais a 6-10 membered aryl or 5-10 membered heteroaryl, any one of which is unsubstituted or substituted by one or two substituents independently selected from the group consisting of C1-6alkoxycarbonyl, ((hydroxyC1-6alkoxy)C1-6alkyl)pyrazolyl, (Ci-6alkoxycarbonyl)pyrazolyl, (Ci-6alkyl)halopyrazolyl, (hydroxyCi-6alkoxy)Ci-6alkoxy,Docket No. P60153

[1131] (hydroxyCi-6alkyl)imidazolyl, (hydroxyCi-6alkyl)pyrazolyl, amino, C1-6alkyl, C1-6alkoxy, C1-6alkylamino, C1-6alkylimidazolyl, C1-6alkylpyrazolyl, C3-7cycloalkylamino, halogen, haloC1-6alkyl, hydroxy, hydroxyC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkylsulfanyl, pyrazolyl and pyrrolidinyl.

[1132] In a further embodiment, R4is R4a, wherein R4ais a 6-10 membered aryl, which is unsubstituted or substituted by one or two substituents independently selected from the group consisting of C1-6alkoxycarbonyl, ((hydroxyC1-6alkoxy)C1-6alkyl)pyrazolyl, (Cn 6alkoxycarbonyl)pyrazolyl, (Ci-6alkyl)halopyrazolyl, (hydroxyCi-6alkoxy)Ci-6alkoxy, (hydroxyCi-6alkyl)imidazolyl, (hydroxyCi-6alkyl)pyrazolyl, amino, C1-6alkyl, C1-6alkoxy, C1-6alkylamino, C1-6alkylimidazolyl, C1-6alkylpyrazolyl, C3-7cycloalkylamino, halogen, haloC1-6alkyl, hydroxy, hydroxyC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkylsulfanyl, pyrazolyl and pyrrolidinyl.

[1133] Embodiment 2: The compound of embodiment 1, wherein

[1134] R1is H or deuterium;

[1135] each R2is independently H, halogen or C1-6alkyl;

[1136] each R3is independently H, halogen, hydroxy or C1-6alkyl;

[1137] R4is 1,2-benzoxazolyl,

[1138] 1,3-benzodioxolylC1-6alkyl,

[1139] 1,3-benzodioxolyl,

[1140] 1,3-benzothiazolyl,

[1141] 2,3-dihydro-1,4-benzodioxinyl,

[1142] benzimidazolyl substituted by C1-6alkyl,

[1143] benzothiophenyl,

[1144] benzoyl,

[1145] imidazo[1,2-a]pyridinyl,

[1146] indazolyl unsubstituted or substituted by halogen or C1-6alkyl,

[1147] indolyl substituted by C1-6alkyl,

[1148] isoindolinyl substituted by C1-6alkoxycarbonyl,

[1149] phenyl unsubstituted or substituted by one or two substitutions independently selected from the group consisting of ((hydroxyC1-6alkoxy)C1-6alkyl)pyrazolyl, (Cn 6alkoxycarbonyl)pyrazolyl, (Ci-6alkyl)halopyrazolyl, (hydroxyCi-6alkoxy)Ci-6alkoxy, (hydroxyCi-6alkyl)imidazolyl, (hydroxyCi-6alkyl)pyrazolyl, amino, C1-6alkyl, Ci- ealkylamino, C1-6alkylimidazolyl, C1-6alkylpyrazolyl, halogen, hydroxy, hydroxyCi- ealkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkylsulfanyl and pyrazolyl,Docket No. P60153

[1150] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino or C1-6alkylamino, pyrazolo[3,4-b]pyridinyl substituted by C1-6alkyl,

[1151] pyrazolo[4,3-b]pyridinyl substituted by C1-6alkyl,

[1152] pyridyl substituted by one or two substitutions independently selected from the group consisting of C1-6alkoxy, C1-6alkyl, C1-6alkylamino, C1-6alkylpyrazolyl, C3- 7cycloalkylamino, haloC1-6alkyl, hydroxyC1-6alkoxy and pyrrolidinyl, or pyrimidinyl substituted by C1-6alkylpyrazolyl or pyrrolidinyl;

[1153] R5is H, (aminophenyl)Ci-6alkoxyCi-6alkyl, (nitrophenyl)Ci-6alkoxyCi-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl;

[1154] R6is H or C1-6alkyl;

[1155] L1is C1-6alkylene;

[1156] L2is a bond or C1-6alkylene;

[1157] m is 0, 1, 2 or 3;

[1158] n is 0, 1, 2, 3 or 4;

[1159] or a pharmaceutically acceptable salt thereof.

[1160] Embodiment 3: The compound of any one of embodiments 1-2, or a pharmaceutically acceptable salt thereof, wherein R1is H.

[1161] Embodiment 4: The compound of any one of embodiments 1-3, or a pharmaceutically acceptable salt thereof, wherein R2is independently H, fluoro or methyl.

[1162] Embodiment 5: The compound of any one of embodiments 1-4, or a pharmaceutically acceptable salt thereof, wherein each R2is independently H or halogen.

[1163] Embodiment 6: The compound of any one of embodiments 1-3 or 5, or a pharmaceutically acceptable salt thereof, wherein each R2is independently H or fluoro.

[1164] Embodiment 7: The compound of any one of embodiments 1-6, or a pharmaceutically acceptable salt thereof, wherein each R3is independently H, fluoro, chloro, hydroxy, methyl or ethyl.

[1165] Embodiment 8: The compound of any one of embodiments 1-7, or a pharmaceutically acceptable salt thereof, wherein

[1166] R4is 1,2-benzoxazolyl,

[1167] 1, 3 -b enzodi oxoly Imethy 1,

[1168] 1,3-benzodioxolyl,

[1169] 1, 3 -b enzothi azoly 1,Docket No. P60153

[1170] 2,3-dihydro-1,4-benzodioxinyl,

[1171] benzimidazolyl substituted by methyl,

[1172] benzothiophenyl,

[1173] benzoyl,

[1174] imidazo[1,2-a]pyridinyl,

[1175] indazolyl unsubstituted or substituted by fluoro or methyl,

[1176] indolyl substituted by methyl,

[1177] isoindolinyl substituted by 2-tert-butoxycarbonyl,

[1178] phenyl unsubstituted or substituted by one or two substitutions independently selected from the group consisting of l-(2-hydroxyethyl)imidazol-4-yl, l-(2-hydroxyethyl)pyrazol-4-yl, 1- [2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl, 1-ethoxycarbonylpyrazol-4-yl, 1-methylimidazol-4-yl, l-methylpyrazol-3-yl, l-methylpyrazol-4-yl, 2-(2- hydroxyethoxy)ethoxy, 2-hydroxyethoxy, 2-hydroxyethyl, 2-hydroxyethylsulfanyl, 4- pyrazol-l-yl, 5-fluoro-l-methyl-pyrazol-4-yl, amino, chloro, fluoro, hydroxy, methyl, methylamino and pyrazol-4-yl,

[1179] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino or methylamino, pyrazolo[3,4-b]pyridinyl substituted by methyl,pyrazolo[4,3-b]pyridinyl substituted by methyl,

[1180] pyridyl substituted by one or two substitutions independently selected from the group consisting of 1-methylpyrazol-4-yl, 2-hydroxyethoxy, cyclopropylamino, methoxy, methyl, methylamino, pyrrolidin-1-yl and trifluoromethyl, or

[1181] pyrimidinyl substituted by 1-methylpyrazol-4-yl or pyrrolidinyl.

[1182] Embodiment 9: The compound of any one of embodiments 1-7, or a pharmaceutically acceptable salt thereof, wherein

[1183] R4is 1,3-benzodioxolyl,

[1184] 2,3-dihydro-1,4-benzodioxinyl,

[1185] phenyl substituted by one or two substitutions independently selected from the group consisting of ((hydroxyC1-6alkoxy)C1-6alkyl)pyrazolyl, (hydroxyCi-6alkyl)pyrazolyl, amino, C1-6alkylamino, C1-6alkylpyrazolyl and hydroxyC1-6alkoxy,

[1186] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[1187] pyridyl substituted by one or two substitutions independently selected from the group consisting of C1-6alkoxy and C1-6alkylpyrazolyl, or

[1188] pyrimidinyl substituted by C1-6alkylpyrazolyl.Docket No. P60153

[1189] Embodiment 10: The compound of any one of embodiments 1-9, or a pharmaceutically acceptable salt thereof, wherein

[1190] R4is 1,3-benzodioxolyl,

[1191] 2,3-dihydro-1,4-benzodioxinyl,

[1192] phenyl substituted by one or two substitutions independently selected from the group consisting of l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl, l-(2-hydroxyethyl)pyrazol-4-yl, amino, methylamino, l-methylpyrazol-3-yl, l-methylpyrazol-4-yl and 2-hydroxyethoxy, pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,pyridyl substituted by one or two substitutions independently selected from the group consisting of methoxy and 1-methylpyrazol-4-yl, orpyrimidinyl substituted by 1-methylpyrazol-4-yl.Embodiment 11: The compound of any one of embodiments 1-10, or a pharmaceutically acceptable salt thereof, wherein R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2,3-dihydro-l,4-benzodioxin-6-yl, 2-amino-4-(l-methylpyrazol-3-yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 3-amino-4-(l-methylpyrazol-4-yl)phenyl, 4-(l-methylpyrazol-4-yl)phenyl, 4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl, 7-aminopyrazolo[l,5-a]pyridin-6-yl or pyrazolo[l,5-a]pyridin-6-yl.

[1193] Embodiment 12: The compound of any one of embodiments 1-11, or a pharmaceutically acceptable salt thereof, wherein R5is H, (3-aminophenyl)methoxymethyl, (3-nitrophenyl)methoxymethyl, 2-hydroxyethyl, benzyloxymethyl, ethyl, hydroxy, hydroxymethyl, methoxymethyl, methyl or propyl.

[1194] Embodiment 13: The compound of any one of embodiments 1-11, or a pharmaceutically acceptable salt thereof, wherein R5is H, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl.

[1195] Embodiment 14: The compound of any one of embodiments 1-13, or a pharmaceutically acceptable salt thereof, wherein R5is H, benzyloxymethyl, ethyl, hydroxy, hydroxymethyl or methyl.

[1196] Embodiment 15: The compound of any one of embodiments 1-14, or a pharmaceutically acceptable salt thereof, wherein R6is H.

[1197] Embodiment 16: The compound of any one of embodiments 1-15, or a pharmaceutically acceptable salt thereof, wherein L1is methylene.Docket No. P60153

[1198] Embodiment 17: The compound of any one of embodiments 1-16, or a pharmaceutically acceptable salt thereof, wherein L2is a bond or methylene.

[1199] Embodiment 18: The compound of any one of embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein m is 1.

[1200] In one embodiment, m is 2. In one embodiment, m is 3.

[1201] Embodiment 19: The compound of any one of embodiments 1-18, or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2.

[1202] In one embodiment, n is 1, 2 or 3. In one embodiment, m is 1, 2, 3 or 4.

[1203] Embodiment 20: The compound of any one of embodiments 1-19, wherein

[1204] R1is H;

[1205] each R2is independently H or halogen;

[1206] each R3is independently H, halogen, hydroxy or C1-6alkyl;

[1207] R4is 1,3-benzodioxolyl,

[1208] 2,3-dihydro-1,4-benzodioxinyl,

[1209] phenyl substituted by one or two substitutions independently selected from the group consisting of ((hydroxyC1-6alkoxy)C1-6alkyl)pyrazolyl, (hydroxyCi-6alkyl)pyrazolyl, amino, C1-6alkylamino, C1-6alkylpyrazolyl and hydroxyC1-6alkoxy,

[1210] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[1211] pyridyl substituted by one or two substitutions independently selected from the group consisting of C1-6alkoxy and C1-6alkylpyrazolyl, or

[1212] pyrimidinyl substituted by C1-6alkylpyrazolyl;

[1213] R5is H, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl;

[1214] R6is H;

[1215] L1is C1-6alkylene;

[1216] L2is a bond or C1-6alkylene;

[1217] m is 1;

[1218] n is 1 or 2;

[1219] or a pharmaceutically acceptable salt thereof.

[1220] Embodiment 21: The compound of any one of embodiments 1-20, wherein

[1221] R1is H;

[1222] each R2is independently H or fluoro;

[1223] each R3is independently H, fluoro, chloro, hydroxy, methyl or ethyl;Docket No. P60153

[1224] R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2,3-dihydro-l,4-benzodioxin-6- yl, 2-amino-4-(l-methylpyrazol-3-yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4- (l-methylpyrazol-3-yl)phenyl, 3-amino-4-(l-methylpyrazol-4-yl)phenyl, 4-(l-methylpyrazol- 4-yl)phenyl, 4-[ 1 -(2-hydroxyethyl)pyrazol-4-yl]phenyl, 4-[ 1 -[2-(2- hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2-pyridyl, 6-methoxy-5- (l-methylpyrazol-4-yl)-2-pyridyl, 7-aminopyrazolo[l,5-a]pyridin-6-yl or pyrazolo[l,5- a]pyridin-6-yl, or

[1225] R5is H, benzyloxymethyl, ethyl, hydroxy, hydroxymethyl or methyl;

[1226] R6is H;

[1227] L1is methylene;

[1228] L2is a bond or methylene;

[1229] m is 1;

[1230] n is 1 or 2;

[1231] or a pharmaceutically acceptable salt thereof.

[1232] Embodiment 22: A compound of formula (la),

[1233]

[1234] wherein

[1235] R1is H;

[1236] R2ais H or halogen;

[1237] R2bis H;

[1238] R2cis H;

[1239] R3ais halogen, hydroxy or C1-6alkyl;

[1240] R3bis H;

[1241] R3cis H;

[1242] R3dis H or C1-6alkyl;Docket No. P60153

[1243] R4is 1,2-benzoxazolyl,

[1244] 1,3-benzodioxolylC1-6alkyl,

[1245] 1,3-benzodioxolyl,

[1246] 1,3-benzothiazolyl,

[1247] 2,3-dihydro-1,4-benzodioxinyl,

[1248] benzimidazolyl substituted by C1-6alkyl,

[1249] benzothiophenyl,

[1250] benzoyl,

[1251] imidazo[1,2-a]pyridinyl,

[1252] indazolyl unsubstituted or substituted by halogen or C1-6alkyl,

[1253] indolyl substituted by C1-6alkyl,

[1254] isoindolinyl substituted by C1-6alkoxycarbonyl,

[1255] phenyl unsubstituted or substituted by one or two substitutions independently selected from the group consisting of ((hydroxyC1-6alkoxy)C1-6alkyl)pyrazolyl, (Cn 6alkoxycarbonyl)pyrazolyl, (Ci-6alkyl)halopyrazolyl, (hydroxyCi-6alkoxy)Ci-6alkoxy, (hydroxyCi-6alkyl)imidazolyl, (hydroxyCi-6alkyl)pyrazolyl, amino, C1-6alkyl, Ci- ealkylamino, C1-6alkylimidazolyl, C1-6alkylpyrazolyl, halogen, hydroxy, hydroxyCi- ealkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkylsulfanyl and pyrazolyl,

[1256] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino or C1-6alkylamino, pyrazolo[3,4-b]pyridinyl substituted by C1-6alkyl,

[1257] pyrazolo[4,3-b]pyridinyl substituted by C1-6alkyl,

[1258] pyridyl substituted by one or two substitutions independently selected from the group consisting of C1-6alkoxy, C1-6alkyl, C1-6alkylamino, C1-6alkylpyrazolyl, C3- 7cycloalkylamino, haloC1-6alkyl, hydroxyC1-6alkoxy and pyrrolidinyl, or pyrimidinyl substituted by C1-6alkylpyrazolyl or pyrrolidinyl;

[1259] R5is H, (aminophenyl)Ci-6alkoxyCi-6alkyl, (nitrophenyl)Ci-6alkoxyCi-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl;

[1260] R6is H or C1-6alkyl;

[1261] or a pharmaceutically acceptable salt thereof.

[1262] Embodiment 23: The compound of embodiment 22, or a pharmaceutically acceptable salt thereof, wherein R2ais H.

[1263] Embodiment 24: The compound of embodiment 22 or 23, or a pharmaceutically acceptable salt thereof, wherein R3ais halogen.Docket No. P60153

[1264] Embodiment 25: The compound of any one of embodiments 22-24, or a pharmaceutically acceptable salt thereof, wherein R3ais fluoro or chloro.

[1265] Embodiment 26: The compound of any one of embodiments 22-25, or a pharmaceutically acceptable salt thereof, wherein R3dis H or ethyl.

[1266] Embodiment 27: The compound of any one of embodiments 22-26, or a pharmaceutically acceptable salt thereof, wherein

[1267] R4is 1,2-benzoxazolyl,

[1268] 1, 3 -b enzodi oxoly Imethy 1,

[1269] 1,3-benzodioxolyl,

[1270] 1,3-benzothiazolyl,

[1271] 2,3-dihydro-1,4-benzodioxinyl,

[1272] benzimidazolyl substituted by methyl,

[1273] benzothiophenyl,

[1274] benzoyl,

[1275] imidazo[1,2-a]pyridinyl,

[1276] indazolyl unsubstituted or substituted by fluoro or methyl,

[1277] indolyl substituted by methyl,

[1278] isoindolinyl substituted by 2-tert-butoxycarbonyl,

[1279] phenyl unsubstituted or substituted by one or two substitutions independently selected from the group consisting of l-(2-hydroxyethyl)imidazol-4-yl, l-(2-hydroxyethyl)pyrazol-4-yl, 1- [2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl, 1-ethoxycarbonylpyrazol-4-yl, 1-methylimidazol-4-yl, l-methylpyrazol-3-yl, l-methylpyrazol-4-yl, 2-(2- hydroxyethoxy)ethoxy, 2-hydroxyethoxy, 2-hydroxyethyl, 2-hydroxyethylsulfanyl, 4- pyrazol-l-yl, 5-fluoro-l-methyl-pyrazol-4-yl, amino, chloro, fluoro, hydroxy, methyl, methylamino and pyrazol-4-yl,

[1280] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino or methylamino, pyrazolo[3,4-b]pyridinyl substituted by methyl,pyrazolo[4,3-b]pyridinyl substituted by methyl,

[1281] pyridyl substituted by one or two substitutions independently selected from the group consisting of 1-methylpyrazol-4-yl, 2-hydroxyethoxy, cyclopropylamino, methoxy, methyl, methylamino, pyrrolidin-1-yl and trifluoromethyl, or

[1282] pyrimidinyl substituted by 1-methylpyrazol-4-yl or pyrrolidinyl.Docket No. P60153

[1283] Embodiment 28: The compound of any one of embodiments 22-27, or a pharmaceutically acceptable salt thereof, wherein

[1284] R4is 1,3-benzodioxolyl,

[1285] 2,3-dihydro-1,4-benzodioxinyl,

[1286] phenyl substituted by one or two substitutions independently selected from the group consisting of ((hydroxyC1-6alkoxy)C1-6alkyl)pyrazolyl, (hydroxyCi-6alkyl)pyrazolyl, amino, C1-6alkylamino, C1-6alkylpyrazolyl and hydroxyC1-6alkoxy,

[1287] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[1288] pyridyl substituted by one or two substitutions independently selected from the group consisting of C1-6alkoxy and C1-6alkylpyrazolyl, or

[1289] pyrimidinyl substituted by C1-6alkylpyrazolyl.

[1290] Embodiment 29: The compound of any one of embodiments 22-28, or a pharmaceutically acceptable salt thereof, wherein

[1291] R4is 1,3-benzodioxolyl,

[1292] 2,3-dihydro-1,4-benzodioxinyl,

[1293] phenyl substituted by one or two substitutions independently selected from the group consisting of l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl, l-(2-hydroxyethyl)pyrazol-4-yl, amino, methylamino, l-methylpyrazol-3-yl, l-methylpyrazol-4-yl and 2-hydroxyethoxy, pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,pyridyl substituted by one or two substitutions independently selected from the group consisting of methoxy and 1-methylpyrazol-4-yl, orpyrimidinyl substituted by 1-methylpyrazol-4-yl.Embodiment 30: The compound of any one of embodiments 22-29, or a pharmaceutically acceptable salt thereof, wherein R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2,3-dihydro-l,4-benzodioxin-6-yl, 2-amino-4-(l-methylpyrazol-3-yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 3-amino-4-(l-methylpyrazol-4-yl)phenyl, 4-(l-methylpyrazol-4-yl)phenyl, 4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl, 7-aminopyrazolo[l,5-a]pyridin-6-yl or pyrazolo[l,5-a]pyridin-6-yl.

[1294] Embodiment 31: The compound of any one of embodiments 22-30, or a pharmaceutically acceptable salt thereof, wherein R5is H, (3-aminophenyl)methoxymethyl, (3-Docket No. P60153

[1295] nitrophenyl)methoxymethyl, 2-hydroxyethyl, benzyloxymethyl, ethyl, hydroxy, hydroxymethyl, methoxymethyl, methyl or propyl.

[1296] Embodiment 32: The compound of any one of embodiments 22-31, or a pharmaceutically acceptable salt thereof, wherein R5is H, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl.

[1297] Embodiment 33: The compound of any one of embodiments 22-32, or a pharmaceutically acceptable salt thereof, wherein R5is H, benzyloxymethyl, ethyl, hydroxy, hydroxymethyl or methyl.

[1298] Embodiment 34: The compound of any one of embodiments 22-33, or a pharmaceutically acceptable salt thereof, wherein R6is H.

[1299] Embodiment 35: The compound of embodiment 22, wherein

[1300] R1is H;

[1301] R2ais H;

[1302] R2bis H;

[1303] R2cis H;

[1304] R3ais halogen;

[1305] R3bis H;

[1306] R3cis H;

[1307] R3dis H or C1-6alkyl;

[1308] R4is 1,3-benzodioxolyl,

[1309] 2,3-dihydro-1,4-benzodioxinyl,

[1310] phenyl substituted by one or two substitutions independently selected from the group consisting of ((hydroxyC1-6alkoxy)C1-6alkyl)pyrazolyl, (hydroxyCi-6alkyl)pyrazolyl, amino, C1-6alkylamino, C1-6alkylpyrazolyl and hydroxyC1-6alkoxy,

[1311] pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,

[1312] pyridyl substituted by one or two substitutions independently selected from the group consisting of C1-6alkoxy and C1-6alkylpyrazolyl, or

[1313] pyrimidinyl substituted by C1-6alkylpyrazolyl;

[1314] R5is H, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl;

[1315] R6is H;

[1316] L1is C1-6alkylene;

[1317] L2is a bond or C1-6alkylene;

[1318] or a pharmaceutically acceptable salt thereof.Docket No. P60153

[1319] Embodiment 36: The compound of embodiment 35, wherein

[1320] R1is H;

[1321] R2ais H;

[1322] R2bis H;

[1323] R2cis H;

[1324] R3ais fluoro or chloro;

[1325] R3bis H;

[1326] R3cis H;

[1327] R3dis H or ethyl;

[1328] R4is 1,3-benzodioxol-5-yl, 2-(1-methylpyrazol-4-yl)pyrimidin-5-yl, 2,3-dihydro-1,4-benzodioxin-6- yl, 2-amino-4-(1-methylpyrazol-3-yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4- (1-methylpyrazol-3-yl)phenyl, 3-amino-4-(1-methylpyrazol-4-yl)phenyl, 4-(1-methylpyrazol- 4-yl)phenyl, 4-[1-(2-hydroxyethyl)pyrazol-4-yl]phenyl, 4-[1-[2-(2- hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(1-methylpyrazol-4-yl)-2-pyridyl, 6-methoxy-5- (1-methylpyrazol-4-yl)-2-pyridyl, 7-aminopyrazolo[1,5-a]pyridin-6-yl or pyrazolo[1,5- a]pyridin-6-yl;

[1329] R5is H, benzyloxymethyl, ethyl, hydroxy, hydroxymethyl or methyl;

[1330] R6is H;

[1331] L1is methylene;

[1332] L2is a bond or methylene;

[1333] or a pharmaceutically acceptable salt thereof.

[1334] Embodiment 41a: A compound selected from:

[1335] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-(2-phenylethyl)indole-3-carboxamide;

[1336] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-[(1-methylindazol-3-yl)methyl]indole-3-carboxamide;

[1337] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-phenacyl-indole-3-carboxamide;

[1338] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-(2-hydroxy-2-phenyl-ethyl)indole-3-carboxamide;

[1339] 4-chloro-1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-ethyl]-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;Docket No. P60153

[1340] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-[(1-methylbenzimidazol-2-yl)methyl]indole-3-carboxamide;

[1341] N-[[2-(2,6-dioxo-3 -piperidyl)- l-oxo-isoindolin-5-yl]methyl]-4-hydroxy-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl]indole-3-carboxamide;

[1342] 1-(1,2-benzoxazol-3-ylmethyl)-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1343] 1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1344] l-benzyl-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1345] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-[(1-methylindol-4-yl)methyl]indole-3-carboxamide;

[1346] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-(imidazo[1,2-a]pyridin-6-ylmethyl)indole-3-carboxamide;

[1347] 1-benzyl-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide;

[1348] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-[[4-(1-methylpyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;

[1349] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-(l-methylpyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;

[1350] l-benzyl-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;

[1351] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl]indole-3-carboxamide;

[1352] N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-fluoro-1-[[4-(1H-pyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;

[1353] Ethyl 4-[4-[[3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]-4-fluoro-indol- 1 -yl]methyl]phenyl]pyrazole- 1 -carboxylate;

[1354] 1-[2-benzyloxy-1-[5-(1-methylpyrazol-4-yl)-2-pyridyl]ethyl]-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;

[1355] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[2-hydroxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethyl]indole-3-carboxamide;Docket No. P60153

[1356] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethoxy)phenyl]methyl]indole-3-carboxamide;

[1357] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethoxy)-4-methyl-phenyl]methyl]indole-3-carboxamide;

[1358] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-4-fluoro-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethoxy)-4-methyl-phenyl]methyl]indole-3-carboxamide;

[1359] l-[[4-chloro-3-(2-hydroxy ethoxy )phenyl]methyl]-7V-[[2-(2, 6-dioxo-3 -piperidyl)- 1-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide;

[1360] 1-[[4-chloro-3-(2-hydroxyethoxy)phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-4-fluoro-1-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide;

[1361] N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-[[3-(2-hydroxyethoxy)-4-methyl-phenyl]methyl]-4-methyl-indole-3-carboxamide;

[1362] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-fluoro-3-(2-hydroxyethoxy)phenyl]methyl]indole-3-carboxamide;

[1363] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2 -hydroxy ethyl)-4-methyl-phenyl]methyl]-4-methyl-indole-3-carboxamide;

[1364] l-[[4-chloro-3-(2 -hydroxy ethyl)phenyl]methyl]-7V-[[2-(2, 6-dioxo-3 -piperidyl)- 1-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide;

[1365] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(2 -hydroxy ethoxy)-5-methyl-2-pyridyl]methyl]-4-methyl-indole-3-carboxamide;

[1366] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-[2-(2-hydroxyethoxy)ethoxy]phenyl]methyl]indole-3-carboxamide;

[1367] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(l-phenylbutyl)indole-3-carboxamide;

[1368] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(lR)-l-[3-(2-hydroxyethoxy)phenyl]ethyl]indole-3-carboxamide;

[1369] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(lS)-l-[3-(2-hydroxyethoxy)phenyl]ethyl]indole-3-carboxamide;

[1370] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethylsulfanyl)phenyl]methyl]-4-methyl-indole-3-carboxamide;

[1371] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;Docket No. P60153

[1372] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(2-hydroxy-l -phenyl-ethyl)indole-3 -carboxamide;

[1373] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(3-hydroxy-l -phenyl-propyl)indole-3 -carboxamide;

[1374] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[2-hydroxy-l-[4-(l-methylpyrazol-4-yl)phenyl]ethyl]indole-3-carboxamide;

[1375] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]-2-[(3-nitrophenyl)methoxy]ethyl]indole-3-carboxamide;

[1376] l-[2-[(3-aminophenyl)methoxy]-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;

[1377] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl]methyl]indole-3-carboxamide;

[1378] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(methylamino)-4-(l-methylpyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;

[1379] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-(5-fluoro-l-methyl-pyrazol-4-yl)-3-(methylamino)phenyl]methyl]indole-3-carboxamide;

[1380] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(methylamino)-4-(l-methylimidazol-4-yl)phenyl]methyl]indole-3-carboxamide;

[1381] l-[[3-amino-4-(l-methylpyrazol-4-yl)phenyl]methyl]-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1382] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[2-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl]methyl]indole-3-carboxamide;

[1383] l-[[2-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1384] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[2-(methylamino)-4-(l-methylimidazol-4-yl)phenyl]methyl]indole-3-carboxamide;

[1385] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[2-(methylamino)-5-(l-methylimidazol-4-yl)phenyl]methyl]indole-3-carboxamide;

[1386] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(methylamino)-5-(l-methylimidazol-4-yl)phenyl]methyl]indole-3-carboxamide;

[1387] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(methylamino)-5-(l-methylpyrazol-3-yl)phenyl]methyl]indole-3-carboxamide;Docket No. P60153

[1388] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[7-(methylamino)pyrazolo[l,5-a]pyridin-6-yl]methyl]indole-3-carboxamide;

[1389] l-[(7-aminopyrazolo[l,5-a]pyridin-6-yl)methyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;

[1390] l-[(4-aminopyrazolo[l,5-a]pyridin-6-yl)methyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;

[1391] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-(methylamino)pyrazolo[l,5-a]pyridin-6-yl]methyl]indole-3-carboxamide;

[1392] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[5-(methylamino)-3-pyridyl]methyl]indole-3-carboxamide;

[1393] l-[(3-amino-4-chloro-phenyl)methyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide;

[1394] l-[[4-chloro-3-(methylamino)phenyl]methyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide;

[1395] l-[(3-amino-4-fluoro-phenyl)methyl]-4-chloro-7V-[[2-(2,6-di oxo-3-piperi dyl)- 1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1396] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-fluoro-3-(methylamino)phenyl]methyl]indole-3-carboxamide;

[1397] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(3-hydroxyphenyl)methyl]indole-3-carboxamide;

[1398] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(4-fluoro-3-hydroxy-phenyl)methyl]-4-methyl-indole-3-carboxamide;

[1399] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-(1H-indazol-5-ylmethyl)indole-3-carboxamide;

[1400] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-(1H-indazol-4-ylmethyl)indole-3-carboxamide;

[1401] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-[(7-fluoro-1H-indazol-4-yl)methyl]indole-3-carboxamide;

[1402] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-[(7-fluoro-1H-indazol-5-yl)methyl]indole-3-carboxamide;

[1403] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[6-(l-methylpyrazol-4-yl)-3-pyridyl]methyl]indole-3 -carboxamide;Docket No. P60153

[1404] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl]indole-3-carboxamide;

[1405] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-(l-methylimidazol-4-yl)phenyl]methyl]indole-3-carboxamide;

[1406] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[2-(l-methylpyrazol-4-yl)pyrimidin-5-yl]methyl]indole-3-carboxamide;

[1407] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(4-pyrazol-l-ylphenyl)methyl]indole-3-carboxamide;

[1408] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-7-ethyl-4-fluoro-l-[[4-(l-methylpyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;

[1409] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[2-fluoro-4-(l-methylpyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;

[1410] l-[(4-chlorophenyl)methyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3 -carboxamide;

[1411] l-(benzothiophen-2-ylmethyl)-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3 -carboxamide;

[1412] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(tri fluoromethyl)-3 -pyridyl]methyl]indole-3 -carboxamide;

[1413] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-methyl-l-[(l-methylindazol-5-yl)methyl]indole-3 -carboxamide;

[1414] l-(l,3-benzothiazol-5-ylmethyl)-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3 -carboxamide;

[1415] l-[2-(l,3-benzodioxol-5-yl)-3-hydroxy-propyl]-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1416] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(6-pyrrolidin-l-yl-3-pyridyl)methyl]indole-3-carboxamide;

[1417] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[(l-methylpyrazolo[4,3-b]pyridin-5-yl)methyl]indole-3-carboxamide;

[1418] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[(l-methylindazol-5-yl)methyl]indole-3 -carboxamide;

[1419] tert-butyl 5-[[3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]-4-fluoro-indol-l-yl]methyl]isoindoline-2-carboxylate;Docket No. P60153

[1420] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[2-methoxy-6-(l-methylpyrazol-4-yl)-3-pyridyl]methyl]indole-3 -carboxamide;

[1421] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-(methylamino)-3-(l-methylimidazol-4-yl)phenyl]methyl]indole-3-carboxamide;

[1422] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(lS)-l-[3-(2-hydroxyethoxy)phenyl]propyl]indole-3-carboxamide;

[1423] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;

[1424] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4,6-difluoro-l-[[4-[l-(2-hydroxy ethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;

[1425] 4-chloro-l-[[3-(l,l-difluoro-2-hydroxy-ethoxy)phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1426] l-[[4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;

[1427] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[2-(2-hydroxyethoxy)-4-(l-methylpyrazol-4-yl)phenyl]methyl]indole-3 -carboxamide;

[1428] l-[[3-amino-4-[l-(2-methoxyethyl)pyrazol-3-yl]phenyl]methyl]-4-chloro-N-[[2-(2,6-di oxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1429] l-[(3-amino-4-pyrimidin-2-yl-phenyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1430] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-[2-[(2-hydroxyacetyl)-methyl-amino]ethyl]pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;

[1431] l-[2-(l,3-benzodioxol-5-yl)ethyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy- 1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1432] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[(lS)-l-[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]propyl]indole-3-carboxamide;

[1433] 1-[[6-amino-5-(1-methylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1434] 1-[[3-amino-4-(1-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[[2-[(3R)-2,6-dioxo-3-piperidyl]-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1435] 1-[[3-amino-4-(1-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[[2-[(3S)-2,6-dioxo-3-piperidyl]-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;Docket No. P60153

[1436] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]-3-methoxy-phenyl]methyl]indole-3-carboxamide;

[1437] N-[[4-amino-2-(2,6-di oxo-3 -piperidyl)- l-oxo-isoindolin-5-yl]methyl]-4-chl oro-1 -(pyrazolo[l,5-a]pyridin-6-ylmethyl)indole-3-carboxamide;

[1438] 1-[[3-amino-4-(1-methyltriazol-4-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1439] 1-[(3-amino-4-pyrazol-1-yl-phenyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1440] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(6-methoxy-5-pyrazol-l-yl-2-pyridyl)methyl]indole-3 -carboxamide;

[1441] l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-4-fluoro-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;

[1442] 1-[[6-amino-5-(triazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1443] 1-[[6-amino-5-(1-methylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-6-fluoro-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1444] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl]indole-3-carboxamide;

[1445] 1-[1-[6-amino-5-(1-methylpyrazol-3-yl)-2-pyridyl]ethyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1446] l-[(6-amino-5-pyridazin-3-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1447] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]-l-(pyrazolo[l,5-a]pyridin-6-ylmethyl)indole-3-carboxamide;

[1448] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4,7-difluoro-l-[[4-[l-(2-hydroxy ethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;

[1449] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[2-[2-(2-hydroxyethoxy)-4-(l-methylpyrazol-3-yl)phenyl]ethyl]indole-3-carboxamide;

[1450] 1-[[3-amino-4-[1-(2-methoxyethyl)pyrazol-3-yl]phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;

[1451] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-[2-[(2-hydroxyacetyl)amino]ethyl]pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;Docket No. P60153

[1452] N-[[2-(2,6-dioxo-3-piperidyl)-4-fluoro-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;

[1453] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[5-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]-6-methoxy-2-pyridyl]methyl]indole-3-carboxamide;

[1454] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]-2-methoxy-phenyl]methyl]indole-3-carboxamide;

[1455] l-[[3-amino-4-(triazol-2-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1456] l-[[3-amino-4-(tetrazol-2-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1457] l-[[4-(3-aminopyrazol-l-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1458] 1-[[3-amino-4-[1-(2-hydroxyethyl)pyrazol-3-yl]phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1459] l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1460] 1-[[5-(3-aminopyrazol-1-yl)-6-methoxy-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1461] tert-butyl N-[[l-[6-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]-2-methoxy-3-pyridyl]pyrazol-4-yl]methyl]carbamate; 1-[[6-amino-5-(1-methylpyrazol-3-yl)pyrazin-2-yl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1462] 1-[(6-amino-5-pyrazol-1-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1463] l-[(4-amino-5-pyrimidin-2-yl-pyrimidin-2-yl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1464] l-[[6-amino-5-(tetrazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1465] l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1466] l-[[4-[l-(2,2-difluoro-3-hydroxy-propyl)pyrazol-4-yl]phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;Docket No. P60153

[1467] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[3-hydroxy-l-[4-(l-methylpyrazol-4-yl)phenyl]propyl]indole-3-carboxamide;

[1468] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[2-(2-hydroxyethoxy)-4-(l-methylpyrazol-3-yl)phenyl]methyl]indole-3 -carboxamide;

[1469] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[2-[4-(2-hydroxyethoxy)phenyl]ethyl]indole-3-carboxamide;

[1470] 4-chloro-N-[l-[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]ethyl]-l-[[3-(2-hydroxyethoxy)phenyl]methyl]indole-3-carboxamide;

[1471] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[2-(2-hydroxyethoxy)-6-(l-methylpyrazol-3-yl)-3-pyridyl]methyl]indole-3 -carboxamide;

[1472] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[2-[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;

[1473] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[2-[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;

[1474] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-hydroxy-4-(l-methylpyrazol-3-yl)phenyl]methyl]indole-3 -carboxamide;

[1475] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(3-hydroxy-4-pyrimidin-2-yl-phenyl)methyl]indole-3-carboxamide;

[1476] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(lS)-l-[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;

[1477] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[2-[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;

[1478] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[(lS)-l-[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;

[1479] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-(3-hydroxypyrrolidin-l-yl)phenyl]methyl]indole-3 -carboxamide;

[1480] l-(l,3-benzodioxol-4-ylmethyl)-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3 -carboxamide;

[1481] l-(l,3-benzodioxol-5-ylmethyl)-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3 -carboxamide;

[1482] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;Docket No. P60153

[1483] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-fluoro-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;

[1484] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-[4-(hydroxymethyl)-4-methyl-l-piperidyl]-3-pyridyl]methyl]indole-3 -carboxamide;

[1485] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(lS)-l-[3-[2-hydroxyethyl(methyl)amino]phenyl]ethyl]indole-3-carboxamide;

[1486] N-[[2-(2,6-di oxo-3 -piperidyl)-4-fluoro- 1 -oxo-isoindolin-5-yl]methyl]-4-fluoro- 1 - [ [4- [ 1 -(2-hydroxyethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;

[1487] N-[[2-(2,6-dioxo-3-piperidyl)-4-fluoro-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethoxy)phenyl]methyl]-2,4-dimethyl-indole-3-carboxamide;

[1488] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[3-fluoro-l-(2-hydroxy ethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;

[1489] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[l-(2-hydroxyethyl)pyrazol-4-yl]-3-methyl-phenyl]methyl]indole-3-carboxamide;

[1490] l-[[4-[l-[2-(l,l-difluoro-2-hydroxy-ethoxy)ethyl]pyrazol-4-yl]phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;

[1491] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[5-fluoro-l-(2-hydroxy ethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;

[1492] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-(2-methoxyethyl)pyrazol-3-yl]-3-(methylamino)phenyl]methyl]indole-3-carboxamide;

[1493] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]-l-[[4-(l-methylpyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;

[1494] N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[l-(2-methoxy ethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;

[1495] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]-l-[2-[4-[l-[2-(2-methoxyethoxy)ethyl]pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;

[1496] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[(lR)-l-[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]propyl]indole-3-carboxamide;

[1497] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(methylamino)-5-(l-methylpyrazol-3-yl)-2-pyridyl]methyl]indole-3-carboxamide;

[1498] l-[2-[3-amino-4-(l-methylpyrazol-3-yl)phenyl]ethyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;Docket No. P60153

[1499] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[3-fluoro-l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;

[1500] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-(3-hydroxy-2-methoxy-propyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;

[1501] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[(lS)-l-[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;

[1502] l-[[6-amino-5-(l,3,4-thiadiazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1503] l-[[5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-di oxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1504] tert-butyl N-[[4-[6-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]-2-methoxy-3-pyridyl]phenyl]methyl]carbamate;

[1505] 4-chloro-l-[[4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1506] 4-chloro-l-[[5-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1507] 4-chloro-l-[[6-(dimethylamino)-3-pyridyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1508] 4-chloro-l-[[5-[l-[2-(dimethylamino)ethyl]pyrazol-4-yl]-6-methoxy-2-pyridyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1509] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(lR)-l-[3-(2-hydroxyethoxy)phenyl]propyl]indole-3-carboxamide;

[1510] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(2 -hydroxy ethoxy)-5-methyl-2-pyridyl]methyl]-4,7-dimethyl-indole-3-carboxamide;

[1511] l-[(3-amino-4-chloro-phenyl)methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4,7-dimethyl-indole-3-carboxamide;

[1512] l-[(3-amino-4-methylsulfanyl-phenyl)methyl]-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1513] l-[[6-amino-5-(5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl]methyl]-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1514] l-[(6-amino-5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-7V-[[2-(2,6-di oxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;Docket No. P60153

[1515] methyl 6-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]-2-methoxy-pyridine-3-carboxylate;

[1516] l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-7V-[l-[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1517] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(methylamino)-5-pyrimidin-2-yl-2-pyridyl]methyl]indole-3-carboxamide;

[1518] l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-N-[(lR)-l-[2-[(3R)-2,6-di oxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1519] l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-N-[(lR)-l-[2-[(3S)-2,6-di oxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1520] l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-N-[(lS)-l-[2-[(3R)-2,6-di oxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1521] l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-N-[(lS)-l-[2-[(3S)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1522] l-[[6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[(lR)-l-[2-[(3R)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1523] l-[[6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[(lR)-l-[2-[(3S)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1524] l-[[6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[(lS)-l-[2-[(3R)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamidel;

[1525] l-[[6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[(lS)-l-[2-[(3 S)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1526] l-[(3-amino-4-pyrimidin-2-yl-phenyl)methyl]-4-chloro-N-[(lR)-l-[2-[(3R)-2,6-di oxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1527] l-[(3-amino-4-pyrimidin-2-yl-phenyl)methyl]-4-chloro-N-[(lR)-l-[2-[(3 S)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1528] l-[(3-amino-4-pyrimidin-2-yl-phenyl)methyl]-4-chloro-N-[(l S)-l-[2-[(3R)-2, 6-di oxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1529] l-[(3-amino-4-pyrimidin-2-yl-phenyl)methyl]-4-chloro-N-[(lS)-l-[2-[(3S)-2, 6-di oxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1530] l-[[3-amino-4-(l-methylpyrazol -3-yl)phenyl]methyl]-4-chloro-N-[(lR)-l-[2-[(3R)-2, 6-di oxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;Docket No. P60153

[1531] l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[(lR)-l-[2-[(3 S)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1532] l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-~{N}-[(l~{S})-l-[2-[(3~{R})-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1533] l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[(lS)-l-[2-[(3S)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1534] l-[[6-amino-5-(5-methylsulfinylpyrimidin-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1535] l-[[6-amino-5-(l-methylpyrazol -3-yl)-2-pyridyl]methyl]-4-chloro-N-[l-[2-(2,6-di oxo-3-piperidyl)-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1536] l-[[6-amino-5-(l-methylpyrazol -3-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-di oxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1537] l-[[6-amino-5-(5-methylsulfanylpyrimidin-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1538] l-[[6-amino-5-(5-methyl-l,3,4-oxadiazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1539] l-[[6-amino-5-(5-methyloxazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-di oxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1540] l-[[6-amino-5-(6,7-dihydro-4H-pyrazolo[5,l-c][l,4]oxazin-2-yl)-2-pyridyl]methyl]-4-chloro- N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1541] l-[[6-amino-5-(5-methyl-l,3,4-thiadiazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1542] l-[[6-amino-5-(6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1543] l-[(6-amino-5-oxazol-2-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1544] l-[[6-amino-5-(l-methyl-l,2,4-triazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1545] l-[(6-amino-5-pyrimidin-4-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1546] l-[(6-amino-5-thiazol-2-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-di oxo-3-piperi dyl)- 1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;Docket No. P60153

[1547] l-[[6-amino-5-(2-pyridyl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1548] 1 -[(6-amino-5-pyrazin-2-yl-2-pyridyl)methyl]-4-chl oro-N-[[2-(2,6-di oxo-3 -piperidyl)- 1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1549] l-[[6-amino-5-(5-methyl-6,7-dihydro-4H-pyrazolo[l,5-a]pyrazin-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1550] l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-7-fluoro-indole-3-carboxamide;

[1551] l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1552] l-[[3-amino-4-(6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide; l-[[3-amino-4-(6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1553] l-[[3-amino-4-(l-methyl-l,2,4-triazol-3-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1554] l-[(3-amino-4-pyrimidin-4-yl-phenyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)- 1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1555] l-[(3-amino-4-thieno[3,4-d]pyrimidin-2-yl-phenyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1556] l-[(6-amino-5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1557] l-[[3-amino-4-[6-(2-hydroxyacetyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1558] methyl 4-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]-2-hydroxy -benzoate;

[1559] methyl 4-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]-2-hydroxy -benzoate;

[1560] l-[[3-amino-4-(5-carbamoylpyrimidin-2-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1561] l-[[3-amino-4-(4-carbamoylpyrimidin-2-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;Docket No. P60153

[1562] methyl 2-[2-amino-4-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]phenyl]pyrimidine-5-carboxylate;

[1563] methyl 2-amino-4-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol- 1 -yl]methyl]benzoate;

[1564] methyl 2-amino-4-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol- 1 -yl]methyl]benzoate;

[1565] l-[(6-amino-5-isoxazol-3-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1566] methyl 2-amino-6-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]pyridine-3 -carboxylate;

[1567] methyl 2-amino-6-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]pyridine-3 -carboxylate;

[1568] l-[[6-amino-5-(6-oxo-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1569] l-[[6-amino-5-(6,6-di oxo-5, 7-dihydrothi eno[3, 4-d]pyrimidin-2-yl)-2-pyri dyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1570] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-hydroxy-4-(6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl)phenyl]methyl]indole-3-carboxamide;

[1571] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-hydroxy-4-(6-methylpyrrolo[3,4-d]pyrimidin-2-yl)phenyl]methyl]indole-3-carboxamide;

[1572] l-[[6-amino-5-(5-methyltetrazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1573] l-[[6-amino-5-(l-tetrahydrothiophen-3-ylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1574] l-[(lS)-l-(6-amino-5-pyrimidin-2-yl-2-pyridyl)ethyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1575] l-[(lR)-l-(6-amino-5-pyrimidin-2-yl-2-pyridyl)ethyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;

[1576] 4-chl oro-1 -[[5-(6,7-dihy dro-5H-pyrazolo[5,l-b][ 1, 3] oxazin-3 -yl)-6-methoxy-2-pyridyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carb oxami de;

[1577] l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-N-[[2-(2,6-di oxo-3-piperi dyl)- 1-oxo-isoindolin-5-yl]methyl]-4,6-difluoro-indole-3-carboxamide;Docket No. P60153

[1578] 4-chl oro-1 -[[5-(2,3-dihy dropyrazolo[5,l -b]oxazol-7-yl)-6-methoxy-2-pyridyl]methyl]-N-[l -[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1579] l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[l-[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;

[1580] l-[[3-amino-4-[l-(cyanomethyl)pyrazol-3-yl]phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide; and

[1581] l-[[3-amino-4-[6-(2-hydroxyacetyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]phenyl]methyl]- 4-chloro-N-[l-[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide

[1582] or a pharmaceutically acceptable salt thereof.

[1583] Embodiment 42a: A process for the preparation of a compound according to any one of embodiments 1-37 or la-41a comprising the following step:

[1584] a) coupling of compound (VI),

[1585]

[1586] (VI), with compound (VII),

[1587]

[1588] the presence of a suitable coupling reagent and a suitable base;

[1589] wherein

[1590] in step a), the coupling reagent is T3P, HATU, PyBOP or EDCI / HOBt; the base is TEA, DIEPA or DMAP;

[1591] R1, R4, R5, R6, R2a, R2b, R2c, R3a, R3b, R3c, R3d, L1and L2are defined as in any one of embodiments 1-36 or la-40a.

[1592] Embodiment 43 a: A compound according to any one of embodiments 1-37 or la-4 la or lb-42b, or a pharmaceutically acceptable salt thereof, when manufactured according to a process of embodiment 38 or 42a.Docket No. P60153

[1593] Embodiment 44a: A pharmaceutical composition comprising a compound in accordance with any one of embodiments 1-37 or la-41a or lb-42b and a pharmaceutically acceptable excipient.

[1594] Embodiment 45a: A compound or pharmaceutically acceptable salt according to any one of embodiments 1-37 or la-41a or lb-42b for use as therapeutically active substance.

[1595] Embodiment 46a: The use of a compound according to any one of embodiments 1-37 or la-41a or lb-42b, or a pharmaceutically acceptable salt thereof, for the treatment or prophylaxis of cancer, wherein the cancer is hematological malignancies, gastric cancer, esophageal cancer, colorectal cancer, pancreatic ductal adenocarcinoma, lung cancer, ovarian cancer, breast cancer, prostate cancer or glioblastoma.

[1596] Embodiment 47a: The use of a compound according to any one of embodiments 1-37 or la-41a or lb-42b, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prophylaxis of cancer, wherein the cancer is hematological malignancies, gastric cancer, esophageal cancer, colorectal cancer, pancreatic ductal adenocarcinoma, lung cancer, ovarian cancer, breast cancer, prostate cancer or glioblastoma.

[1597] Embodiment 48a: The use according to embodiment 46a or 47a, wherein the cancer is lung cancer or breast cancer.

[1598] Embodiment 49a: The use according to any one of embodiments 46a-48a, wherein the cancer is lung cancer or breast cancer.

[1599] Embodiment 50a: A compound according to any one of embodiments 1-37 or la-41a or lb-42b, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancer, wherein the cancer is lung cancer or breast cancer.

[1600] Embodiment 51a: A method of treating cancer in a subject in need thereof, wherein the cancer is lung cancer or breast cancer, and wherein the method comprises administering a therapeutically effective amount of a compound according to any one of claims 1-37 or la-4 la or lb-42b, or a pharmaceutically acceptable salt thereof, to the subject.

[1601] PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION

[1602] Another embodiment provides pharmaceutical compositions or medicaments containing the compounds of the invention and a therapeutically inert carrier, diluent or excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments. In one example, compounds of formula (I) may be formulated by mixing at ambient temperature at theDocket No. P60153

[1603] appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form. The pH of the formulation depends mainly on the particular use and the concentration of compound but preferably ranges anywhere from about 3 to about 8. In one example, a compound of formula (I) is formulated in an acetate buffer, at pH 5. In another embodiment, the compounds of formula (I) are sterile. The compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.

[1604] Compositions are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The “effective amount” of the compound to be administered will be governed by such considerations and is the minimum amount necessary to induce proximity between GSPT1 and E3 ubiquitin ligase, leading to GSPT1 ubiquitination and its proteasomal degradation. This affects protein translation and leads to ribosome stalling and activation of the integrated stress response, which can trigger apoptosis in cells. Cancer cells, reliant on rapid protein synthesis, are more sensitive to GSPT1 loss. Selective toxicity spares normal cells due to differential stress response thresholds. For example, such amount may be below the amount that is toxic to normal cells, or the mammal as a whole.

[1605] In one example, the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.01 to 100 mg / kg, alternatively about 0.1 to 20 mg / kg of patient body weight per day, with the typical initial range of compound used being 0.3 to 15 mg / kg / day. In another embodiment, oral unit dosage forms, such as tablets and capsules, preferably contain from about 25 to about 100 mg of the compound of the invention.

[1606] The compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal, epidural, and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.

[1607] The compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventionalDocket No. P60153

[1608] in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents.

[1609] A typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C., et al., Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al.

[1610] Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).

[1611] An embodiment, therefore, includes a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof. In a further embodiment includes a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.

[1612] Another embodiment includes a pharmaceutical composition comprising a compound of formula (I) for use in the treatment of a hyperproliferative disease. Another embodiment includes a pharmaceutical composition comprising a compound of formula (I) for use in the treatment of cancer.

[1613] INDICATIONS AND METHODS OF TREATMENT

[1614] The compounds of the invention bind to and reshape the surface of cereblon (CRBN) and induce the binding of GSPT1, leading to a ternary complex formation. This leads to the ubiquitination of GSPT1 and its subsequent proteasomal degradation. By degrading GSPT1, these treatments can disrupt protein synthesis and induce apoptosis in cancer cells. GSPT1 overexpression has been implicated in several cancer types, particularly those with rapid proliferation, dysregulated protein synthesis, or resistance to conventional therapies. In one embodiment, the compounds can be used for the treatment of cancers, including hematological malignancies, gastric cancer, esophageal cancer, colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), lung cancer, ovarian cancer, breast cancer, prostate cancer andDocket No. P60153

[1615] glioblastoma (GBM). In one embodiment, compounds of the invention are useful for the treatment of cancer, wherein the cancer is hematological malignancies, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), multiple myeloma (MM), and diffuse large B-cell lymphoma (DLBCL). In one embodiment, compounds of the invention are useful for the treatment of cancer, wherein the cancer is lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). In one embodiment, compounds of the invention are useful for the treatment of cancer, wherein the cancer is gastric cancer. In one embodiment, compounds of the invention are useful for the treatment of cancer, wherein the cancer is esophageal cancer. In one embodiment, compounds of the invention are useful for the treatment of cancer, wherein the cancer is colorectal cancer (CRC). In one embodiment, compounds of the invention are useful for the treatment of cancer, wherein the cancer is pancreatic ductal adenocarcinoma (PDAC). In one embodiment, compounds of the invention are useful for the treatment of cancer, wherein the cancer is ovarian cancer. In one embodiment, compounds of the invention are useful for the treatment of cancer, wherein the cancer is breast cancer. In one embodiment, compounds of the invention are useful for the treatment of cancer, wherein the cancer is prostate cancer. In one embodiment, compounds of the invention are useful for the treatment of cancer, wherein the cancer is glioblastoma (GBM).

[1616] Another embodiment includes a method of treating or preventing cancer in a mammal in need of such treatment, wherein the method comprises administering to said mammal a therapeutically effective amount of a compound of formula (I), a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof.

[1617] SYNTHESIS

[1618] The compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular, R1, R4, R5, R6, R2a, R2b, R2c, R3a, R3b, R3c, R3d, L1and L2are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.

[1619] General synthetic routes for preparing the compound of formula (I) are shown below.

[1620] Scheme 1Docket No. P60153

[1621]

[1622] Substitution of compound of formula (IV) with compound (XII) in the presence of a suitable base, such as NaH, K2CO3, in a suitable solvent, such as DFM, THF, affords the compound of formula (V). Compound (V) can also be obtained by condensation of compound of formula (IV) with compound of formula (XIII) via Mitsunobu reaction by using a suitable condensation reagent, such as CMBP. Hydrolysis of the compound of formula (V) with a suitable base, such as LiOH, affords the compound of formula (VI). Coupling compound (VI) with compound (VII) in the presence of a suitable coupling reagent(s), such as T3P, HATU, PyBOP and EDCI / HOBt, a suitable base, such as TEA, DIEPA and DMAP, affords compound of formula (la).

[1623] The compound (VI) can also be obtained by substitution of compound of formula (IX) with compound (XII) in the presence of a suitable base, such as NaH, K2CO3.

[1624] Alternatively Compound (VI) can also be obtained by the following approach: substitution of compound of formula (X) with compound (XII) can be achieved with suitable base, such as NaH, K2CO3, to afford the compound of formula (XI). Oxidation of compound (XI) with suitable oxidant, such as sodium chlorite, afford the compound (VI).Docket No. P60153

[1625] In case R2a, R2b, R2c, R3a, R3b, R3c, R3d, L2, R4or R5containing an amino or hydroxy group with a protection group, such as THP, TMS, Bn or Boc, the compound can be further deprotected to give the corresponding amino or hydroxy derivatives in the presence of an acid, such as TFA, or under hydrogenation condition with a catalyst, such as Pd / C and Pd(OH)2 / C.

[1626] A process for the preparation of a compound comprising the following step:

[1627] a) coupling of compound (VI),

[1628]

[1629] (VI), with compound (VII),

[1630]

[1631] the presence of a suitable coupling reagent and a suitable base;

[1632] wherein

[1633] in step a), the coupling reagent is T3P, HATU, PyBOP or EDCI / HOBt; the base is TEA, DIEPA or DMAP;

[1634] R1, R4, R5, R6, R2a, R2b, R2c, R3a, R3b, R3c, R3d, L1and L2are defined as above.

[1635] EXAMPLES

[1636] The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.

[1637] ABBREVIATIONS BCI3: Boron trichloride

[1638] BBr3: Boron tribromide

[1639] Brett Phos Pd G4: Palladium, [dicyclohexyl[3,6-dimethoxy-2',4',6'-tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine-κP](methanesulfonato-κO)[2'-(methylamino-κN)[1,1'-biphenyl]-2-yl-κC]-, (SP-4-3)- (ACI)Docket No. P60153

[1640] (BOC)2O: tert-butoxycarbonyl tert-butyl carbonate

[1641] CaCl2: Calcium chloride

[1642] CMBP: 2-(tributyl-λ5-phosphanylidene)acetonitrile

[1643] CDC13: Chloroform -d

[1644] DBAD: benzyl N-benzyloxycarbonyliminocarbamate

[1645] DCE: 1,2-Dichloroethane

[1646] DMAc or DMA: N,N-Dimethylacetamide

[1647] EtOH: Ethanol

[1648] FA: Formic acid

[1649] HFIP: 1, 1, 1, 3,3, 3 -Hexafluoro-2-propanol

[1650] LiAlH4: Lithium Aluminum Hydride

[1651] LDA: Lithium diisopropylamide

[1652] LiBH4: Lithium borohydride

[1653] MTBE: tert-Butyl methyl ether

[1654] MeOTf: methyl trifluoromethanesulfonate

[1655] NaBH4: Sodium borohydride

[1656] NMI: 1 -Methylimidazole

[1657] n-BuLi: n-Butyllithium

[1658] Pd(dppf)Cl2·CH2Cl2: 1,1'-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex Pd(dppf)Cl2: 1,1'-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride

[1659] Pd(amphos)2Cl2: Bis(di-tert-butyl(4- dimethylaminophenyl)phosphine)dichloropalladium (II) PE: petroleum ether

[1660] PTSA: para-Toluenesulfonic acid

[1661] Pd(PPh3)4: Tetrakis(triphenylphosphine)palladium

[1662] Pd2(dba)3: Tris(dibenzylideneacetone)dipalladium

[1663] SnCl2.2H2O: Stannous chloride dihydrate

[1664] TCFH: Tetramethylchloroformamidinium hexafluorophosphate TBAI: Tetrabutylammonium iodide

[1665] T4P: 2,4,6-tributyl-1,3,5,2λ5,4λ5,6λ5-trioxatriphosphinane 2,4,6-trioxideDocket No. P60153

[1666] TBAF: Tetrabutylammonium fluoride

[1667] TFAA: Trifluoroacetic anhydride

[1668] X-PHOS-Pd-G4: Palladium, [dicyclohexyl[2',4',6'-tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine](methanesulfonato-κO)[2'-(methylamino-κN)[1,1'-biphenyl]-2-yl-κC]-, (SP-4-3)- (ACI) 4Me-t-BuXphos: di-tert-butyl(2',4',6'-triisopropyl-3,4,5,6-tetramethyl-[l,l'- biphenyl]-2-yl)phosphane

[1669] tBuXPhos pd G3: [2'-(Amino)[1,1'-biphenyl]-2-yl][bis(1,1-dimethylethyl)[2',4',6'-tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine](methanesulfonato)palladium

[1670] BINOL: [1,1 '-binaphthal ene]-2,2'-diol

[1671] DPPH: 2,2-diphenyl- 1 -(2,4,6-trinitrophenyl)-hydrazinyl Ir[dF(CF3)ppy]2(dtbpy)(PF6): [4,4'-Bis(1,1-dimethylethyl)-2,2'-bipyridine-N1,N1']bis[3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridinyl-N]phenylC]Iridium(III) hexa

[1672] NiCl2.dtbbpy: [4,4'-bis(1,1-dimethylethyl)-2,2'-bipyridine] Nickel (II)

[1673] di chloride

[1674] Ruphos Pd G4: Methanesulfonato(2-dicyclohexylphosphino-2,6-di-i- propoxy- 1, 1 -biphenyl)(2 -methylamino- 1, 1 -biphenyl-2- yl)palladium(II)

[1675] GENERAL EXPERIMENTAL CONDITIONS

[1676] Intermediates and final compounds were purified by flash chromatography using one of the following instruments: i) Biotage SP1 system and the Quad 12 / 25 Cartridge module, ii) ISCO combi-flash chromatography instrument. Silica gel brand and pore size: i) KP-SIL 60 A, particle size: 40-60 pm; ii) CAS registry NO: Silica Gel: 63231-67-4, particle size: 47-60 micron silica gel; iii) ZCX from Qingdao Haiyang Chemical Co., Ltd, pore: 200-300 or 300-400.

[1677] Intermediates and final compounds were purified by preparative HPLC on reversed phase column using XBridge™ Prep-C18 (5 pm, OBDTM 30 x 100 mm) column, SunFire™ Prep-C18 (5 pm, OBD™ 30 x 100 mm) column, Phenomenex Synergi-C18 (10 pm, 25 x 150 mm) or Phenomenex Gemini-C18 (10 pm, 25 x 150 mm). Waters AutoP purification System (Sample Manager 2767, Pump 2525, Detector: Micromass ZQ and UV 2487, solvent system: acetonitrileDocket No. P60153

[1678] and 0.1% ammonium hydroxide in water; acetonitrile and 0.1% FA in water or acetonitrile and 0.1% TFA in water). Or Gilson-281 purification System (Pump 322, Detector: UV 156, solvent system: acetonitrile and 0.05% ammonium hydroxide in water; acetonitrile and 0.225% FA in water; acetonitrile and 0.05% HC1 in water; acetonitrile and 0.075% TFA in water; or acetonitrile and water).

[1679] For SFC chiral separation, intermediates were separated by chiral column (Daicel chiralpak IC, 5 pm, 30 x 250 mm), AS (10 pm, 30 x 250 mm) or AD (10 pm, 30 x 250 mm) using Mettler Toledo Multigram III system SFC, Waters 80Q preparative SFC or Thar 80 preparative SFC, solvent system: CO2 and IPA (0.5% TEA in IP A) or CO2 and MeOH (0.1% NH3·H2O in MeOH), back pressure lOObar, detection UV@ 254 or 220 nm.

[1680] LC / MS spectra of compounds were obtained using a LC / MS (Waters™ Alliance 2795-Micromass ZQ, Shimadzu Alliance 2020-Micromass ZQ or Agilent Alliance 6110-Micromass ZQ), LC / MS conditions were as follows (running time 3 or 1.5 mins):

[1681] Acidic condition I: A: 0.1% TFA in H2O; B: 0.1% TFA in acetonitrile;

[1682] Acidic condition II: A: 0.0375% TFA in H2O; B: 0.01875% TFA in acetonitrile;

[1683] Basic condition I: A: 0.1% NH3·H2O in H2O; B: acetonitrile;

[1684] Basic condition II: A: 0.025% NH3·H2O in H2O; B: acetonitrile;

[1685] Neutral condition: A: H2O; B: acetonitrile.

[1686] Mass spectra (MS): generally, only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion (MH)+.

[1687] NMR Spectra were obtained using Bruker Avance 400 MHz or 500MHz.

[1688] The microwave assisted reactions were conducted in a Biotage Initiator Sixty microwave synthesizer. All reactions involving air-sensitive reagents were performed under an argon or nitrogen atmosphere. Reagents were used as received from commercial suppliers without further purification unless otherwise noted.

[1689] PREPARATIVE EXAMPLES

[1690] Example 1

[1691] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(2-phenylethyl) indole- 3-carboxamideDocket No. P60153

[1692]

[1693] Example 1

[1694] Step a: Preparation of 4-chloro-l-(2-phenylethyl)indole-3-carboxylic acid

[1695]

[1696] Compound la

[1697] To a solution of 4-chloro-1H-indole-3-carboxylic acid (200 mg, 1.02 mmol) in DMF (6 mL) cooled at 0 °C was added NaH (123 mg, 3.07 mmol) and the mixture was then stirred at 0 °C for 10 minutes. Subsequently, 2-bromoethylbenzene (284 mg, 1.53 mmol) was added to the resulting mixture. The reaction mixture was stirred at room temperature for another 2 hours. The reaction mixture was then quenched by saturated NH4Cl solution (30 mL) and extracted with EtOAc (30 mL) three times. The combined organic layer was concentrated under reduced pressure, and the residue was purified by flash chromatography (0 - 5% MeOH in DCM) to give 4-chloro-1-(2-phenylethyl)indole-3-carboxylic acid (96 mg). MS obsd. (ESI+) [{35C1 } (M+H)+]:299.9.

[1698] Step b: Preparation of 4-chloro-V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(2-phenylethyl) indole-3-carboxamide

[1699]

[1700] Example 1

[1701] To a solution of 4-chloro-1-(2-phenylethyl)indole-3-carboxylic acid (45.0 mg, 0.15 mmol) in acetonitrile (1 mL) were added 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride (55.8mg, 0.18 mmol), 1 -methylimidazole (82.4 mg, 1.00 mmol), and TCFH (46.3 mg, 0.16 mmol). The reaction mixture was stirred at room temperature for 4 hours. The mixture wasDocket No. P60153

[1702] concentrated under reduced pressure. The residue was diluted with water (20 mL) and extracted with EtOAc (25 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by pre-HPLC purification (FA) to give 4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(2-phenylethyl) indole-3 -carboxamide (57 mg).

[1703] 1H NMR (400 MHz, DMSO-d6) δ = 11.02 - 10.96 (m, 1H), 8.67 - 8.58 (m, 1H), 7.82 - 7.79 (m, 1H), 7.72 - 7.68 (m, 1H), 7.59 - 7.57 (m, 1H), 7.56 - 7.54 (m, 1H), 7.53 - 7.51 (m, 1H), 7.30 -7.27 (m, 1H), 7.27 - 7.24 (m, 3H), 7.23 - 7.18 (m, 1H), 7.15 (d, J= 7.6 Hz, 1H), 7.14 - 7.11 (m, 1H), 5.16 - 5.08 (m, 1H), 4.61 - 4.53 (m, 2H), 4.48 - 4.42 (m, 3H), 4.35 - 4.29 (m, 1H), 3.11 - 3.04 (m, 2H), 2.97 - 2.86 (m, 1H), 2.65 - 2.56 (m, 1H), 2.47 - 2.35 (m, 1H), 2.05 - 1.97 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:555.2.

[1704] Example 2

[1705] 4-chloro- / V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(l-methylindazol-3- yl)methyl] indole-3-carboxamide

[1706]

[1707] Example 2

[1708] Step a: Preparation of methyl 4-chloro-l-[(l-methylindazol-3-yl)methyl]indole-3-carboxylate

[1709]

[1710] Compound 2a

[1711] To a solution of methyl 4-chloro-1H-indole-3-carboxylate (220 mg, 1.05 mmol) in toluene (8.8 mL) were added (l-methylindazol-3-yl)methanol (221 mg, 1.36 mmol) and 2-(tributyl-λ5-phosphanylidene)acetonitrile (380 mg, 1.57 mmol) at rt. The reaction mixture was stirred at 95 °C for 18 hours. The volatile was removed under reduced pressure, and the crude material was purified by flash chromatography (0 - 50% EtOAc in PE) to give methyl 4-chloro-l-[(l-methylindazol-3-yl)methyl]indole-3 -carboxylate (315 mg). MS obsd. (ESI+) [{35C1} (M+H)+]:354.1.Docket No. P60153

[1712] Step b: Preparation of 4-chloro-l-[(l-methylindazol-3-yl)methyl]indole-3-carboxylic acid

[1713]

[1714] Compound 2b

[1715] To a solution of methyl 4-chloro-l-[(l-methylindazol-3-yl)methyl]indole-3-carboxylate (200 mg, 0.56 mmol) in MeOH (5 mL) and water (2 mL) was added lithium hydroxide monohydrate (142 mg, 3.39 mmol). The reaction mixture was stirred at 65 °C for 2 hours. The mixture was diluted with toluene (30 mL) and then concentrated under reduced pressure. The residue was then purified by flash chromatography (0 - 5% MeOH in DCM) to give 4-chloro-l-[(l-methylindazol-3-yl)methyl]indole-3 -carboxylic acid (170.1 mg). MS obsd. (ESI+) [{35C1} (M+H)+]:340.0.

[1716] Step c: Preparation of 4-chloro-V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(l-methylindazol-3-yl)methyl]indole-3-carboxamide

[1717]

[1718] Example 2

[1719] To a solution of 4-chloro-l-[(l-methylindazol-3-yl)methyl]indole-3-carboxylic acid (170 mg, 0.500 mmol) in DMF (5 mL) were added 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2,6-dione hydrochloride (186 mg, 600 pmol), DIPEA (323 mg, 2.50 mmol), and HATU (209 mg, 550 pmol). The reaction mixture was stirred at room temperature for 3 hours. The mixture was concentrated under vacuum. The residue was purified by pre-HPLC purification (FA) to give 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(l-methylindazol-3-yl)methyl]indole-3 -carboxamide (55 mg).

[1720] 1H NMR (400 MHz, DMSO-d6) 6 = 11.01 - 10.94 (m, 1H), 8.75 - 8.68 (m, 1H), 8.03 - 7.99 (m, 1H), 7.72 - 7.68 (m, 2H), 7.67 - 7.63 (m, 1H), 7.61 - 7.57 (m, 2H), 7.53 - 7.49 (m, 1H), 7.38 (dt, J= 0.8, 7.7 Hz, 1H), 7.20 - 7.15 (m, 1H), 7.14 - 7.08 (m, 2H), 5.83 - 5.76 (m, 2H), 5.16 - 5.08 (m, 1H), 4.61 - 4.53 (m, 2H), 4.48 - 4.40 (m, 1H), 4.35 - 4.27 (m, 1H), 4.05 - 3.99 (m, 3H), 2.99 - 2.86 (m, 1H), 2.66 - 2.56 (m, 1H), 2.46 - 2.33 (m, 1H), 2.05 - 1.96 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:595.2.Docket No. P60153

[1721] Example 3

[1722] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-phenacyl-indole-3- carboxamide

[1723]

[1724] Example 3

[1725] Step a: Preparation of 4-chloro-l-phenacyl-indole-3-carboxylic acid

[1726]

[1727] Compound 3a

[1728] To a solution of 4-chloro-1H-indole-3-carboxylic acid (100 mg, 0.51 mmol) in DMF (3 mL) was added NaH (40.9 mg, 1.02 mmol) at 0 °C. The mixture was then stirred at 0 °C for 10 minutes. Then to the resulting solution was added 2-bromo-l-phenyl-ethanone (284 mg, 1.53 mmol) and the reaction mixture was stirred at room temperature for another 2 hours. The volatile was removed under reduced pressure, and the crude material was purified by flash chromatography (0 - 5% MeOH in DCM) to give 4-chloro-l-phenacyl-indole-3 -carboxylic acid (55 mg). MS obsd. (ESI+) [{35C1} (M+H)+]: 314.0.

[1729] Step b: Preparation of 4-chloro-V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-phenacyl-indole-3-carboxamide

[1730]

[1731] Example 3Docket No. P60153

[1732] To a solution of 4-chloro-l-phenacyl-indole-3 -carboxylic acid (70.0 mg, 223 pmol) in DMF (1.5 mL) were added 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride (89.8 mg, 290 pmol), DIPEA (144 mg, 1.12 mmol), and HATU (93.3 mg, 245 pmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated under vacuum, and the residue was diluted with brine (25 mL) and extracted with EtOAc three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by pre-HPLC purification (FA) to give 4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-phenacyl-indole-3-carboxamide (23 mg).

[1733] 'H NMR (400 MHz, DMSO-6) 8 = 10.99 - 10.94 (m, 1H), 8.78 - 8.70 (m, 1H), 8.13 - 8.07 (m, 2H), 7.80 - 7.78 (m, 1H), 7.77 - 7.72 (m, 1H), 7.71 - 7.67 (m, 1H), 7.65 - 7.59 (m, 3H), 7.54 - 7.50 (m, 1H), 7.46 - 7.42 (m, 1H), 7.18 - 7.13 (m, 2H), 6.06 - 5.96 (m, 2H), 5.16 - 5.05 (m, 1H), 4.60 - 4.53 (m, 2H), 4.48 - 4.41 (m, 1H), 4.36 - 4.27 (m, 1H), 2.97 - 2.85 (m, 1H), 2.64 - 2.56 (m, 1H), 2.46 - 2.34 (m, 1H), 2.04 - 1.96 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:569.2.

[1734] Example 4

[1735] 4-chloro- / V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(2-hydroxy-2-phenyl- ethyl)indole-3-carboxamide

[1736]

[1737] 4

[1738] Step a: Preparation of methyl 4-chloro-l-phenacyl-indole-3-carboxylate

[1739]

[1740] Compound 4a

[1741] To a solution of methyl 4-chloro-1H-indole-3-carboxylate (2.00 g, 9.54 mmol) in DMF (50 mL) cooled at 0 °C was added NaH (763 mg, 19.1 mmol) and the mixture was then stirred at 0 °C for 10 minutes. Then to the resulting solution was added 2-bromo-l-phenyl-ethanone (2.85 g, 14.3Docket No. P60153

[1742] mmol) and the reaction mixture was stirred at room temperature for another 7 hours. The volatile was removed under reduced pressure, and the crude material was purified by flash chromatography (0 - 50% EtOAc in PE) to give methyl 4-chloro-l-phenacyl-indole-3 -carboxylate (2.68 g). MS obsd. (ESI+) [{35C1} (M+H)+]: 328.0.

[1743] Step b: Preparation of methyl 4-chloro-l-(2-hydroxy-2-phenyl-ethyl)indole-3-carboxylate

[1744]

[1745] Compound 4b

[1746] To a solution of methyl 4-chloro-l-phenacyl-indole-3 -carboxylate (2.80 g, 8.54 mmol) in MeOH (80 mL) cooled at 0 °C was added NaBH4(485 mg, 12.8 mmol). The reaction mixture was stirred at room temperature for 30 minutes. The volatile was removed under reduced pressure, and the crude material was purified by flash chromatography (0 - 50% EtOAc in PE) to give methyl 4-chloro-1 -(2 -hydroxy-2-phenyl-ethyl)indole-3 -carboxylate (2.66 g). MS obsd. (ESI+) [{35C1 } (M+H)+]: 330.0

[1747] Step c: Preparation of 4-chloro-l-(2-hydroxy-2-phenyl-ethyl)indole-3-carboxylic acid

[1748]

[1749] Compound 4c

[1750] To a solution of methyl 4-chloro-l -(2 -hydroxy-2-phenyl-ethyl)indole-3 -carboxylate (100 mg, 303 pmol) in a mixed solvent of MeOH (1 mL), THF (1 mL) and water (1 mL) was added lithium hydroxide monohydrate (127 mg, 3.03 mmol). The reaction mixture was stirred at 60 °C for 2 hours. The mixture was diluted with toluene (30 mL) and then concentrated under reduced pressure. The residue was purified by flash chromatography (0 - 5% MeOH in DCM) to give 4-chloro-l -(2-hydroxy-2-phenyl-ethyl)indole-3-carboxylic acid (77 mg). MS obsd. (ESI+) [{35C1} (M+H)+]:

[1751] 316.0.

[1752] Step d: Preparation of 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(2-hydroxy-2-phenyl-ethyl)indole-3-carboxamideDocket No. P60153

[1753]

[1754] Example 4

[1755] To a solution of 4-chloro-l-(2-hydroxy-2-phenyl-ethyl)indole-3 -carboxylic acid (50.0 mg, 158 pmol) in DMF (3 mL) were added 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride (58.9 mg, 190 pmol), DIPEA (102 mg, 792 pmol), and HATU (66.2 mg, 174 pmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated under vacuum, and the residue was diluted with brine (25 mL) and extracted with EtOAc three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by pre-HPLC purification (FA) to give 4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(2-hydroxy-2-phenyl-ethyl)indole-3 -carboxamide (48 mg).

[1756] ’H NMR (400 MHz, DMSO-6) δ = 11.00 - 10.96 (m, 1H), 8.66 - 8.59 (m, 1H), 7.82 - 7.78 (m, 1H), 7.72 - 7.68 (m, 1H), 7.62 - 7.57 (m, 1H), 7.54 - 7.49 (m, 2H), 7.44 (d, J= 13 Hz, 2H), 7.37 - 7.31 (m, 2H), 7.30 - 7.24 (m, 1H), 7.17 - 7.10 (m, 2H), 5.17 - 5.08 (m, 1H), 4.97 - 4.90 (m, 1H), 4.60 - 4.54 (m, 2H), 4.49 - 4.43 (m, 1H), 4.40 - 4.23 (m, 3H), 2.98 - 2.86 (m, 1H), 2.60 (br d, J= 16.9 Hz, 1H), 2.47 - 2.30 (m, 2H), 2.06 - 1.96 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:571.2.

[1757] Example 5

[1758] 4-chloro-l-[2-(2,3-dihydro-l,4-benzodioxin-6-yl)-2-hydroxy-ethyl]-V-[[2-(2,6-dioxo-3- piperidyl)-l-oxo-isoindolin-5-yl] methyl] indole-3-carboxamide

[1759]

[1760] Example 5

[1761] The title compound (10 mg) was prepared in analogy to the preparation of Example 4. By using 2-bromo-l-(2,3-dihydro-l,4-benzodioxin-6-yl)ethanone instead of 2-bromo-l-phenyl-Docket No. P60153

[1762] ethanone in Step a H NMR (400 MHz, DMSO-6) 6 = 10.98 (s, 1H), 8.62 (t, J= 6.0 Hz, 1H), 7.81 (s, 1H), 7.72 - 7.68 (m, 1H), 7.59 (s, 1H), 7.52 (s, 2H), 7.18 - 7.09 (m, 2H), 6.95 (s, 1H), 6.91 - 6.86 (m, 1H), 6.83 - 6.78 (m, 1H), 5.68 - 5.37 (m, 1H), 5.16 - 5.07 (m, 1H), 4.85 - 4.77 (m, 1H), 4.56 (br d, J= 5.8 Hz, 2H), 4.49 - 4.43 (m, 1H), 4.35 - 4.27 (m, 2H), 4.24 - 4.18 (m, 5H), 2.97 - 2.86 (m, 1H), 2.63 - 2.57 (m, 1H), 2.45 - 2.35 (m, 1H), 2.05 - 1.97 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]: 629.2.

[1763] Example 6

[1764] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(l- methylbenzimidazol-2-yl)methyl]indole-3-carboxamide

[1765]

[1766] Example 6

[1767] The title compound (10.0 mg) was prepared in analogy to the preparation of Example 2. By using (l-methylbenzimidazol-2-yl)methanol instead of (l-methylindazol-3-yl)methanol in Step a.

[1768] 1H NMR (400 MHz, DMSO-6) δ = 11.02 - 10.94 (m, 1H), 8.80 - 8.71 (m, 1H), 7.96 - 7.92 (m, 1H), 7.71 - 7.67 (m, 1H), 7.63 - 7.60 (m, 1H), 7.60 - 7.58 (m, 1H), 7.58 - 7.54 (m, 2H), 7.52 (d, J= 7.9 Hz, 1H), 7.28 - 7.23 (m, 1H), 7.21 - 7.14 (m, 3H), 5.89 - 5.83 (m, 2H), 5.15 - 5.06 (m, 1H), 4.60 - 4.54 (m, 2H), 4.49 - 4.40 (m, 1H), 4.35 - 4.27 (m, 1H), 3.87 - 3.79 (m, 3H), 2.99 - 2.84 (m, 1H), 2.65 - 2.56 (m, 1H), 2.46 - 2.33 (m, 1H), 2.05 - 1.95 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]: 595.2.

[1769] Example 7

[1770] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-hydroxy-l-[[6-methoxy-5-(l- methylpyrazol-4-yl)-2-pyridyl] methyl] indole-3-carboxamide

[1771]

[1772] Example 7Docket No. P60153

[1773] Step a: Preparation of 4-benzyloxy-l-[(5-bromo-6-methoxy-2-pyridyl)methyl]indole-3-carbaldehyde

[1774]

[1775] Compound 7a

[1776] To a solution of 4-benzyloxy-17 / -indole-3-carbaldehyde (200 mg, 796 pmol) in DMF (6 mL) cooled at 0 °C was added NaH (47.8 mg, 1.19 mmol) and the mixture was then stirred at 0 °C for 10 minutes. Then to the resulting solution were added TBAI (294 mg, 796 pmol) and 3-bromo-6-(chloromethyl)-2-methoxy-pyridine (245 mg, 1.03 mmol). The reaction mixture was stirred at 55 °C for 3 hours. The volatile was removed under reduced pressure, and the crude material was purified by flash chromatography (0 - 50% EtOAc in PE) to give 4-benzyloxy-l-[(5-bromo-6-methoxy-2-pyridyl)methyl]indole-3-carbaldehyde (140 mg). MS obsd. (ESI+) [{79Br} (M+H)+]: 451.1.

[1777] Step b: Preparation of 4-benzyloxy-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl] methyl] indole-3-carbaldehyde

[1778]

[1779] Compound 7b

[1780] To a solution of 4-benzyloxy-l-[(5-bromo-6-methoxy-2-pyridyl)methyl]indole-3-carbaldehyde (70.0 mg, 0.155 mmol) and (l-methylpyrazol-4-yl)boronic acid (23.4 mg, 186 pmol) in 1,4-dioxane (4 mL) and water (0.6 mL) were added Pd(dppf)Cl2CH2C12 (12.8 mg, 15.5 pmol) and K2CO3(364.3 mg, 465 pmol), the reaction mixture was stirred at 75 °C for 2 hours. The mixture was cooled to room temperature and concentrated under vacuum. The residue was purified by silica gel flash chromatography (0-5% MeOH in DCM) to afford 4-benzyloxy-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl] indole-3 -carbaldehy de (56.0 mg) as white solid. MS obsd. (ESI+) [(M+H)+]:453.4.Docket No. P60153

[1781] Step c: Preparation of 4-benzyloxy-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl] methyl] indole-3-carboxylic acid

[1782]

[1783] Compound 7c

[1784] To a solution of 4-benzyloxy-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl] indole-3 -carbaldehy de (70.0 mg, 0.155 mmol) in acetonitrile (1.5 mL) and water (0.5 mL) were added sodium dihydrogen phosphate anhydrous (186 mg, 1.55 mmol) and 2-methyl-2-butene (243 mg, 3.46 mmol) and sodium chlorite (70.0 mg, 773 pmol). The reaction mixture was stirred at room temperature for 15 hours. The resulting mixture was quenched with saturated Na2S2O3solution (10 mL) and 1 M HC1 (10 mL). The mixture was then extracted with EtOAc (50 mL) twice. The combined organic layer was washed with brine, dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0-5% MeOH in DCM) to afford 4-benzyloxy-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl] indole-3 -carboxylic acid (55.0 mg) as white solid. MS obsd. (ESI+) [(M+H)+]:469.4.

[1785] Step d: Preparation of 4-hydroxy-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl] methyl] indole-3-carboxylic acid

[1786]

[1787] Compound 7d

[1788] To a solution of 4-benzyloxy-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl] indole-3 -carboxylic acid (20.0 mg, 42.7 pmol) in MeOH (1 mL) was added Pd / C (10.0 mg) and the reaction mixture was stirred at room temperature under H2 atmosphere for 1 hour. The mixture was diluted with EtOAc (20 mL) and filtered through silica pad. The combined organic layer was concentrated under reduced pressure, and the residue was purified by silica gel flash chromatography (0-5% MeOH in DCM) to afford 4-hydroxy-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl] indole-3 -carboxylic acid (10.0 mg). MS obsd. (ESI+) [(M+H)+]:469.4.Docket No. P60153

[1789] Step e: Preparation of N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-hydroxy-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl]indole-3-carboxamide

[1790]

[1791] Example 7

[1792] To a solution of 4-hydroxy-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl] indole-3-carboxylic acid (20.0 mg, 52.9 pmol) in DMF (2 mL) were added 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride_(21.3 mg, 68.7 pmol), DIPEA (54.7 mg, 423 pmol), and HATU (24.1 mg, 63.4 pmol). The reaction mixture was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by pre-HPLC purification (FA) to give N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-hydroxy-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl]indole-3-carboxamide (5.40 mg).

[1793] 'H NMR (400 MHz, DMSO-6) 8 = 12.52 (s, 1H), 10.97 (s, 1H), 8.31 - 8.30 (m, 1H), 8.11 (s, 1H), 7.96 - 7.93 (m, 1H), 7.90 (s, 1H), 7.71 (d, J= 7.8 Hz, 1H), 7.56 (s, 1H), 7.49 (d, J= 7.4 Hz, 1H), 7.05 - 6.98 (m, 2H), 6.85 (d, J= 7.6 Hz, 1H), 6.43 (dd, J= 1.4, 7.1 Hz, 1H), 5.40 (s, 2H), 5.10 (dd, J = 5.3, 13.3 Hz, 1H), 4.64 (d, J= 5.8 Hz, 2H), 4.49 - 4.43 (m, 1H), 4.35 - 4.29 (m, 1H), 3.90 (s, 3H), 3.85 (s, 3H), 2.59 (br d, J= 18.6 Hz, 1H), 2.40 - 2.31 (m, 2H), 2.03 - 1.95 (m, 2H). MS obsd. (ESI+) [(M+H)+]: 634.5.

[1794] Example 8

[1795] l-(l,2-benzoxazol-3-ylmethyl)-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5- yl] methyl] indole-3-carboxamide

[1796]

[1797] Example 8

[1798] Step a: Preparation of methyl l-(l,2-benzoxazol-3-ylmethyl)-4-chloro-indole-3-carboxylateDocket No. P60153

[1799]

[1800] Compound 8a

[1801] To a solution of methyl 4-chloro- IT / -indole-3 -carboxylate (300 mg, 1.43 mmol) in DMF (7.5 mL) cooled at 0 °C was added NaH (68.7 mg, 2.86 mmol) and the mixture was then stirred at 0 °C for 10 minutes. Then to the resulting solution was added 3 -(brom om ethyl)- 1,2-benzoxazole (455 mg, 2.15 mmol) and the reaction mixture was stirred at room temperature for another 4 hours. The volatile was removed under reduced pressure, and the crude material was purified by flash chromatography (0 - 50% EtOAc in PE) to give methyl l-(l,2-benzoxazol-3-ylmethyl)-4-chloro-indole-3 -carboxylate (380 mg). MS obsd. (ESI+) [{35C1} (M+H)+]: 341.0.

[1802] Step b: Preparation of l-(l,2-benzoxazol-3-ylmethyl)-4-chloro-indole-3-carboxylic acid

[1803]

[1804] Compound 8b

[1805] To a solution of methyl l-(l,2-benzoxazol-3-ylmethyl)-4-chloro-indole-3-carboxylate (380 mg, 1.12 mmol) in a mixed solvent of MeOH (6 mL), THF (3 mL) and water (4 mL) was added lithium hydroxide monohydrate (234 mg, 4.77 mmol). The reaction mixture was stirred at 60 °C for 3 hours. The mixture was diluted with toluene (30 mL) and then concentrated under reduced pressure. The residue was purified by flash chromatography (0 - 5% MeOH in DCM) to give 1 -(1,2-benzoxazol-3-ylmethyl)-4-chloro-indole-3 -carboxylic acid (200 mg). MS obsd. (ESI+) [{35C1 } (M+H)+]: 327.0.

[1806] Step c: Preparation of l-(1.2-benzoxazol-3-ylmethyl)-4-chloro-\-||2-(2.6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl] methyl] indole-3-carboxamide

[1807]

[1808] Example 8Docket No. P60153

[1809] To a solution of l-(l,2-benzoxazol-3-ylmethyl)-4-chloro-indole-3-carboxylic acid (100 mg, 306 pmol) in DMF (3 mL) were added 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2,6-dione hydrochloride_(104 mg, 337 pmol), DIPEA (198 mg, 1.53 mmol), and HATU (140 mg, 367 pmol). The reaction mixture was stirred at room temperature for 3 hours. The mixture was then concentrated under reduced pressure, the residue was diluted with brine (25 mL) and extracted with EtOAc (30 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by pre-HPLC purification (FA) to give l-(l,2-benzoxazol-3-ylmethyl)-4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide (60 mg).

[1810] 'H NMR (400 MHz, DMSO-6) 8 = 10.98 (s, 1H), 8.81 - 8.75 (m, 1H), 8.09 (s, 1H), 7.77 - 7.72 (m, 1H), 7.72 - 7.68 (m, 2H), 7.67 - 7.58 (m, 3H), 7.52 (d, J= 8.0 Hz, 1H), 7.37 (t, J= 7.3 Hz, 1H), 7.24 - 7.12 (m, 2H), 6.01 (s, 2H), 5.11 (dd, J= 5.1, 13.3 Hz, 1H), 4.57 (d, J= 6.0 Hz, 2H), 4.45 (d, J= 17.4 Hz, 1H), 4.39 - 4.25 (m, 1H), 2.97 - 2.85 (m, 1H), 2.64 - 2.56 (m, 1H), 2.45 - 2.35 (m, 1H), 2.07 - 1.95 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:582.3.

[1811] Example 9

[1812] l-[2-( l,3-benzodioxol-5-yl)ethyl]-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5- yl] methyl] indole-3-carboxamide

[1813]

[1814] Example 9

[1815] The title compound (50.0 mg) was prepared in analogy to the preparation of Example 8. By using 5-(2-bromoethyl)-l,3-benzodioxole instead of 3 -(bromomethyl)- 1,2-benzoxazole in Step a.

[1816] 1H NMR (400 MHz, DMSO-6) 6 = 10.98 (s, 1H), 8.63 (t, J= 6.1 Hz, 1H), 7.81 (s, 1H), 7.70 (d, J= 7.9 Hz, 1H), 7.60 - 7.58 (m, 1H), 7.57 - 7.54 (m, 1H), 7.53 - 7.48 (m, 1H), 7.19 - 7.11 (m, 2H), 6.92 (d, J= 1.5 Hz, 1H), 6.79 (d, J= 7.9 Hz, 1H), 6.67 (dd, J= 1.6, 7.9 Hz, 1H), 5.95 (s, 2H), 5.12 (dd, J = 5.1, 13.3 Hz, 1H), 4.56 (d, J= 6.0 Hz, 2H), 4.49 - 4.42 (m, 1H), 4.42 - 4.36 (m, 2H), 4.35 - 4.29 (m, 1H), 3.03 - 2.96 (m, 2H), 2.96 - 2.85 (m, 1H), 2.63 - 2.55 (m, 1H), 2.46 - 2.35 (m, 1H), 2.06 -1.96 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]: 599.4.Docket No. P60153

[1817] Example 10

[1818] l-benzyl-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3- carboxamide

[1819]

[1820] Example 10

[1821] The title compound (68.6 mg) was prepared in analogy to the preparation of Example 8. By using bromomethylbenzene instead of 3 -(bromomethyl)- 1,2-benzoxazole in Step a.'HNMR (400 MHz, DMSO-6) 6 = 11.03 - 10.91 (m, 1H), 8.74 (t, J= 6.0 Hz, 1H), 7.98 (s, 1H), 7.70 (d, J= 8.0 Hz, 1H), 7.60 (s, 1H), 7.54 - 7.48 (m, 2H), 7.34 - 7.30 (m, 2H), 7.28 - 7.25 (m, 3H), 7.18 - 7.12 (m, 2H), 5.48 (s, 2H), 5.11 (dd, J = 5.2, 13.3 Hz, 1H), 4.57 (d, J= 6.0 Hz, 2H), 4.48 - 4.28 (m, 2H), 2.91 (dd, J= 5.2, 13.6, 17.6 Hz, 1H), 2.58 (br dd, J= 2, 4.0 Hz, 1H), 2.40 (br dd, J= 4.8, 12.8 Hz, 1H), 2.03 - 1.96 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:541.2.

[1822] Example 11

[1823] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(l-methylindol-4- yl)methyl] indole-3-carboxamide

[1824]

[1825] Example 11

[1826] The title compound (20.5 mg) was prepared in analogy to the preparation of Example 2. By using (l-methylindol-4-yl)m ethanol instead of (l-methylindazol-3-yl)methanol in Step a.1H NMR (400 MHz, DMSO-6) 8 = 10.98 (s, 1H), 8.80 (t, J= 1.6 Hz, 1H), 8.06 (s, 1H), 7.70 (s, 1H), 7,68-7.60 (m, 1H), 7.58- 7.50 (m, 1H), 7.48 (s, 1H), 7.44- 7.40 (m, 1H), 7.36 (s, 1H), 7.18- 7.12 (m, 1H), 7.10- 7.04 (m, 1H), 6.92- 6.82 (m, 1H), 6.50- 6.40 (m, 1H), 6.30- 6.20(m, 1H), 5.80 (s, 2H), 5.10 (dd, J= 5.2, 13.2 Hz, 1H), 4.59 (d, J= 6.0 Hz, 2H), 4.49 - 4.26 (m, 2H), 3.65 - 3.56 (m, 3H), 2.97 -Docket No. P60153

[1827] 2.85 (m, 1H), 2.63 - 2.56 (m, 1H), 2.43 - 2.34 (m, 1H), 2.03 - 1.94 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]: 594.2.

[1828] Example 12

[1829] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(pyrazolo[l,5-a]pyridin- 6-ylmethyl)indole-3-carboxamide

[1830]

[1831] Example 12

[1832] The title compound (63.5 mg) was prepared in analogy to the preparation of Example 2. By using pyrazolo[l,5-a]pyridin-6-ylmethanol instead of (l-methylindazol-3-yl)methanol in Step a.

[1833] 1H NMR (400 MHz, DMSO-d6) δ = 10.99 (s, 1H), 8.84 (s, 1H), 8.77 (t, J= 6.0 Hz, 1H), 8.06 (s, 1H), 7.98 (d, J= 2.4 Hz, 1H), 7.75 - 7.68 (m, 2H), 7.66 - 7.57 (m, 2H), 7.52 (d, J= 8.0 Hz, 1H), 7.22 -7.17 (m, 1H), 7.16 - 7.12 (m, 2H), 6.59 - 6.56 (m, 1H), 5.50 (s, 2H), 5.11 (dd, J= 5.2, 13.2 Hz, 1H), 4.57 (d, J= 6.0 Hz, 2H), 4.49 - 4.41 (m, 1H), 4.36 - 4.26 (m, 1H), 3.01 - 2.81 (m, 1H), 2.60 (d, J= 16.4 Hz, 1H), 2.40 (dq, J= 4.0, 13.2 Hz, 1H), 2.07 - 1.94 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:581.2.

[1834] Example 13

[1835] 4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-(imidazo[1,2-a]pyridin- 6-ylmethyl)indole-3-carboxamide

[1836]

[1837] Example 13

[1838] The title compound (48.1 mg) was prepared in analogy to the preparation of Example 2. By using imidazo[l,2-a]pyridin-6-ylmethanol instead of (l-methylindazol-3-yl)methanol in Step a.1H NMR (400 MHz, DMSO-d6) δ = 10.98 (s, 1H), 8.80 (t, J= 1.6 Hz, 1H), 8.06 (s, 1H), 7.70 (s, 1H), 7,68- 7.60 (m, 1H), 7.58- 7.50 (m, 1H), 7.48 (s, 1H), 7.44- 7.40 (m, 1H), 7.36 (s, 1H), 7.18- 7.12 (m, 1H), 7.10- 7.04 (m, 1H), 6.92- 6.82 (m, 1H), 6.50- 6.40 (m, 1H), 6.30- 6.20(m, 1H), 5.80 (s, 2H),Docket No. P60153

[1839] 5.10 (dd, J= 5.2, 13.2 Hz, 1H), 4.59 (d, J= 6.0 Hz, 2H), 4.49 - 4.26 (m, 2H), 3.65 - 3.56 (m, 3H), 2.97 - 2.85 (m, 1H), 2.63 - 2.56 (m, 1H), 2.43 - 2.34 (m, 1H), 2.03 - 1.94 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:581.2.

[1840] Example 14

[1841] l-benzyl-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3- carboxamide

[1842]

[1843] Example 14

[1844] The title compound (59.9 mg) was prepared in analogy to the preparation of Example 1. By using 4-methyl-1H-indole-3-carboxylic acid and benzyl bromide instead of 4-chloro-l / Z-indole-3-carboxylic acid and 2-bromoethylbenzene in Step a. ’H NMR (400 MHz, DMSO-d6) δ = 10.97 (s, 1H), 8.72 ( t, J= 6.0 Hz, 1H), 7.94 (s, 1H), 7.70 (d, J= 7.6 Hz, 1H), 7.58 (s, 1H), 7.51 (d, J= 7.6 Hz, 1H), 7.33 - 7.28 (m, 3H), 7.24 - 7.24 (m, 3H), 7.05 (t, J= 7.6 Hz, 1H), 6.86 (d, J= 7.2 Hz, 1H), 5.44 (s, 2H), 5.11 (dd, J= 5.2, 13.2 Hz, 1H), 4.56 (d, J= 6.0 Hz, 2H), 4.47 - 4.28 (m, 2H), 3.00 - 2.86 (m, 1H), 2.61 (d, J= 2.4 Hz, 1H), 2.57 (s, 3H), 2.43 - 2.32 (m, 1H), 2.02 - 1.98 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:521.3.

[1845] Example 15

[1846] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-(l-methylpyrazol-4- yl)phenyl] methyl] indole-3-carboxamide

[1847]

[1848] Example 15

[1849] Step a: Preparation of [4-(l-methylpyrazol-4-yl)phenyl]methanol

[1850]

[1851] Compound 15aDocket No. P60153

[1852] To a mixture of 4-bromobenzyl alcohol (1.00 g, 5.32 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.22 g, 5.85 mmol) and K2CO3(2.20 g, 16.0 mmol) in 1,4-dioxane (10.0 mL) was added Pd(dppf)Cl2(217 mg, 0.270 mmol) under nitrogen. The reaction mixture was stirred at 95 °C for 12 hours under N2 atmosphere. After cooling to room temperature, the mixture was filtered, and the filtrate was concentrated under vacuum. The residue was purified by silica gel flash chromatography (0 - 50% EtOAc in PE) to give [4-(l-methylpyrazol-4-yl)phenyl]methanol (950 mg). 'H NMR (400 MHz, CHLOROFORM-d) 5 = 7.75 (s, 1H), 7.61 (s, 1H), 7.47 (d, J= 8.0 Hz, 2H), 7.36 (d, J= 8.0 Hz, 2H), 4.70 (s, 2H), 3.95 (s, 3H). MS obsd. (ESI+) [{35C1} (M+H)+]: 189.0.

[1853] Step b: Preparation of 4-chloro-V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-(l-methylpyrazol-4-yl)phenyl]methyl]indole-3-carboxamide

[1854]

[1855] Example 15

[1856] The title compound (45.8 mg) was prepared in analogy to the preparation of Example 2. By using [4-(l-methylpyrazol-4-yl)phenyl]methanol instead of (l-methylindazol-3-yl)methanol in Step a.1H NMR (400 MHz, DMSO-d6) δ = 10.98 (s, 1H), 8.73 (t, J= 6.0 Hz, 1H), 8.07 (s, 1H), 7.98 (s, 1H), 7.80 (s, 1H), 7.70 (d, J= 8.0 Hz, 1H), 7.60 (s, 1H), 7.57 - 7.45 (m, 4H), 7.26 (d, J= 8.4 Hz, 2H), 7.19 - 7.11 (m, 2H), 5.44 (s, 2H), 5.16 - 5.06 (m, 1H), 4.57 (d, J= 6.0 Hz, 2H), 4.49 - 4.40 (m, 1H), 4.37 - 4.28 (m, 1H), 3.83 (s, 3H), 2.96 - 2.86 (m, 1H), 2.62 (br d, J= 13.6 Hz, 1H), 2.45 (s, 1H), 2.05 - 1.96 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:621.2.

[1857] Example 16

[1858] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-(l- methyl pyr azol-4-yl)phenyl] methyl] indole-3-carboxamide

[1859]

[1860] Example 16Docket No. P60153

[1861] The title compound (16.0mg) was prepared in analogy to the preparation of Example 2. By using [4-(1-methylpyrazol-4-yl)phenyl]methanol and methyl 4-fluoro-1H-indole-3-carboxylate instead of (1-methylindazol-3-yl)methanol and methyl 4-chloro-1H-indole-3-carboxylate in Step a.

[1862] 1H NMR (400 MHz, DMSO-d6) δ = 11.18 - 10.75 (m, 1H), 8.46 - 8.39 (m, 1H), 8.10 (d, J= 18.8 Hz, 2H), 7.81 (s, 1H), 7.71 (d, J= 7.8 Hz, 1H), 7.62 - 7.55 (m, 1H), 7.53 - 7.51 (m, 1H), 7.50 (s, 1H), 7.42 (d, J= 8.3 Hz, 1H), 7.31 - 7.15 (m, 3H), 6.93 (dd, J= 7.9, 11.8 Hz, 1H), 5.46 (s, 2H), 5.17 - 5.01 (m, 1H), 4.60 (d, J= 5.9 Hz, 2H), 4.50 - 4.40 (m, 1H), 4.37 - 4.23 (m, 1H), 3.84 (s, 3H), 2.98 - 2.84 (m, 1H), 2.68 - 2.53 (m, 2H), 2.43 - 2.30 (m, 1H), 2.04 - 1.98 (m, 1H). MS obsd. (ESI+) [(M+H)+]: 605.2.

[1863] Example 17

[1864] l-benzyl-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3- carboxamide

[1865]

[1866] Example 17

[1867] The title compound (57.0 mg) was prepared in analogy to the preparation of Example 1. By using 4-fluoro-l / / -indole-3 -carboxylic acid and benzyl bromide instead of 4-chloro-l / / -indole-3-carboxylic acid and 2-bromoethylbenzene in Step a.1H NMR (400 MHz, DMSO-d6) δ = 10.98 (s, 1H), 8.42 (br d, J= 4.4 Hz, 1H), 8.11 (s, 1H), 7.70 (d, J= 7.6 Hz, 1H), 7.58 (s, 1H), 7.51 (d, J= 8.0 Hz, 1H), 7.39 (d, J= 8.4 Hz, 1H), 7.36 - 7.31 (m, 2H), 7.29 - 7.25 (m, 3H), 7.17 (dt, J= 5.2, 8.0 Hz, 1H), 6.92 (dd, J= 8.0, 12.0 Hz, 1H), 5.49 (s, 2H), 5.13 - 5.06 (m, 1H), 4.59 (br d, J= 6.0 Hz, 2H), 4.48 - 4.41 (m, 1H), 4.35 - 4.27 (m, 1H), 2.96 - 2.86 (m, 1H), 2.59 (br d, J= 17.2 Hz, 1H), 2.44 -2.36 (m, 1H), 2.04 - 1.96 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]: 525.1.

[1868] Example 18

[1869] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[6-methoxy-5-(l- methylpyrazol-4-yl)-2-pyridyl] methyl] indole-3-carboxamideDocket No. P60153

[1870]

[1871] Example 18

[1872] Step a: Preparation of methyl 6-methoxy-5-(l-methylpyrazol-4-yl)pyridine-2-carboxylate

[1873]

[1874] Compound 18a

[1875] To a mixture of methyl 5-bromo-6-methoxy-pyridine-2-carboxylate (2.00 g, 8.13 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (3.38 g, 16.3 mmol) and K2CO3(2.58 g, 24.4 mmol) in 1,4-dioxane (40.0 mL) and water (5 mL) was added Pd(dppf)Cl2(33.0 mg, 0.410 mmol), and the reaction mixture was stirred at 95 °C for 12 hours under N2 atmosphere. After cooling to room temperature, the mixture was filtered and the filtrate was concentrated under vacuum, the residue was purified by silica gel chromatography (0 - 50% EtOAc in PE) to give methyl 6-methoxy-5-(l-methylpyrazol-4-yl)pyridine-2-carboxylate ( 1.60 g). MS obsd. (ESI+) [(M+H)+]:248.0.

[1876] Step b: Preparation of [6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methanol

[1877]

[1878] Compound 18b

[1879] To a mixture of methyl 6-methoxy-5-(l-methylpyrazol-4-yl)pyridine-2-carboxylate (900 mg, 3.64 mmol) in THF (30.0 mL) was added LiAlH4THF solution (2M, 2.18 mL, 5.46 mmol) at 0 °C under N2 atmosphere. After being stirred at 0 °C for 2 hours, the reaction was quenched by slow addition of water (0.2 mL) / 15% NaOH (0.2 mL) / water (0.6 mL) in sequence. The resulting mixture was dried over Na2SO4and concentrated under vacuum to give the crude of [6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methanol (790 mg), which was used in the next step directly without further purification. MS obsd. (ESI+) [(M+H)+]:220.2.

[1880] Step c: Preparation of N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl]indole-3-carboxamideDocket No. P60153

[1881]

[1882] Example 18

[1883] The title compound (69.3 mg) was prepared in analogy to the preparation of Example 2. By using [6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methanol and methyl 4-fluoro-1H-indole-3-carboxylate instead of (1-methylindazol-3-yl)methanol and methyl 4-chloro-1H-indole-3-carboxylate in Step a.1H NMR (400 MHz, DMSO-d6) δ = 10.98 (s, 1H), 8.46 - 8.37 (m, 1H), 8.12 (d, J= 8.4 Hz, 2H), 7.96 - 7.88 (m, 2H), 7.70 (d, J= 8.0 Hz, 1H), 7.57 (s, 1H), 7.52 - 7.43 (m, 2H), 7.19 (dt, J= 5.2, 8.0 Hz, 1H), 6.92 (dd, J= 8.0, 11.6 Hz, 1H), 6.82 (d, J= 7.6 Hz, 1H), 5.48 (s, 2H), 5.11 (dd, J= 5.2, 13.2 Hz, 1H), 4.60 (d, J= 6.0 Hz, 2H), 4.50 - 4.40 (m, 1H), 4.35 - 4.25 (m, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 3.01 - 2.82 (m, 1H), 2.59 (d, J= 18.0 Hz, 1H), 2.42 - 2.31 (m, 1H), 2.04 -1.95 (m, 1H). MS obsd. (ESI+) [(M+H)+]:636.2.

[1884] Example 19

[1885] N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-fluoro-1-[[4-(1H-pyrazol-4-yl)phenyl]methyl]indole-3-carboxamide

[1886]

[1887] Example 19

[1888] Step a: Preparation of methyl l-[(4-bromophenyl)methyl]-4-fluoro-indole-3-carboxylate

[1889]

[1890] Compound 19a

[1891] To a solution of methyl 4-fluoro-1H-indole-3-carboxylate (1.50 g, 7.76 mmol) and K2CO3(2.14 g, 15.5 mmol) in DMF (15.0 mL) was added 4-bromobenzyl bromide (2.13 g, 8.54 mmol) and the mixture was then stirred at 25 °C for 16 hours. The resulting reaction mixture was poured into waterDocket No. P60153

[1892] (30 mL) and extracted with EtOAc (80 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 50% EtOAc in PE) to afford methyl l-[(4-bromophenyl)methyl]-4-fluoro-indole-3-carboxylate (2.10 g). MS obsd. (ESI+) [(M+H)+]:361.9.

[1893] Step b: Preparation of methyl l-[[4-(l-tert-butoxycarbonylpyrazol-4-yl)phenyl]methyl]-4-fluoro-indole-3-carboxylate

[1894]

[1895] Compound 19b

[1896] To a solution of methyl l-[(4-bromophenyl)methyl]-4-fluoro-indole-3-carboxylate (1.50 g, 4.14 mmol) and tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazole-l-carboxylate (1.31 g, 4.45 mmol) in 1,4-dioxane (20.0 mL) and water (2.0 mL) was added Pd(dppf)Cl2(0.330 g, 0.45 mmol) and K3PO4(1.42 g, 6.68 mmol). The mixture was stirred at 80 °C for 3 hours under N2 atmosphere and then cooled to room temperature. The resulting reaction mixture was poured into water (100 mL) and extracted with EtOAc (120 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 80% EtOAc in PE) to give methyl 1 -[[4-(l -tert-butoxycarbonylpyrazol-4-yl)phenyl]methyl]-4-fluoro-indole-3-carboxylate (1.80 g). MS obsd. (ESI+) [(M+H)+]: 450.2.

[1897] Step c: Preparation of 4-fluoro-1-[[4-(1H-pyrazol-4-yl)phenyl]methyl]indole-3-carboxylic acid

[1898]

[1899] Compound 19c

[1900] To a solution of methyl l-[[4-(l-tert-butoxycarbonylpyrazol-4-yl)phenyl]methyl]-4-fluoro-indole-3 -carboxylate (1.00 g, 2.22 mmol) in MeOH (10.0 mL) and water (2.0 mL) was added NaOH (445 mg, 11.1 mmol) and the mixture was stirred at 50 °C for 16 hours. The mixture was then cooled to room temperature and pH was adjusted to 5.0 by adding 3 M aq. HCl. The resulting solution wasDocket No. P60153

[1901] directly purified by prep-HPLC (FA as additive) and lyophilized to give 4-fluoro-1-[[4-(1H-pyrazol-4-yl)phenyl]methyl]indole-3-carboxylic acid (400 mg). MS obsd. (ESI+) [(M+H)+]: 336.0.

[1902] Step d: Preparation of N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-fluoro-1-[[4-(1H-pyrazol-4-yl)phenyl]methyl]indole-3-carboxamide

[1903]

[1904] Example 19

[1905] To a solution of 4-fluoro-l-[[4-(l / / -pyrazol-4-yl)phenyl]methyl]indole-3-carboxylic acid (200 mg, 0.600 mmol), 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride (221 mg, 0.720 mmol) in DCM (2.0 mL) was added DIPEA (231 mg, 1.79 mmol), T4P (561 mg, 1.19 mmol). The mixture was stirred at 25 °C for 16 hours. The reaction mixture was purified by prep-HPLC (FA as additive) to afford N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-fluoro-1-[[4-(1H-pyrazol-4-yl)phenyl]methyl]indole-3-carboxamide (170 mg) as a white solid.

[1906] 1H NMR (400 MHz, DMSO-d6) δ = 13.21 - 12.59 (m, 1H), 10.98 (brs, 1H), 8.52 - 8.37 (m, 1H), 8.12 (s, 1H), 8.10 - 7.84 (m, 2H), 7.70 (d, J= 7.8 Hz, 1H), 7.57 (br d, J= 6.8 Hz, 2H), 7.55 - 7.53 (m, 1H), 7.51 (br d, J= 8.0 Hz, 1H), 7.42 (d, J= 8.4 Hz, 1H), 7.27 (d, J= 8.0 Hz, 2H), 7.18 (dt, J= 5.0, 8.0 Hz, 1H), 6.92 (dd, J= 8.0, 11.6 Hz, 1H), 5.46 (s, 2H), 5.10 (dd, J= 5.2, 13.2 Hz, 1H), 4.59 (br d, J= 6.0 Hz, 2H), 4.49 - 4.40 (m, 1H), 4.36 - 4.26 (m, 1H), 2.97 - 2.85 (m, 1H), 2.61 (br s, 1H), 2.41 - 2.32 (m, 1H), 2.04 - 1.94 (m, 1H). MS obsd. (ESI+) [(M+H)+]:591.3.

[1907] Example 20

[1908] Ethyl 4-[4-[[3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]-4-fluoro-indol-l-yl]methyl]phenyl]pyrazole-l-carboxylate

[1909]

[1910] Docket No. P60153

[1911] To a solution of N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-fluoro-1-[[4-(1H-pyrazol-4-yl)phenyl]methyl]indole-3-carboxamide (150 mg, 0.250 mmol) and DIPEA (98.4 mg, 0.760 mmol) in DCM (1.0 mL) was added ethyl chloroformate (290 mg, 2.67 mmol) at 0 °C, and the mixture was stirred at 25 °C for 3 hours. The reaction was then concentrated under reduced pressure and the residue which was purified by prep-HPLC (FA as additive) to give ethyl 4-[4-[[3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]-4-fluoro-indol-l-yl]methyl]phenyl]pyrazole-l -carboxylate (32.0 mg).

[1912] ’H NMR (400 MHz, DMSO-6) 8 = 10.98 (s, 1H), 8.77 (s, 1H), 8.50 - 8.37 (m, 1H), 8.31 (d, J= 0.6 Hz, 1H), 8.14 (s, 1H), 7.73 (s, 1H), 7.71 (d, J= 1.6 Hz, 1H), 7.58 (s, 1H), 7.51 (d, J= 8.4 Hz, 1H), 7.41 (d, J= 8.4 Hz, 1H), 7.31 (d, J= 8.4 Hz, 2H), 7.18 (dt, J= 4.8, 8.0 Hz, 1H), 6.92 (dd, J= 7.8, 11.7 Hz, 1H), 5.50 (s, 2H), 5.11 (dd, J= 5.2, 13.2 Hz, 1H), 4.60 (br d, J= 6.0 Hz, 2H), 4.48 - 4.43 (m, 2H), 4.43 - 4.41 (m, 1H), 4.35 - 4.27 (m, 1H), 3.51 - 3.48 (m, 1H), 2.97 - 2.84 (m, 1H), 2.61 (br d, J= 2.0 Hz, 1H), 2.40 - 2.31 (m, 1H), 2.023 – 1.979 (m, 1H), 1.36 (t, J= 7.2 Hz, 3H). MS obsd. (ESI+) [(M+H)+]:663.2.

[1913] Example 21

[1914] 1-[2-benzyloxy-1-[5-(1-methylpyrazol-4-yl)-2-pyridyl]ethyl]-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide

[1915]

[1916] Example 21

[1917] Step a: Preparation of 2-bromo-5-(l-methylpyrazol-4-yl)pyridine

[1918]

[1919] Compound 21a

[1920] To the solution of 2-bromo-5-iodopyridine (10.0 g, 35.2 mmol) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (9.53 g, 45.8 mmol) in 1,4-dioxane (120 mL) and water (10.0 mL) was added K2CO3(14.6 g, 106 mmol) and Pd(dppf)Cl2(2.57 g, 3.52 mmol) underDocket No. P60153

[1921] N2. The mixture was stirred at 60 °C for 12 hours under N2 atmosphere and then cooled to room temperature. The resulting reaction mixture was poured into water (50 mL), and the mixture was extracted with EtOAc (80 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 70% EtOAc in PE) to give 2-bromo-5-(l-methylpyrazol-4-yl)pyridine (8.00 g). MS obsd. (ESI+) [(M+H)+]:237.9.

[1922] Step b: Preparation of 2-benzyloxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethanol

[1923]

[1924] Compound 21b

[1925] To a solution of 2-bromo-5-(l-methylpyrazol-4-yl)pyridine (4.0 g, 16.8 mmol) in THF (10 mL) was added isopropylmagnesium chloride-lithium chloride complex (1.3 M in THF, 25.8 mL, 33.6 mmol) under -78 °C for 5 minutes. To the resulting solution was added benzyloxyacetaldehyde (1.68 g, 11.2 mmol) cooled at -78 °C slowly. The mixture was then warmed to room temperature and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 50% EtOAc in PE) to give 2-benzyloxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethanol (400 mg). MS obsd. (ESI+) [(M+H)+]:310.2.

[1926] Step c: Preparation of 1-[2-benzyloxy-1-[5-(1-methylpyrazol-4-yl)-2-pyridyl]ethyl]-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide

[1927]

[1928] Example 21

[1929] The title compound (59.9 mg) was prepared in analogy to the preparation of Example 2. By using 2-benzyloxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethanol and methyl 4-fluoro-1H-indole-3-carboxylate instead of (1-methylindazol-3-yl)methanol and methyl 4-chloro-1H-indole-3-Docket No. P60153

[1930] carboxylate in Step a.1H NMR (400 MHz, DMSO-6) 8 = 10.98 (s, 1H), 8.78 (d, J= 2.0 Hz, 1H), 8.45 - 8.41 (m, 1H), 8.24 (s, 1H), 8.20 (s, 1H), 7.94 - 7.89 (m, 2H), 7.69 (d, J= 8.0 ( Hz, 1H), 7.58 (s, 1H), 7.50 (t, J= 9.2 Hz, 2H), 7.37 (d, J= 8.0 Hz, 1H), 7.29 - 7.21 (m, 3H), 7.20 - 7.11 (m, 3H), 6.91 (dd, J= 7.6, 11.6 Hz, 1H), 6.12 (dd, J= 5.2, 8.4 Hz, 1H), 5.10 (dd, J= 5.2, 13.2 Hz, 1H), 4.69 -4.50 (m, 4H), 4.49 - 4.35 (m, 2H), 4.34 - 4.19 (m, 2H), 3.85 (s, 3H), 2.91 (ddd, J= 5.6, 13.6, 17.6 Hz, 1H), 2.64 - 2.55 (m, 1H), 2.47 - 2.34 (m, 1H), 2.05 - 1.91 (m, 1H). MS obsd. (ESI+) [(M+H)+]:725.3.

[1931] Example 22

[1932] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[2-hydroxy-l-[5-(l- methylpyrazol-4-yl)-2-pyridyl] ethyl] indole-3-carboxamide

[1933]

[1934] Example 22

[1935] To a solution of 1 -[2 -benzyloxy- l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethyl]-7V-[[2-(2, 6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide (50.0 mg, 0.070 mmol) in DCM (2 mL) was added BCl3(1.0 mL, 0.070 mmol). The mixture was stirred at 20 °C for 2 hours and quenched by water (2 mL). The resulting mixture was concentrated under reduced pressure, and the residue was purified by prep-HPLC (FA as additive) to give N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[2-hydroxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethyl]indole-3-carboxamide (13.6 mg) as a white solid.

[1936] 1H NMR (400 MHz, DMSO-6) δ = 10.98 (s, 1H), 8.85 (m, 1H), 8.72 (s, 1H), 8.33 (s, 1H), 8.13 (s, 1H), 8.03 (s, 1H), 7.89 (s, 1H), 7.80 (s, 1H), 7.14 (s, 1H), 7.69 (d, J= 7.6 Hz, 1H), 7.63 (d, J= 1.6 Hz, 1H), 7.59 (s, 1H), 7.53 (d, J= 7.6 Hz, 1H), 7.20 (m, 1H), 7.18 (t, J= 2.0 Hz, 1H), 5.65 (s, 2H), 5.10 (dd, J= 5.2, 13.2 Hz, 1H), 4.57 (d, J= 6.0 Hz, 2H), 4.71- 4.28 (m, 1H), 4.71- 4.28 (m, 1H), 4.33 - 4.29 (m, 1H), 3.37-3.13 (m, 3H),2.92 - 2.88 (m, 1H), 2.62 -2.53 (m, 1H), 2.43 - 2.39 (m, 1H), 2.02 - 1.99 (m, 1H). MS obsd. (ESI+) [(M+H)+]:636.3.

[1937] Example 23Docket No. P60153

[1938] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2- hydroxyethoxy)phenyl]methyl]indole-3-carboxamide

[1939]

[1940] Example 23

[1941] Step a: Preparation of methyl 4-chloro-l-[[3-(2-tetrahydropyran-2-yloxyethoxy)phenyl] methyl] indole-3-carboxylate

[1942]

[1943] Compound 23a

[1944] To a solution of 2-(2 -bromoethoxy )tetrahydro-27 / -pyran (497 mg, 2.38 mmol) and methyl 4-chloro-l-[(3-hydroxyphenyl)methyl]indole-3-carboxylate (500 mg, 1.58 mmol) in DMF (10.0 mL) was added Cs2CO3(1.54 g, 4.75 mmol). The mixture was stirred at room temperature for 15 hours and then concentrated under reduced pressure. The residue was purified by prep-HPLC (FA as additive) to give methyl 4-chloro-l-[[3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxylate (200 mg). MS obsd. (ESI+) [{35C1} (M+H)+]:444.3.

[1945] Step b: Preparation of 4-chloro-l-[[3-(2-tetrahydropyran-2-yloxyethoxy)phenyl] methyl] indole-3-carboxylic acid

[1946]

[1947] Compound 23b

[1948] To a solution of methyl 4-chloro-l-[[3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxylate (200 mg, 0.110 mmol)in MeOH (10.0 mL) and water (2.0 mL) was added NaOH (22.0 mg, 0.550 mmol) and the solution was stirred at 60 °C for 15 hours. After cooling to room temperature, the mixture was concentrated, and the residue wasDocket No. P60153

[1949] purified by prep-HPLC (FA as additive) to give 4-chloro-l-[[3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxylic acid (150 mg). MS obsd. (ESI+) [{35C1} (M+H)+]:430.1.

[1950] Step c: Preparation of 4-chloro-V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl] methyl] - 1- [ [3-(2-tetrahydropyran-2-yloxyethoxy)phenyl] methyl] indole-3-car boxamide

[1951]

[1952] Compound 23c

[1953] To a solution of 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride (130mg, 0.420 mmol) and 4-chloro-l-[[3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxylic acid (150 mg, 0.350 mmol) in ACN (5.0 mL) were added NMI (0.20 mL, 0.350 mmol) and TCFH (195 mg, 0.700 mmol). After being stirred at 20 °C for 2 hours, the mixture was concentrated, and the residue was purified by prep-HPLC to give 4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxamide (80.0 mg). MS obsd. (ESI+) [{35C1} (M+H)+]:685.2.

[1954] Step d: Preparation of 4-chloro-V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl] methyl] - 1- [ [3-(2-hydroxyethoxy)phenyl] methyl] indole-3-carboxamide

[1955]

[1956] To a solution of 4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxamide (80.0 mg, 0.120 mmol) in EtOH (1.0 mL) was added PTSA (29.3 mg, 0.120 mmol) and the mixture was stirred at 60 °C for 15 hours. After cooling to room temperature, the mixture was concentrated. The residue was purified by prep-HPLC (FA as additive) to give 4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethoxy)phenyl]methyl]indole-3-carboxamide (30.5 mg).1H NMR (400 MHz, DMSO-6) δ = 10.99 (s, 1H), 8.76 (t, = 6.0 Hz, 1H), 7.98 (s, 1H), 7.70 (d, = 7.6 Hz, 1H),Docket No. P60153

[1957] 7.60 (s, 1H), 7.53 (s, 1H), 7.51 - 7.48 (m, 1H), 7.22 (t, J= 8.0 Hz, 1H), 7.19 - 7.12 (m, 2H), 6.83 (br s, 1H), 6.82 (br d, J= 2.0 Hz, 2H), 5.44 (s, 2H), 5.12 (dd, J = 5.2, 13.2 Hz, 1H), 4.84 (t, J= 5.6 Hz, 1H), 4.57 (d, J= 6.0 Hz, 2H), 4.49 - 4.41 (m, 1H), 4.36 - 4.28 (m, 1H), 3.92 (t, J= 4.8 Hz, 2H), 3.70 - 3.63 (m, 2H), 2.98 - 2.83 (m, 1H), 2.60 (br dd, J= 2.0, 15.2 Hz, 1H), 2.40 (m, 1H), 2.05 - 1.96 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:601.2.

[1958] Example 24

[1959] 4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethoxy)- 4-methyl-phenyl]methyl]indole-3-carboxamide

[1960]

[1961] Step a: Preparation of 4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)benzaldehyde

[1962]

[1963] Compound 24a

[1964] A mixture of 3-hydroxy-4-methyl-benzaldehyde (3.00 g, 22.1 mmol), Cs2CO3(21.5 g, 66.1 mmol) and 2-(2 -bromoethoxy )tetrahydro-27 / -pyran (4.61 mg, 22.1 mmol) in DMF (50 mL) was stirred at 80 °C for 12 hours. After cooling to room temperature, the mixture was poured into water (200 mL) and extracted with EtOAc (50 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 50% EtOAc in PE) to afford 4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)benzaldehyde (3.70 g). MS obsd. (ESI+) [{35C1} (M+H)+]:265.1.

[1965] Step b: Preparation of [4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methanol

[1966]

[1967] Docket No. P60153

[1968] To a solution of 4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)benzaldehyde (2.00 g, 7.57 mmol) in ethanol (50.0 mL) was added NaBH4(1.43g, 37.8 mmol) at 0 °C. The mixture was stirred at 25 °C for 2 hours under N2 atmosphere. The mixture was poured into water (200 mL) and extracted with EtOAc (50 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 50% EtOAc in PE) to afford to give [4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methanol (1.70 g).

[1969] 1H NMR (400 MHz, DMSO-6) δ = 7.12 (d, = 7.6 Hz, 1H), 6.89 (s, 1H), 6.85 (d, J= 7.6 Hz, 1H), 4.76 (t, J= 3.2 Hz, 1H), 4.65 (s, 2H), 4.21 - 4.15 (m, 2H), 4.13 - 4.03 (m, 1H), 3.98 - 3.89 (m, 1H), 3.88 - 3.80 (m, 1H), 3.62 - 3.47 (m, 1H), 2.23 (s, 3H), 1.90 - 1.81 (m, 1H), 1.80 - 1.70 (m, 1H), 1.69 - 1.62 (m, 2H), 1.59 - 1.49 (m, 2H).

[1970] Step c: Preparation of methyl 4-chloro-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl] methyl] indole-3-carboxylate

[1971]

[1972] Compound 24c

[1973] To a mixture of methyl [4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methanol (1.70g, 1.31 mmol) and methyl 4-chloro-1-indole-3-carboxylate (1.82 g, 1.28 mmol) in toluene (20 mL) was added CMBP (2.62g, 2.33 mmol). The mixture was stirred at 60 °C for 12 hours. After cooling to room temperature, the mixture was concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 50% EtOAc in PE) to afford methyl 4-chloro-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxylate (500 mg). MS obsd. (ESI+) [{35C1} (M+H)+]:458.2.

[1974] Step d: Preparation of 4-chloro-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl] methyl] indole-3-carboxylic acidDocket No. P60153

[1975]

[1976] Compound 24d

[1977] To a mixture of methyl 4-chloro-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxylate (600 mg, 1.31 mmol,) in methanol (4.0 mL) was added NaOH solution (262 mg in water 4.0 mL). The mixture was stirred at 60 °C for 12 hours. After cooling to room temperature, the mixture was poured into water (150 mL), and pH was adjusted to about 2 by adding 1M HCl. The solution was extracted with DCM (50 mL) three times. The combined organic layer was washed with brine (150 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by prep-HPLC (FA as additive) to give 4-chloro-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxylic acid (500 mg). MS obsd. (ESI-) [{35Cl} (M+H)+]: 442.1.

[1978] Step e: Preparation of 4-chloro-V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxamide

[1979]

[1980] Compound 24e

[1981] To a mixture of 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride (209 mg, 0.680 mmol), DIPEA (363 mg, 2.82 mmol), HATU (256 mg, 0.680 mmol) in DMF (3.0 mL) was added 4-chloro-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxylic acid (250 mg, 0.56 mmol). The mixture was stirred at 25 °C for 1 hour. The solution was purified by prep-HPLC (FA as additive) to give 4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxamide (300 mg). MS obsd. (ESI+) [{35C1} (M+H)+]: 699.2.

[1982] Step f: Preparation of 4-chloro-V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethoxy)-4-methyl-phenyl]methyl]indole-3-carboxamideDocket No. P60153

[1983]

[1984] Example 24

[1985] A mixture of 4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxamide (150 mg, 0.210 mmol) in DCM (5.0 mL) and TFA (1.0 mL, 0.210 mmol) was stirred at 25 °C for 1 hour. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (FA as additive) to afford 4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethoxy)-4-methyl-phenyl]methyl]indole-3-carboxamide (14.2 mg).1H NMR (400 MHz, DMSO-6) δ = 10.99 (s, 1H), 8.73 (t, = 6.0 Hz, 1H), 7.96 (s, 1H), 7.72 - 7.67 (m, 1H), 7.59 (s, 1H), 7.56 - 7.49 (m, 2H), 7.19 - 7.11 (m, 2H), 7.08 - 7.02 (m, 1H), 7.00 (s, 1H), 6.71 - 6.65 (m, 1H), 5.39 (s, 2H), 5.12 (dd, J= 5.2, 13.2 Hz, 1H), 4.61 - 4.51 (m, 2H), 4.49 - 4.40 (m, 1H), 4.35 - 4.27 (m, 1H), 3.95 (t, J= 5.2 Hz, 2H), 3.71 (t, J= 5.2 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.60 (d, J= 16.8 Hz, 1H), 2.46 -2.34 (m, 1H), 2.10 (s, 3H), 2.05 - 1.95 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]: 615.3.

[1986] Example 25

[1987] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-4-fluoro-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2- hydroxyethoxy)-4-methyl-phenyl]methyl]indole-3-carboxamide

[1988]

[1989] The title compound (12.2 mg) was prepared in analogy to the preparation of Example 24 By using 3-[5-(aminomethyl)-4-fluoro-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride instead of 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride in Step e.

[1990] 1H NMR (400 MHz, DMSO-6) δ = 11.02 (s, 1H), 8.72 (t, J= 6.0 Hz, 1H), 7.98 (s, 1H), 7.68 - 7.63 (m, 1H), 7.61 - 7.57 (m, 1H), 7.54 (dd, J= 1.6, 7.2 Hz, 1H), 7.19 - 7.12 (m, 2H), 7.05 (d, J= 7.6 Hz, 1H), 7.01 (s, 1H), 6.68 (d, J= 7.6 Hz, 1H), 5.40 (s, 2H), 5.13 (dd, J= 5.2, 13.2 Hz, 1H), 4.96 - 4.74 (m, 1H), 4.64 - 4.54 (m, 3H), 4.45 - 4.36 (m, 1H), 3.96 (t, J= 5.2 Hz, 2H), 3.72 (t, J= 5.2 Hz, 2H),Docket No. P60153

[1991] 2.98 - 2.88 (m, 1H), 2.61 (d, J= 17.2 Hz, 1H), 2.49 - 2.38 (m, 1H), 2.11 (s, 3H), 2.06 - 1.96 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:633.2.

[1992] Example 26

[1993] l-||4-cliloro-3-(2-liydroxyethoxy)phenyl|methyl|-\-||2-(2.6-dioxo-3-piperidyl)-l-oxo- isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide

[1994]

[1995] Example 26

[1996] The title compound (12.2 mg) was prepared in analogy to the preparation of Example 24. By using 4-chl oro-3 -hydroxy -benzaldehyde instead of 3-hydroxy-4-methyl-benzaldehyde in step a and methyl 4-methyl-1-indole-3-carboxylate instead of methyl 4-chloro-1-indole-3-carboxylate in Step c.1H NMR (400 MHz, DMSO-6) δ = 10.99 (br s, 1H), 8.72 (t, J= 6.0 Hz, 1H), 7.93 (s, 1H), 7.70 (d, J= 7.8 Hz, 1H), 7.57 (s, 1H), 7.51 (d, J= 7.6 Hz, 1H), 7.32 (d, J= 8.0 Hz, 2H), 7.24 (d, J= 1.2 Hz, 1H), 7.06 (t, J= 7.6 Hz, 1H), 6.87 (d, J= 7.2 Hz, 1H), 6.70 (dd, J= 1.2, 8.0 Hz, 1H), 5.41 (s, 2H), 5.11 (dd, J= 4.8, 13.2 Hz, 1H), 4.89 (t, J= 5.2 Hz, 1H), 4.57 (br d, J= 6.0 Hz, 2H), 4.49 - 4.41 (m, 1H), 4.36 - 4.26 (m, 1H), 4.05 (t, J= 5.2 Hz, 2H), 3.73 (q, J= 4.8 Hz, 2H), 2.99 - 2.85 (m, 1H), 2.57 (s, 3H), 2.43 - 2.30 (m, 1H), 2.05 - 1.95 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:615.2.

[1997] Example 27

[1998] l-[[4-chloro-3-(2-hydroxyethoxy)phenyl]methyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-4-fluoro-l-oxo- isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide

[1999]

[2000] Example 27

[2001] The title compound (12.2 mg) was prepared in analogy to the preparation of Example 24. By using 4-chloro-3-hydroxy-benzaldehyde instead of 3-hydroxy-4-methyl-benzaldehyde in step a, methyl 4-methyl-1-indole-3-carboxylate instead of methyl 4-chloro-1-indole-3-carboxylate in Step c, and 3-[5-(aminomethyl)-4-fluoro-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochlorideDocket No. P60153

[2002] instead of 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride in Step e.

[2003] 'H NMR (400 MHz, DMSO-6) δ = 11.01 (s, 1H), 8.71 (t, J= 6.0 Hz, 1H), 7.95 (s, 1H), 7.70 - 7.50 (m, 2H), 7.33 (d, J= 8.0 Hz, 2H), 7.24 (d, J= 1.2 Hz, 1H), 7.06 (t, J= 7.6 Hz, 1H), 6.87 (d, J= 7.2 Hz, 1H), 6.75 - 6.57 (m, 1H), 5.41 (s, 2H), 5.12 (dd, J= 4.8, 13.2 Hz, 1H), 4.89 (t, J= 5.6 Hz, 1H), 4.59 (br d, J= 6.4 Hz, 2H), 4.57 - 4.54 (m, 1H), 4.44 - 4.37 (m, 1H), 4.06 (t, J= 5.2 Hz, 2H), 3.74 (q, J= 5.2 Hz, 2H), 3.01 - 2.80 (m, 1H), 2.60 (br d, J= 17.2 Hz, 1H), 2.55 (s, 3H), 2.45 (br dd, J= 4.4, 13.2 Hz, 1H), 2.08 - 1.95 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:633.2.

[2004] Example 28

[2005] 7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethoxy)-4-methyl- phenyl]methyl]-4-methyl-indole-3-carboxamide

[2006]

[2007] The title compound (71.3 mg) was prepared in analogy to the preparation of Example 24. By using methyl 4-methyl-1-indole-3-carboxylate instead of methyl 4-chloro-1-indole-3-carboxylate in Step c.1H NMR (400 MHz, DMSO-6) δ = 10.99 (s, 1H), 8.71 (t, = 6.0 Hz, 1H), 7.92 (s, 1H), 7.70 (d, J= 8.0 Hz, 1H), 7.57 (s, 1H), 7.51 (d, J= 8.0 Hz, 1H), 7.33 (d, J= 8.4 Hz, 1H), 7.08 - 7.01 (m, 2H), 6.98 (s, 1H), 6.86 (d, J= 7.2 Hz, 1H), 6.66 (d, J= 8.0 Hz, 1H), 5.35 (s, 2H), 5.11 (dd, J= 5.2, 13.3 Hz, 1H), 4.83 (t, J= 5.6 Hz, 1H), 4.56 (d, J= 6.0 Hz, 2H), 4.49 - 4.39 (m, 1H), 4.36 - 4.25 (m, 1H), 3.95 (t, J= 5.2 Hz, 2H), 3.71 (q, = 5.2 Hz, 2H), 2.99 - 2.84 (m, 1H), 2.64 - 2.58 (m, 1H), 2.56 (s, 3H), 2.43 - 2.43 (m, 1H), 2.10 (s, 3H), 2.04 - 1.95 (m, 1H). MS obsd. (ESI+) [(M+H)+]:595.2.

[2008] Example 29

[2009] 4-chloro-\-| [2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl ] methyl ]-!-[ [4-fluoro-3-(2- hydroxyethoxy)phenyl]methyl]indole-3-carboxamideDocket No. P60153

[2010]

[2011] Example 29

[2012] The title compound (48.9 mg) was prepared in analogy to the preparation of Example 24. By using 4-fluoro-3 -hydroxy -benzaldehyde instead of 3-hydroxy-4-methyl-benzaldehyde in step a.1H NMR (400 MHz, DMSO-6) δ = 10.99 (s, 1H), 8.73 (t, = 6.0 Hz, 1H), 7.99 (s, 1H), 7.70 (d, J= 8.0 Hz, 1H), 7.59 (s, 1H), 7.56 (dd, J= 1.6, 7.6 Hz, 1H), 7.52 (d, J= 7.6 Hz, 1H), 7.27 (dd, J= 2.0, 8.4 Hz, 1H), 7.19 - 7.10 (m, 3H), 6.77 (ddd, J= 2.0, 4.0, 6.4 Hz, 1H), 5.41 (s, 2H), 5.12 (dd, J= 5.2, 13.2 Hz, 1H), 4.91 (t, J= 5.6 Hz, 1H), 4.57 (d, J= 6.0 Hz, 2H), 4.48 - 4.29 (m, 2H), 4.04 (t, J= 4.8 Hz, 2H), 3.71 (q, J= 5.2 Hz, 2H), 2.98 - 2.85 (m, 1H), 2.64 - 2.55 (m, 1H), 2.46 - 2.38 (m, 1H), 2.05 -1.95 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:619.2.

[2013] Example 30

[2014] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethyl)-4-methyl- phenyl]methyl]-4-methyl-indole-3-carboxamide

[2015]

[2016] Example 30

[2017] Step a: Preparation of methyl l-[(3-bromo-4-methylphenyl)methyl]-4-methyl-lH-indole-3-carboxylate

[2018]

[2019] Compound 30a

[2020] To a stirred solution of methyl 4-methyl-1-indole-3-carboxylate (1.00 g, 5.29 mmol) in DMF (20 mL) were added 2-bromo-4-(bromomethyl)-l -methylbenzene (2.10 g, 7.93 mmol) and K2CO3(1.46 g, 10.6 mmol). The reaction mixture was stirred at room temperature for 16 hours. The reactionDocket No. P60153

[2021] mixture was quenched with water (50 mL) and extracted with EtOAc (50 mL) three times. The combined organic layer was washed with brine (100 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0 - 15% EtOAc in PE) to afford methyl l-[(3-bromo-4-methylphenyl)methyl]-4-methyl-lH-indole-3-carboxylate (1.80 g). MS obsd. (ESI+) [(M+H)+]:372.1

[2022] Step b: Preparation of methyl 4-methyl-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethyl)phenyl] methyl] indole-3-carboxylate

[2023]

[2024] Compound 30b

[2025] A mixture of methyl l-[(3-bromo-4-methylphenyl)methyl]-4-methyl-lH-indole-3-carboxylate (500 mg, 1.34 mmol), potassium trifluoro(2-tetrahydropyran-2-yloxyethyl)borate (476 mg, 2.01 mmol), Pd(amphos)2C12 (95.1 mg, 0.134 mmol) and Cs2CO3(1.31g, 4.03 mmol) in toluene (8 mL) and water (2 mL) was degassed and backfilled with nitrogen for five times. The reaction mixture was heated at 100 °C for 16 hours. The cooled reaction mixture was quenched with water (30 mL) and extracted with ethyl acetate (40 mL) three times. The combined organic layer was washed with brine (100 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0 - 11% EtOAc in PE) to afford methyl 4-methyl-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethyl)phenyl]methyl]indole-3-carboxylate (510 mg). MS obsd. (ESI+) [(M+H)+]:422.1.

[2026] Step c: Preparation of N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethyl)-4-methyl-phenyl]methyl]-4-methyl-indole-3-carboxamide

[2027]

[2028] Example 30

[2029] The title compound (38.0 mg) was prepared in analogy to the preparation of Example 24. By using methyl 4-methyl-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethyl)phenyl]methyl]indole-3-carboxylate instead of methyl 4-chloro-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxylate in step d.. H NMR (400 MHz, DMSO-ifc) 5 =Docket No. P60153

[2030] 10.98 (s, 1H), 8.70 (t, J= 6.2 Hz, 1H), 7.90 (s, 1H), 7.70 (d, J= 7.8 Hz, 1H), 7.57 (s, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.30 (d, J= 8.2 Hz, 1H), 7.18 - 7.10 (m, 1H), 7.08 - 7.00 (m, 2H), 6.96 - 6.90 (m, 1H), 6.86 (d,.7= 7.2 Hz, 1H), 5.34 (s, 2H), 5.11 (dd, J= 13.3, 5.1 Hz, 1H), 4.71 - 4.60 (m, 1H), 4.56 (d, J= 6.0 Hz, 2H), 4.50 - 4.27 (m, 2H), 3.57 - 3.45 (m, 2H), 2.97 - 2.82 (m, 1H), 2.68 (t, J= 7.2 Hz, 2H), 2.64 - 2.54 (m, 4H), 2.45 - 2.32 (m, 1H), 2.22 (s, 3H), 2.06 - 1.94 (m, 1H).. MS obsd. (ESI+) [(M+H)+]: 579.2.

[2031] Example 31

[2032] l-[[4-chloro-3-(2-hydroxyethyl)phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin- 5-yl] methyl] -4-methyl-indole-3-carboxamide

[2033]

[2034] Example 31

[2035] Step a: Preparation of methyl l-[(3-bromo-4-chloro-phenyl)methyl]-4-methyl-indole-3-carboxylate

[2036]

[2037] Compound 31a

[2038] Compound 31a was prepared in analogy to the preparation of 30a. By using 2-bromo-4-(bromomethyl)-l -chloro-benzene instead of 2-bromo-4-(brom om ethyl)- 1 -methylbenzene. MS obsd. (ESI+) [{35C1} (M+H)+]:392.9.

[2039] Step b: Preparation of methyl l-[[4-chloro-3-(2-tetrahydropyran-2-yloxyethyl)phenyl]methyl]-4-methyl-indole-3-carboxylate

[2040]

[2041] Compound 31bDocket No. P60153

[2042] Compound 31b was prepared in analogy to the preparation of 30b by using methyl l-[(3-bromo-4-chloro-phenyl)methyl]-4-methyl-indole-3-carboxylate instead of methyl l-[(3-bromo-4-methylphenyl)methyl]-4-methyl-lH-indole-3-carboxylate. MS obsd. (ESI+) [{35C1} (M+H)+]: 442.1.

[2043] Step c: Preparation of l-[[4-chloro-3-(2-hydroxyethyl)phenyl]methyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide

[2044]

[2045] Example 31

[2046] The title compound (59.3 mg) was prepared in analogy to the preparation of Example 24. By using methyl l-[[4-chloro-3-(2-tetrahydropyran-2-yloxyethyl)phenyl]methyl]-4-methyl-indole-3-carboxylate instead of methyl 4-chloro-l-[[4-methyl-3-(2-tetrahydropyran-2-yloxyethoxy)phenyl]methyl]indole-3-carboxylate in step d. 'H NMR (400 MHz, DMSO-6) 5 = 10.98 (s, 1H), 8.71 (t, J= 6.0 Hz, 1H), 7.92 (s, 1H), 7.70 (d, J= 7.8 Hz, 1H), 7.58 (s, 1H), 7.51 (d, J = 7.9 Hz, 1H), 7.38 - 7.26 (m, 3H), 7.09 - 6.98 (m, 2H), 6.87 (d, J= 7.2 Hz, 1H), 5.40 (s, 2H), 5.11 (dd, J= 13.3, 5.1 Hz, 1H), 4.74 (s, 1H), 4.57 (d, J= 6.0 Hz, 2H), 4.49 - 4.23 (m, 2H), 3.61 - 3.50 (m, 2H), 2.99 - 2.85 (m, 1H), 2.81 (t, J= 7.1 Hz, 2H), 2.67 - 2.54 (m, 4H), 2.47 - 2.30 (m, 1H), 2.06 -1.92 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]: 599.2.

[2047] Example 32

[2048] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(2-hydroxyethoxy)-5-methyl- 2-pyridyl]methyl]-4-methyl-indole-3-carboxamide

[2049]

[2050] Example 32

[2051] Step a: Preparation of methyl 5-bromo-6-[2-[tert-butyl(dimethyl)silyl] oxy ethoxy] pyridine-2-carboxylateDocket No. P60153

[2052]

[2053] Compound 32a

[2054] To a mixture of methyl 5-bromo-6-hydroxy-pyridine-2-carboxylate (4.00 g, 17.2 mmol), 2-[tert-butyl(dimethyl)silyl]oxyethanol (3.95 g, 22.4 mmol) and triphenylphosphine (9.04 g, 34.5 mmol) in THF (100 mL) under nitrogen atmosphere was added a solution of DBAD (7.94 g, 34.5 mmol) in THF (10 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with water (150 mL) and extracted with EtOAc (200 mL) three times. The combined organic layer was dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 20% EtOAc in PE) to afford methyl 5-bromo-6-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]pyridine-2-carboxylate (6.00 g). MS obsd. (ESI+) [(M+H)+]:390.1.

[2055] Step b: Preparation of methyl 6-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-5-methyl-pyridine-2-carboxylate

[2056]

[2057] Compound 32b

[2058] To a mixture of methyl 5-bromo-6-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]pyridine-2-carboxylate (6.00 g, 15.4 mmol) and methylboronic acid (1.38 g, 23.1 mmol) in 1,4-dioxane (90 mL) and water (10 mL) were added K2CO3(4.25 g, 30.7 mmol) and Pd(dppf)Cl2(1.26 g, 1.54 mmol). The reaction mixture was degassed and backfilled with nitrogen for five times and then stirred at 100 °C for 16 hours. The reaction mixture was diluted with water (200 mL) and extracted with EtOAc (300 mL) three times. The combined organic layer was washed with brine (200 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 10% EtOAc in PE) to afford methyl 6-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-5-methyl-pyridine-2-carboxylate (3.00g). MS obsd. (ESI+) [(M+H)+]:326.0.Docket No. P60153

[2059] Step c: Preparation of [6-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-5-methyl-2-pyridyl] methanol

[2060]

[2061] Compound 32c

[2062] To a solution of methyl 6-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-5-methyl-pyridine-2-carboxylate (2.90 g, 8.91 mmol) in THF (30 mL) was added LiAlH4 (676 mg, 17.8 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 2 hours. Then the reaction mixture was quenched with sodium sulfate decahydrate at 0 °C. The resulting mixture was filtered, and the collected solid was washed with EtOAc (100 mL) three times. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel flash chromatography (0 - 12% EtOAc in PE) to afford [6-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-5-methyl-2-pyridyl]methanol (2.00 g). MS obsd. (ESI+) [(M+H)+]:298.1.

[2063] Step d: Preparation of methyl l-[[6-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-5-methyl-2-pyridyl]methyl]-4-methyl-indole-3-carboxylate

[2064]

[2065] Compound 32d

[2066] To a mixture of methyl 4-methyl-1H-indole-3-carboxylate (300 mg, 1.59 mmol) and [6-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-5-methyl-2-pyridyl]methanol (518 mg, 1.74 mmol) in toluene (8 mL) under nitrogen atmosphere was added a solution of CMBP (765 mg, 3.17 mmol) in toluene (2 mL). The reaction mixture was stirred at 120 °C for 3 hours. The cooled reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 9% EtOAc in PE) to afford methyl l-[[6-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-5-methyl-2-pyridyl]methyl]-4-methyl-indole-3 -carboxylate (700 mg). (ESI+) [(M+H)+]:469.3.

[2067] Step e: Preparation of l-[[6-(2-hydroxyethoxy)-5-methyl-2-pyridyl]methyl]-4-methyl-indole-3-carboxylic acidDocket No. P60153

[2068]

[2069] Compound 32e

[2070] To a mixture of methyl l-[[6-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-5-methyl-2-pyridyl]methyl]-4-methyl-indole-3-carboxylate (400 mg, 0.850 mmol) in MeOH (6.0 mL) and water (3 mL) was added lithium hydroxide monohydrate (215 mg, 5.12 mmol). The reaction mixture was stirred at 65 °C for 16 hours. The reaction mixture was diluted with water (20 mL), acidified with HC1 (1 M) until a large amount of solid appeared in the reaction. The precipitate was collected by filtration, washed with water (50 mL) and dried under reduced pressure to give l-[[6-(2-hydroxyethoxy)-5-methyl-2-pyridyl]methyl]-4-methyl-indole-3 -carboxylic acid (260 mg) as a white solid. (ESI+) [(M+H)+]:341.2.

[2071] Step f: Preparation of N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(2-hydroxyethoxy)-5-methyl-2-pyridyl]methyl]-4-methyl-indole-3-carboxamide

[2072]

[2073] Example 32

[2074] To a mixture of l-[[6-(2-hydroxyethoxy)-5-methyl-2-pyridyl]methyl]-4-methyl-indole-3-carboxylic acid (150 mg, 0.440 mmol) and HATU (155 mg, 0.660 mmol) in DMF (6 mL) were added 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride (205 mg, 0.660 mmol) and DIPEA (285 mg, 2.20 mmol). The reaction mixture was stirred at room temperature for 3 hours and the reaction mixture was quenched by the addition of water (50 mL). The suspension was filtered and the solid was collected to give the crude product of N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(2 -hydroxy ethoxy)-5-methyl-2-pyridyl]methyl]-4-methyl-indole-3-carboxamide. The crude product was further purified by Prep-HPLC (FA) to give N-[[2-(2,6-dioxo-3-piperi dyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(2 -hydroxy ethoxy)-5-methyl -2-pyri dyl]methyl]-4-methyl-indole-3 -carboxamide (61.1 mg).

[2075] 'H NMR (400 MHz, DMSO-6) 8 = 10.99 (s, 1H), 8.71 (t, J = 6.0 Hz, 1H), 7.92 (s, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.57 (s, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.08 - 7.01 (m, 2H), 6.98 (s, 1H), 6.86 (d, J = 7.2 Hz, 1H), 6.66 (d, J= 8.0 Hz, 1H), 5.35 (s, 2H), 5.11 (dd, J = 5.2,Docket No. P60153

[2076] 13.3 Hz, 1H), 4.83 (t, J= 5.6 Hz, 1H), 4.56 (d, J= 6.0 Hz, 2H), 4.49 - 4.39 (m, 1H), 4.36 - 4.25 (m, 1H), 3.95 (t, J= 5.2 Hz, 2H), 3.71 (q, J= 5.2 Hz, 2H), 2.99 - 2.84 (m, 1H), 2.64 - 2.58 (m, 1H), 2.56 (s, 3H), 2.43 - 2.43 (m, 1H), 2.10 (s, 3H), 2.04 - 1.95 (m, 1H). (ESI+) [(M+H)+]: 596.2.

[2077] Example 33

[2078] 4-chloro-V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-[2-(2- hydroxy ethoxy)ethoxy] phenyl] methyl] indole-3-carboxamide

[2079]

[2080] Step a: Preparation of l-||3-|2-(2-benzyloxyethoxy)ethoxy|phenyl|methyl|-4-chloro-\-||2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide

[2081]

[2082] Compound 33a was prepared in analogy to the preparation of Example 1. By using 2-(2-bromoethoxy)ethoxymethylbenzene instead of 2-bromoethylbenzene in Step a. (ESI+) [{35C1} (M+H)+]:735.1.

[2083] Step b: Preparation of 2-(2-(3-((4-chloro-3-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)methyl)carbamoyl)-lH-indol-l-yl)methyl)phenoxy)ethoxy)ethyl 2,2,2-trifluoroacetate

[2084]

[2085] Docket No. P60153

[2086] The mixture of l-[[3-[2-(2-benzyloxyethoxy)ethoxy]phenyl]methyl]-4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide (100 mg, 0.140 mmol) and TFA (55.8 mg, 0.680 mmol) was stirred at 60 °C for 12 hours. After cooling to room temperature, the solution was concentrated under reduced pressure to give the crude of 2-[2-[3-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]phenoxy]ethoxy]ethyl 2,2,2-trifluoroacetate (100 mg), which was used in the next step directly without further purification. (ESI+) [{35C1} (M+H)+]:741.1.

[2087] Step c: Preparation of 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-[2-(2-hydroxyethoxy)ethoxy]phenyl]methyl]indole-3-carboxamide

[2088]

[2089] Example 33

[2090] To the solution of 2-[2-[3-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]phenoxy]ethoxy]ethyl 2,2,2-trifluoroacetate (100 mg, 0.130 mmol) in petroleum ether (1.0 mL) and tert-butyl methyl ether (1.0 mL) were added TEA (55.3 mg, 0.670 mmol) and silica gel (50.0 mg). After being stirred at 25 °C for 0.5 hours, the solution was poured into a mixture solvent of DCM and MeOH (DCM: MeOH=10: 1, 20 mL), and the resulting suspension was filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by prep-HPLC (FA as additive) to give 4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-[2-(2-hydroxyethoxy)ethoxy]phenyl]methyl]indole-3-carboxamide (16.3 mg).

[2091] 'H NMR (400 MHz, DMSO-6) δ = 11.03 - 10.93 (m, 1H), 8.75 (t, J= 6.0 Hz, 1H), 7.98 (s, 1H), 7.70 (d, J= 7.6 Hz, 1H), 7.60 (s, 1H), 7.55 - 7.47 (m, 2H), 7.25 - 7.20 (m, 1H), 7.18 - 7.11 (m, 2H), 6.88 - 6.80 (m, 3H), 5.43 (s, 2H), 5.11 (dd, J= 5.2, 13.2 Hz, 1H), 4.65 - 4.54 (m, 3H), 4.48 -4.41 (m, 1H), 4.35 - 4.27 (m, 1H), 4.07 - 3.98 (m, 2H), 3.73 - 3.66 (m, 2H), 3.51 - 3.43 (m, 4H), 2.96 - 2.86 (m, 1H), 2.61 (br d, J= 2.8 Hz, 1H), 2.40 (br dd, J= 4.4, 13.2 Hz, 1H), 2.04 - 1.97 (m, 1H). (ESI+) [{35C1} (M+H)+]:645.1.

[2092] Example 34

[2093] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(l-phenylbutyl)indole-3- carboxamideDocket No. P60153

[2094]

[2095] Example 34

[2096] The title compound (58 mg) was prepared in analogy to the preparation of Example 2. By using 1 -phenyl- 1 -butanol instead of (l-methylindazol-3-yl)m ethanol in Step a.'HNMR (400 MHz, DMSO-6) 8 = 11.04 - 10.96 (m, 1H), 8.76 (t, J = 6.0 Hz, 1H), 8.14 (s, 1H), 7.71 (d, J= 8.0 Hz, 1H), 7.64 - 7.62 (m, 2H), 7.56 - 7.54 (m, 1H), 7.42 (d, J= 7.2 Hz, 2H), 7.32 (t, J= 7.6 Hz, 2H), 7.27 -7.23 (m, 1H), 7.17 - 7.10 (m, 2H), 5.73 - 5.69 (m, 1H), 5.13 (dd, J= 5.2, 13.2 Hz, 1H), 4.59 (d, J= 6.0 Hz, 2H), 4.49 - 4.31 (m, 2H), 2.97 - 2.88 (m, 1H), 2.61 (dd, J= 2.1, 15.2 Hz, 1H), 2.44 - 2.38 (m, 2H), 2.25 - 2.18 (m, 1H), 2.04 - 1.99 (m, 1H), 1.31 - 1.23 (m, 2H), 0.94 (t, J= 7.2 Hz, 3H). MS obsd. (ESI+) [{35C1} (M+H)+]: 583.1.

[2097] Example 35

[2098] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[ (lR)-l-[3-(2- hydroxyethoxy)phenyl] ethyl] indole-3-carboxamide

[2099]

[2100] Example 35

[2101] Step a: Preparation of (15)-l-(3-benzyloxyphenyl)ethanol

[2102]

[2103] Compound 35a

[2104] To a solution of N-[(lS,2S)-2-amino-l,2-diphenyl-ethyl]-4-methyl-benzenesulfonamide (48.5 mg, 0.130 mmol) and dichloro(p-cymene)ruthenium(II) dimer (54.1 mg, 0.090 mmol) in DMF (5 mL) was added TEA (17.9 mg, 0.180 mmol) under N2. The mixture was stirred at 25 °C for 1 hour under N2 to get a solution of reductive catalyst. To a stirring mixture of TEA (893 mg, 8.84 mmol) and FA (1.02 g, 22.1 mmol) was added a solution of l-(3-benzyloxyphenyl)ethanone (1.00 g, 4.42 mmol) inDocket No. P60153

[2105] MTBE (5 mL) at 25 °C. To the resulting solution was added the prepared catalyst solution and the mixture was stirred at 25 °C for 12 hours under N2. The reaction mixture was poured into water (100 mL) and extracted with EtOAc (50 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 20% EtOAc in PE) to afford (15)-l-(3-benzyloxyphenyl)ethanol(900 mg). MS obsd. (ESI+) [{35C1} (M+H)+]: 211.1.

[2106] Step b: Preparation of methyl l-[(lR)-l-(3-benzyloxyphenyl)ethyl]-4-chloro-indole-3-carboxylate

[2107]

[2108] Compound 35b

[2109] A mixture of (15)-l-(3-benzyloxyphenyl)ethanol (900 mg, 3.94 mmol), methyl 4-chloro-1H-indole-3-carboxylate (826 mg, 3.94 mmol) and 2-(tributyl-k5-phosphanylidene)acetonitrile (1.90 g, 7.88 mmol) in toluene (10 mL) was stirred at 100 °C for 12 hours. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 50% EtOAc in PE) to afford methyl l-[(lA)-l-(3-benzyloxyphenyl)ethyl]-4-chloro-indole-3 -carboxylate (600 mg). MS obsd. (ESI+) [{35C1} (M+H)+]: 420.1.

[2110] Step c: Preparation of methyl 4-chloro-l-[(ll?)-l-(3-hydroxyphenyl)ethyl]indole-3-carboxylate

[2111]

[2112] Compound 35c

[2113] To a mixture of methyl l-[(lA)-l-(3-benzyloxyphenyl)ethyl]-4-chloro-indole-3-carboxylate (600 mg, 1.43 mmol), LiCl (180 mg, 4.29 mmol) in THF (2 mL) was added Pd / C (200.0 mg, 5% contained 50% water) at 25 °C under N2. The mixture was degassed and purged with H2 three times and was stirred at 25 °C for 1 hour under H2 atmosphere (15 psi). The reaction mixture was filtered,Docket No. P60153

[2114] and the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC (TFA as additive) and lyophilized to give methyl 4-chloro-l-[(17?)-l-(3-hydroxyphenyl)ethyl]indole-3-carboxylate (330 mg). MS obsd. (ESI+) [{35C1 } (M+H)+]: 330.0.

[2115] Step d: Preparation of methyl 4-chloro-l-[(ll?)-l-[3-(2-hydroxyethoxy)phenyl] ethyl] indole-3-carboxylate

[2116]

[2117] Compound 35d

[2118] A mixture of 2-bromoethanol (170 mg, 1.36 mmol), methyl 4-chloro-l-[(17?)-l-(3-hydroxyphenyl)ethyl]indole-3-carboxylate (300 mg, 0.910 mmol) and Cs2CO3(593 mg, 1.82 mmol) in DMF (5.0 mL) was stirred at 100 °C for 4 hours. After cooling to room temperature, the reaction mixture was poured into water (20 mL) and extracted with EtOAc (50 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 50% EtOAc in PE) to afford methyl 4-chloro-l-[(lA)-l-[3-(2-hydroxyethoxy)phenyl]ethyl]indole-3-carboxylate (300 mg). MS obsd. (ESI+) [{35C1} (M+H)+]: 374.1.

[2119] Step e: Preparation of 4-chloro-l-[(ll?)-l-[3-(2-hydroxyethoxy)phenyl] ethyl] indole-3-carboxylic acid

[2120]

[2121] Compound 35e

[2122] A mixture of methyl 4-chloro-l-[(17?)-l-[3-(2-hydroxyethoxy)phenyl]ethyl]indole-3-carboxylate (300 mg, 0.800 mmol) and NaOH (32.0 mg, 8.03 mmol) in MeOH (3.0 mL) and water (1.0 mL) was stirred at 70 °C for 1.5 hours. After cooling to room temperature, the mixture was poured into water (50 mL), and pH was adjusted to 2 by adding HC1 (1 M). The solution was extracted with DCM (50 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by prep-HPLC (FADocket No. P60153

[2123] as additive) to give 4-chloro-l-[(lA)-l-[3-(2-hydroxyethoxy)phenyl]ethyl]indole-3-carboxylic acid (200 mg). MS obsd. (ES ) [{35C1} (M-H) ]: 358.0.

[2124] Step f: Preparation of 4-chloro-V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl] methyl] -l-[ (ll?)-l-[3-(2-hydroxyethoxy)phenyl] ethyl] indole-3-carboxamide

[2125]

[2126] Example 35

[2127] A mixture of 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride (206 mg, 0.670 mmol), 4-chloro-l-[(lA)-l-[3-(2-hydroxyethoxy)phenyl]ethyl]indole-3-carboxylic acid (200 mg, 0.560 mmol), DIPEA (358 mg, 2.78 mmol) and HATU (232.34 mg, 0.61 mmol) in DMF (2 mL) was stirred at 25 °C for 1 hour. The mixture was then concentrated under reduced pressure, and the residue was purified by prep-HPLC (FA as additive) to give 4-chloro-A-[[2-(2,6-di oxo-3 -piperidyl)- 1 -oxo-isoindolin-5-yl]methyl]- 1 -[( 1R)- 1 -[3 -(2-hydroxyethoxy)phenyl]ethyl]indole-3-carboxamide (167 mg).

[2128] 1HNMR (400MHz, DMSO-de) 8 = 11.01 (s, 1H), 8.78 (t, J= 6.0 Hz, 1H), 8.13 (s, 1H), 7.71 (d, J= 8.0 Hz, 1H), 7.62 (s, 1H), 7.54 (d, J= 8.0 Hz, 1H), 7.47 (q, J= 4.4 Hz, 1H), 7.22 (t, J= 8.0 Hz, 1H), 7.12 (d, J= 4.4 Hz, 2H), 6.89 - 6.78 (m, 3H), 5.85 (q, J= 7.2 Hz, 1H), 5.13 (dd, J= 5.2, 13.2 Hz, 1H), 4.59 (d, J= 6.0 Hz, 2H), 4.49 - 4.41 (m, 1H), 4.37 - 4.28 (m, 1H), 3.93 (t, J= 4.8 Hz, 2H), 3.67 (t, J= 4.8 Hz, 2H), 2.98 - 2.86 (m, 1H), 2.60 (br d, J= 16.8 Hz, 1H), 2.41 (dq, J= 4.4, 13.2 Hz, 1H), 2.06 - 1.96 (m, 1H), 1.88 (d, J= 6.8 Hz, 3H). MS obsd. (ESI+) [{35C1} (M+H)+]: 615.2.

[2129] Example 36

[2130] 4-chloro-V-[ [2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[ (lS)-l-[3-(2- hydroxyethoxy)phenyl] ethyl] indole-3-carboxamide

[2131]

[2132] Docket No. P60153

[2133] Example 36

[2134] Step a: Preparation of (ll?)-l-(3-benzyloxyphenyl)ethanol

[2135]

[2136] Compound 36a

[2137] To a solution of N-[(lR,2A)-2-amino-l,2-diphenyl-ethyl]-4-methyl-benzenesulfonamide (48.5 mg, 0.130 mmol) and dichloro(p-cymene)ruthenium(II) dimer (54.1 mg, 0.090 mmol) in DMF (5 mL) was added TEA (17.9 mg, 0.180 mmol) under N2. The mixture was stirred at 25 °C for 1 hour under N2 to get a solution of reductive catalyst. To a stirring mixture of TEA (893 mg, 8.84 mmol) and FA (1.02 g, 22.1 mmol) was added a solution of l-(3-benzyloxyphenyl)ethanone (1.00 g, 4.42 mmol) in MTBE (5 mL) at 25 °C. To the resulting solution was added the prepared catalyst solution and the mixture was stirred at 25 °C for 12 hours under N2. The reaction mixture was poured into water (100 mL) and extracted with EtOAc (50 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 10% EtOAc in PE) to afford (17?)-l-(3-benzyloxyphenyl)ethanol (900 mg). MS obsd. (ESI+) [{35C1} (M+H)+]: 211.1.

[2138] Step b: Preparation of 4-chloro-V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl] methyl] -l-[ (lS)-l-[3-(2-hydroxyethoxy)phenyl]ethyl]indole-3-carboxamide

[2139]

[2140] Example 36

[2141] The title compound (62.9 mg) was prepared in analogy to the preparation of Example 35. By using (lA)-l-(3-benzyloxyphenyl)ethanol instead of (15)-l-(3-benzyloxyphenyl)ethanol in Step b.

[2142] 'H NMR (400 MHz, DMSO-6) δ = 11.00 (s, 1H), 8.77 (t, J= 6.0 Hz, 1H), 8.12 (s, 1H), 7.71 (d, J= 7.6 Hz, 1H), 7.61 (s, 1H), 7.54 (d, J= 7.6 Hz, 1H), 7.50 - 7.44 (m, 1H), 7.21 (t, J= 8.0 Hz, 1H), 7.12 (d, J= 4.4 Hz, 2H), 6.88 - 6.77 (m, 3H), 5.85 (q, J= 6.4 Hz, 1H), 5.12 (dd, J= 4.8, 13.2 Hz, 1H), 4.58 (d, J= 6.0 Hz, 2H), 4.50 - 4.41 (m, 1H), 4.36 - 4.27 (m, 1H), 3.96 - 3.88 (m, 2H), 3.67 (t, J= 4.8 Hz, 2H), 2.97 - 2.86 (m, 1H), 2.59 (d, J= 17.2 Hz, 1H), 2.46 - 2.35 (m, 1H), 2.05 - 1.96 (m, 1H), 1.88 (d, J= 6.8 Hz, 3H). MS obsd. (ESI+) [{35C1} (M+H)+]: 615.3.Docket No. P60153

[2143] Example 37

[2144] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2- hydroxyethylsulfanyl)phenyl]methyl]-4-methyl-indole-3-carboxamide

[2145]

[2146] Example 37

[2147] Step a: Preparation of 2-(3-bromophenyl)sulfanylethoxy-tert-butyl-dimethyl-silane

[2148]

[2149] Compound 37a

[2150] To a mixture of 3 -bromothiophenol (6.00 g, 31.7 mmol) and (2-bromoethoxy)-tert-butyldimethylsilane (9.87 g, 41.2 mmol) in DMF (50 mL) was added K2CO3(6.58 g, 47.6 mmol) and the reaction mixture was stirred at 60 °C for 4 hours. The reaction mixture was then diluted with water (150 mL) and extracted with EtOAc (200 mL) three times. The combined organic layer was washed with brine (200 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 5% EtOAc in PE) to afford 2-(3-bromophenyl)sulfanylethoxy-tert-butyl-dimethyl-silane (12.0 g). 'H NMR (400 MHz, CDCh) 8 = 7.51 (t,.7= 2.0 Hz, 1H), 7.34 - 7.25 (m, 2H), 7.15 (t, = 7.8 Hz, 1H), 3.83 (t, = 7.0 Hz, 2H), 3.09 (t, J= 6.8 Hz, 2H), 0.91 (s, 9H), 0.08 (s, 6H).

[2151] Step b: Preparation of [3- [2- [tert-butyl(dimethyl)silyl]oxyethylsulfanyl] phenyl] methanol

[2152]

[2153] Compound 37b

[2154] To a mixture of 2-(3-bromophenyl)sulfanylethoxy-tert-butyl-dimethyl-silane (12.0 g, 34.5 mmol) and tributylstannylmethanol (15.5 g, 48.4 mmol) in 1,4-dioxane (100 mL) was added XPhos Pd G2 (2.71 g, 3.45 mmol). The reaction mixture was then stirred at 100 °C under N2 atmosphere for 16 hours. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0- 11% EtOAc in PE) to afford [3-[2-[tert-butyl(dimethyl)silyl]oxyethylsulfanyl]phenyl]methanol (8.00Docket No. P60153

[2155] g). 'H NMR (400 MHz, CDCI3) 6 = 7.38 - 7.35 (m, 1H), 7.31 - 7.27 (m, 2H), 7.20 - 7.15 (m, 1H), 4.66 (d, J= 4.8 Hz, 2H), 3.82 (t, J = 7.2 Hz, 2H), 3.09 (t, J = 7.0 Hz, 2H), 2.01 (br s, 1H), 0.91 (s, 9H), 0.07 (s, 6H).

[2156] Step c: Preparation of N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethylsulfanyl)phenyl]methyl]-4-methyl-indole-3-carboxamide

[2157]

[2158] Example 37

[2159] The title compound (25.3 mg) was prepared in analogy to the preparation of Example 32. By using [3-[2-[tert-butyl(dimethyl)silyl]oxyethylsulfanyl]phenyl]methanol instead of [6-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-5-methyl-2-pyridyl]methanol in step d. 'HNMR (400 MHz, DMSO-6) 8 = 10.95 (s, 1H), 8.70 (t, J= 6.0 Hz, 1H), 7.93 (s, 1H), 7.70 (d, J= 7.6 Hz, 1H), 7.58 (s, 1H), 7.51 (d,.7= 7.6 Hz, 1H), 7.31 (d, = 8.0 Hz, 1H), 7.28 - 7.18 (m, 3H), 7.06 (t, J= 7.6 Hz, 1H), 7.01 - 6.96 (m, 1H), 6.87 (d, J= 7.2 Hz, 1H), 5.41 (s, 2H), 5.11 (dd, J= 13.2, 4.8 Hz, 1H), 4.90 (br s, 1H), 4.57 (d, J= 6.0 Hz, 2H), 4.45 (d, J= 17.2 Hz, 1H), 4.32 (d, J= 17.2 Hz, 1H), 3.53 (t, J= 7.0 Hz, 2H), 3.01 (t, J= 6.8 Hz, 2H), 2.97 - 2.84 (m, 1H), 2.64 - 2.53 (m, 4H), 2.45 - 2.32 (m, 1H), 2.08 - 1.93 (m, 1H). MS obsd. (ESI+) [(M+H)+]: 597.2.

[2160] Example 38

[2161] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[l-(2- hydroxyethyl)pyrazol-4-yl] phenyl] methyl] indole-3-carboxamide

[2162]

[2163] Example 38

[2164] Step a: Preparation of tert-butyl-dimethyl-[2-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazol-l-yl] ethoxy] silaneDocket No. P60153

[2165]

[2166] Compound 38a

[2167] To a solution of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-U / -pyrazole and 2-bromoethoxy-tert-butyl-dimethyl-silane (3.19 g, 13.4 mmol)in ACN (20 mL) was added K2CO3(1.42 g, 10.3 mmol). The mixture was stirred at 80 °C for 12 hours. After cooling to room temperature, the mixture was poured into water (150 mL) and extracted with EtOAc (50 mL) three times. The combined organic layer was washed with brine (100 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 10% EtOAc in PE) to afford tert-butyl-dimethyl-[2-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazol-l-yl]ethoxy]silane (2.20 g). MS obsd. (ESI+) [(M+H)+]:353.1.

[2168] Step b: Preparation of [4-[l-[2-[tert-butyl(dimethyl)silyl]oxyethyl]pyrazol-4-yl] phenyl] methanol

[2169]

[2170] Compound 38b

[2171] To a solution of tert-butyl-dimethyl-[2-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazol-l-yl]ethoxy]silane (1.90 g, 5.39 mmol) and 4-bromobenzyl alcohol (1.01 g, 5.39 mmol) in 1,4-dioxane (8 mL) and water (1 mL) was added K3PO4(2.23 g, 16.1 mmol) and Pd(dppf)Cl2(394 mg, 0.540 mmol). The mixture was stirred at 80 °C under N2 atmosphere for 12 hours. After cooling to room temperature, the mixture was poured into water (100 mL) and extracted with EtOAc (50 mL) three times. The combined organic layer was washed with brine (100 mL), dried over Na2SO4and concentrated under reduced pressure to give the crude of [4-[l-[2-[tert-butyl(dimethyl)silyl]oxyethyl]pyrazol-4-yl]phenyl]methanol (1.40 g), which was used in the next step directly without further purification. MS obsd. (ESI+) [(M+H)+]:333.1.

[2172] Step c: Preparation of N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamideDocket No. P60153

[2173]

[2174] Example 38

[2175] The title compound (63.3 mg) was prepared in analogy to the preparation of Example 32. By using [4-[l-[2-[tert-butyl(dimethyl)silyl]oxyethyl]pyrazol-4-yl]phenyl]methanol instead of [6-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-5-methyl-2-pyridyl]methanol in step d.1H NMR (400 MHz, DMSO-6) 8 = 10.98 (s, 1H), 8.46 - 8.40 (m, 1H), 8.10 (d, J= 13.6 Hz, 2H), 7.82 (s, 1H), 7.70 (d, J= 8.0 Hz, 1H), 7.58 (s, 1H), 7.54 - 7.49 (m, 3H), 7.41 (d, J= 8.4 Hz, 1H), 7.26 (d, J= 8.4 Hz, 2H), 7.17 (dt, J= 5.2, 8.0 Hz, 1H), 6.92 (dd, J= 7.6, 11.6 Hz, 1H), 5.46 (s, 2H), 5.10 (dd, J= 5.2, 13.2 Hz, 1H), 4.91 (t, J= 5.2 Hz, 1H), 4.59 (br d, J= 5.6 Hz, 2H), 4.48 - 4.41 (m, 1H), 4.34 - 4.28 (m, 1H), 4.12 (t, J= 5.6 Hz, 2H), 3.73 (q, J= 5.6 Hz, 2H), 2.96 - 2.86 (m, 1H), 2.61 (br d, J= 1.6 Hz, 1H), 2.38 (br dd, J= 4.0, 12.8 Hz, 1H), 2.03 - 1.96 (m, 1H). MS obsd. (ESI+) [(M+H)+]:635.1.

[2176] Example 39

[2177] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(2-hydroxy-l-phenyl- ethyl)indole-3-carboxamide

[2178]

[2179] Example 39

[2180] Step a: Preparation of 2-(benzyloxy)-l-phenylethan-l-ol

[2181]

[2182] Compound 39a

[2183] To the solution of benzyloxyacetaldehyde (2.00 g, 13.3 mmol) in THF (20.0 mL) was added phenylmagnesium bromide (3M in THF, 13.3 mL, 39.9 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at 0 °C for 2 hours. The solution was poured into saturated aqueous NH4Cl solution (20 mL), and the mixture was extracted with EtOAc (20 mL) three times. The combined organic layerDocket No. P60153

[2184] was washed with brine (20 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / ethyl acetate 0-20%) to give 2-benzyloxy-l-phenyl-ethanol (2.00 g, 65.6%). MS obsd. (ESI+) [{35C1} (M+H)+]: 229.0.

[2185] Step b: Preparation of methyl l-(2-(benzyloxy)-l-phenylethyl)-4-chloro-lZ7-indole-3-carboxylate

[2186]

[2187] Compound 39b

[2188] To a solution of 2-benzyloxy-l-phenyl-ethanol (1.70 g, 7.45 mmol) and methyl 4-chloro-1H-indole-3-carboxylate (1.60 g, 7.45 mmol) in toluene (20.0 mL) was added CMBP (2.69 g, 11.2 mmol) and the mixture was stirred at 90 °C for 12 hours. After cooling to room temperature, The mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (petroleum ether / ethyl acetate 0-50%) to give methyl 1 -(2 -benzyloxy- 1 -phenyl-ethyl)-4-chl oro-indole-3 -carboxylate (2.10 g). MS obsd. (ESI+) [{35C1} (M+H)+]: 420.1.

[2189] Step c: Preparation of l-(2-(benzyloxy)-l-phenylethyl)-4-chloro-lZ7-indole-3-carboxylic acid

[2190]

[2191] Compound 39c

[2192] To a solution of methyl 1 -(2 -benzyloxy- l-phenyl-ethyl)-4-chloro-indole-3 -carboxylate (500 mg, 1.19 mmol) in MeOH (2.0 mL) was added NaOH (4.0 mL, 2 M in water, 4.00 mmol) and the mixture was stirred at 60 °C for 12 hours. After cooling to room temperature, the solution was poured into water (10 mL), and the mixture was extracted with EtOAc (10 mL) three times. The combined organic layer was washed with brine (10 mL), dried over Na2SO4and concentrated under reduced pressure toDocket No. P60153

[2193] give the crude of 1 -(2 -benzyloxy- l-phenyl-ethyl)-4-chloro-indole-3 -carboxylic acid (380 mg), which was used in the next step directly without further purification. MS obsd. (ESI‘) [ {35Cl } (M-H)']:404.1.

[2194] Step d: Preparation of l-(2-benzyloxy-l-phenyl-ethyl)-4-chloro-\-||2-(2.6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl] methyl] indole-3-carboxamide

[2195]

[2196] Compound 39d

[2197] To a solution of 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione (230 mg, 0.840 mmol) and l-(2-benzyloxy-l-phenyl-ethyl)-4-chloro-indole-3-carboxylic acid (342 mg, 0.840 mmol) in ACN (2.5 mL) were added NMI (345 mg, 4.21 mmol) and TCFH (471 mg, 1.68 mmol). After being stirred at 25 °C for 5 hours, the mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / ethyl acetate 0-100%) to give l-(2-benzyloxy-l-phenyl-ethyl)-4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide (400 mg). MS obsd. (ESI+) [{35C1} (M+H)+]:661.1.

[2198] Step e: Preparation of 2-(4-chloro-3-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)methyl)carbamoyl)-lEZ-indol-l-yl)-2-phenylethyl 2,2,2-trifluoroacetate

[2199]

[2200] Compound 39e

[2201] A solution of l-(2-benzyloxy-l-phenyl-ethyl)-4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide (120 mg, 0.180 mmol) in TFA (1.0 mL, 0.040 mmol) was stirred at 80 °C for 12 hours. After cooling to room temperature, the solution was concentrated under reduced pressure to give the crude of [2-[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]-2-phenyl-ethyl] 2,2,2-trifluoroacetate (100 mg), which was used into next step directly without further purification. MS obsd. (ESI+) [{35C1 } (M+H)+]: 667.2.Docket No. P60153

[2202] Step f: Preparation of 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(2-hydroxy-l-phenyl-ethyl)indole-3-carboxamide

[2203]

[2204] Example 39

[2205] To a solution of [2-[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]-2-phenyl-ethyl] 2,2,2-trifluoroacetate (100 mg, 0.150 mmol) in MTBE (1.0 mL) were added TEA (30.2 mg, 0.300 mmol) and silica gel (50.0 mg). After being stirred at 25 °C for 0.5 hours, the solution was poured into DCM / MeOH (20 mL, 10 / 1) and the resulting suspension was filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by prep-HPLC (FA as additive) to give 4-chloro-A-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]- 1 -(2-hydroxy- 1 -phenyl-ethyl)indole-3 -carboxamide (13.7 mg).

[2206] 'HNMR (400 MHz, DMSO-6) 8 = 10.98 (br s, 1H), 8.72 (t, J= 6.4 Hz, 1H), 8.15 (s, 1H), 7.71 (d, J= 7.6 Hz, 1H), 7.62 (s, 1H), 7.54 (d, J= 8.0 Hz, 1H), 7.45 (dd, J= 3.2, 5.6 Hz, 1H), 7.33 - 7.26 (m, 5H), 7.13 - 7.09 (m, 2H), 5.75 (dd, J=4.8, 8.8 Hz, 1H), 5.31 (t,. / = 5.2 Hz, 1H), 5.12 (dd, J= 5.2, 13.6 Hz, 1H), 4.59 (br t, J= 4.8 Hz, 2H), 4.49 - 4.42 (m, 1H), 4.34 (s, 1H), 4.29 - 4.22 (m, 1H), 4.06 (td, J= 4.8, 11.6 Hz, 1H), 2.96 - 2.87 (m, 1H), 2.62 (br d, J= 2.4 Hz, 1H), 2.41 (br dd, J= 4.8, 13.2 Hz, 1H), 2.04 - 1.97 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]: 571.1.

[2207] Example 40

[2208] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(3-hydroxy-l-phenyl- propyl)indole-3-carboxamide

[2209]

[2210] Example 40

[2211] Step a: Preparation of 3-benzyloxypropanalDocket No. P60153

[2212]

[2213] Compound 40a

[2214] To a solution of oxalyl dichloride (3.41 mg, 27.1 mmol) in DCM (20.0 mL) cooled at -78 °C was added DMSO (2.82 g, 36.1 mmol) dropwise. After being stirred for 30 min, to the resulting solution was added the solution of 3 -benzyloxy- 1 -propanol (3.00 g, 18.1 mmol) in DCM (5.0 mL). The mixture was stirred at -78 °C for another 1 hour. The resulting mixture was quenched with TEA (6.86 mg, 72.2 mmol) slowly and the mixture was stirred at 20 °C for 30 minutes. The reaction mixture was diluted with water (100 mL) and extracted with DCM (100 mL) three times. The combined organic layer was dried over MgSO₄ and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (petroleum ether / ethyl acetate 0-50%) to give 3-benzyloxypropanal (2.60 g). MS obsd. (ESI+) [{35C1} (M+H)+]: 165.1.

[2215] Step b: Preparation of 4-chloro-V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(3-hydroxy-l-phenyl-propyl)indole-3-carboxamide

[2216]

[2217] Example 40

[2218] The title compound (4.14 mg) was prepared in analogy to the preparation of Example 39. By using 3-benzyloxypropanal instead of benzyloxyacetaldehyde in step a. 'H NMR (400 MHz, DMSO-6) 5 = 11.00 - 10.92 (m, 1H), 8.74 (t, J= 5.6 Hz, 1H), 8.13 (s, 1H), 7.70 (d, J= 7.6 Hz, 1H), 7.61 (s, 1H), 7.56 - 7. 53(m, 2H), 7.41 (d, J= 7.2 Hz, 2H), 7.32 (t, J= 7.2 Hz, 2H), 7.26 - 7.23 (m, 1H), 7.15 -7.11 (m, 2H), 5.83 (t, J= 7.2 Hz, 1H), 5.14 - 5.09 (m, 1H), 4.74 - 4.71 (m, 1H), 4.58 (d, J= 5.6 Hz, 2H), 4.48 - 4.28 (m, 2H), 2.96 - 2.86 (m, 1H), 2.59 (d, J= 14.4 Hz, 3H), 2.43 - 2.33 (m, 3H), 2.03 -1.99 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]:585.2.

[2219] Example 41

[2220] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[2-hydroxy-l-[4-(l- methylpyrazol-4-yl)phenyl] ethyl] indole-3-carboxamideDocket No. P60153

[2221]

[2222] Example 41

[2223] Step a: Preparation of 2-[tert-butyl(dimethyl)silyl]oxy-l-[4-(l-methylpyrazol-4-yl)phenyl] ethanol

[2224]

[2225] Compound 41a

[2226] To a stirred solution of 4-(4-bromophenyl)-l -methyl- IJT-pyrazole (1.30 g, 5.51 mmol) in THF (26 mL) under nitrogen was added n-BuLi (2.63 mL, 6.61 mmol, 2.5 M in THF) at -78 °C. The reaction mixture was stirred at -78 °C for 30 minutes. Then to the reaction solution was added 2-((tert-butyldimethylsilyl)oxy)acetaldehyde (1.43 g, 8.26 mmol). The reaction mixture was stirred at -78 °C for 2 hours. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (80 mL) three times. The combined organic layer was washed with brine (200 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0 -24% EtOAc in PE) to afford 2-[tert-butyl(dimethyl)silyl]oxy-l-[4-(l-methylpyrazol-4-yl)phenyl] ethanol (850 mg). MS obsd. (ESI+) [(M+H)+]:333.0.

[2227] Step b: Preparation of N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[2-hydroxy-l-[4-(l-methylpyrazol-4-yl)phenyl]ethyl]indole-3-carboxamide

[2228]

[2229] Example 41

[2230] The title compound (4.14 mg) was prepared in analogy to the preparation of Example 32. By using 2-[tert-butyl(dimethyl)silyl]oxy-l-[4-(l-methylpyrazol-4-yl)phenyl]ethanol instead of [6-[2-Docket No. P60153

[2231] [tert-butyl(dimethyl)silyl]oxyethoxy]-5-methyl-2-pyridyl]methanol in step d.1H NMR (400 MHz, DMSO-6) 8 = 10.98 (s, 1H), 8.43 (d, J= 5.9 Hz, 1H), 8.35 - 8.29 (m, 1H), 8.07 (s, 1H), 7.80 (d, J= 2.0 Hz, 1H), 7.71 (d, J= 8.0 Hz, 1H), 7.60 (s, 1H), 7.54 (d, J= 7.9 Hz, 1H), 7.51 - 7.45 (m, 2H), 7.36 (d, J= 8.4 Hz, 1H), 7.32 - 7.26 (m, 2H), 7.17 - 7.09 (m, 1H), 6.90 (dd, J= 11.6, 7.8 Hz, 1H), 5.79 - 5.67 (m, 1H), 5.11 (dd, J= 13.5, 5.0 Hz, 1H), 4.62 (d, J= 5.8 Hz, 2H), 4.51 - 4.22 (m, 3H), 4.15 - 4.00 (m, 1H), 3.83 (s, 3H), 2.98 - 2.84 (m, 1H), 2.66 - 2.55 (m, 1H), 2.46 - 2.29 (m, 1H), 2.06 - 1.94 (m, 1H). MS obsd. (ESI+) [(M+H)+]:635.6.

[2232] Example 42

[2233] N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[l-[5-(l-methylpyrazol- 4-yl)-2-pyridyl]-2-[(3-nitrophenyl)methoxy]ethyl]indole-3-carboxamide

[2234]

[2235] Example 42

[2236] Example 42 was prepared according to the following scheme.Docket No. P60153

[2237]

[2238] Step a: Preparation of l-(5-bromo-2-pyridyl)-2-[tert-butyl(dimethyl)silyl]oxy-ethanol

[2239]

[2240] Compound 42a

[2241] To a solution of 5-bromo-2-iodopyridine (15.8 g, 55.5 mmol) in THF (150 mL) at 0 °C under N2 atmosphere was added isopropyl magnesium chloride (30.0 mL, 60.0 mmol, 2 M in THF) dropwise. The reaction was stirred at 0 °C for 1 hour after addition. Then to the resulting solution was added (tert-butyldimethylsilyloxy)acetaldehyde solution (15.0 g, 86.0 mmol, in tetrahydrofuran (40 mL)) dropwise while keeping temperature below 0 °C. The reaction mixture was stirred at room temperatureDocket No. P60153

[2242] for 16 hours and then quenched by hydrochloric acid (1 M, 60 mL). The resulting mixture was extracted with EtOAc (200 mL) three times. The combined organic layer was washed with brine (100 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 8% EtOAc in PE) to afford l-(5-bromo-2-pyridyl)-2-[tert-butyl(dimethyl)silyl]oxy-ethanol (14.6 g). MS obsd. (ESI+) [(M+H)+]:331.9.

[2243] Step b: Preparation of 2-[tert-butyl(dimethyl)silyl]oxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl] ethanol

[2244]

[2245] Compound 42b

[2246] A mixture of l-(5-bromo-2-pyridyl)-2-[tert-butyl(dimethyl)silyl]oxy-ethanol (14.6 g, 43.9 mmol), l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-U / -pyrazole (13.7 g, 65.9 mmol), Pd(dppf)Cl2(3.59 g, 4.39 mmol) and K2CO3(18.2 g, 132 mmol) in 1,4-dioxane (270 mL) and water (30 mL) was degassed and backfilled with N2 for five times. The reaction mixture was stirred at 100 °C under N2 atmosphere for 16 hours. The reaction mixture was cooled to room temperature and filtered through a celite pad. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 58% EtOAc in PE) to afford 2-[tert-butyl(dimethyl)silyl]oxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethanol (8.80 g). MS obsd. (ESI+) [(M+H)+]:334.2.

[2247] Step c: Preparation of methyl l-[2-[tert-butyl(dimethyl)silyl]oxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl] ethyl] -4-fluor o-indole-3-car boxylate

[2248]

[2249] Compound 42c

[2250] To a mixture of methyl 4-fluoro-1H-indole-3-carboxylate (4.52 g, 23.4 mmol), 2-[tert-butyl(dimethyl)silyl]oxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethanol (7.80 g, 23.4 mmol) andDocket No. P60153

[2251] triphenylphosphine (12.3 g, 46.8 mmol) in THF (90 mL) under N2 atmosphere was added a solution of DBAD (10.8 g, 46.8 mmol) in THF (10 mL) at 0 °C. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with water (100 mL) and extracted with EtOAc (200 mL) three times. The combined organic layer was dried over Na2SO4and concentrated under reduced pressure. The crude product was purified by silica gel flash chromatography (0 - 44% EtOAc in PE) to afford methyl l-[2-[tert-butyl(dimethyl)silyl]oxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethyl]-4-fluoro-indole-3-carboxylate (6.60 g). MS obsd. (ESI+) [(M+H)+]:509.0.

[2252] Step d: Preparation of methyl 4-fluoro-l-[2-hydroxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl] ethyl] indole-3-carboxylate

[2253]

[2254] Compound 42d

[2255] To a mixture of methyl l-[2-[tert-butyl(dimethyl)silyl]oxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethyl]-4-fluoro-indole-3-carboxylate (6.60 g, 13.0 mmol) in THF (70 mL) was added TBAF (19.5 mL, 19.5 mmol, 1 M in THF). After being stirred at room temperature for 2 hours, the reaction mixture was poured into water (100 mL) and extracted with EtOAc (200 mL) three times. The combined organic layer was washed with brine (200 mL), dried over anhydrous Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 5% EtOAc in PE) to afford methyl 4-fluoro-l-[2-hydroxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethyl]indole-3-carboxylate (2.00 g). MS obsd. (ESI+) [(M+H)+]:395.0.

[2256] Step e: Preparation of methyl 4-fluoro-l-[l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]-2-[(3-nitrophenyl)methoxy]ethyl]indole-3-carboxylate

[2257]

[2258] Compound 42eDocket No. P60153

[2259] To a mixture of methyl 4-fluoro-l-[2-hydroxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethyl]indole-3-carboxylate (400 mg, 1.01 mmol) and 1 -(brom omethyl)-3 -nitro-benzene (657 mg, 3.04 mmol) in THF (10 mL) was added NaH (162 mg, 4.06 mmol, 60%). After being stirred at room temperature for 1 hour, the reaction mixture was poured into a mixture of ice water (30 mL) and HC1 (1 M, 2 mL). The resulting mixture was extracted with EtOAc (50 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 30% EtOAc in PE) to afford methyl 4-fluoro-l-[l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]-2-[(3-nitrophenyl)methoxy]ethyl]indole-3-carboxylate (230 mg). MS obsd. (ESI+) [(M+H)+]:530.0.

[2260] Step f: Preparation of 4-fluoro-l-[l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]-2-[(3-nitrophenyl)methoxy]ethyl]indole-3-carboxylic acid

[2261]

[2262] Compound 42f

[2263] To a solution of methyl 4-fluoro-l-[l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]-2-[(3-nitrophenyl)methoxy]ethyl]indole-3-carboxylate (230 mg, 0.430 mmol) in DCE (10 mL) was added trimethyltin hydroxide (1.58 g, 8.69 mmol). The reaction mixture was stirred at 80 °C for 168 hours. After the reaction was completed, the cooled reaction mixture was quenched with water (30 mL) and extracted with EtOAc (50 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4and concentrated under reduced pressure to give the crude of 4-fluoro-l-[l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]-2-[(3-nitrophenyl)methoxy]ethyl]indole-3-carboxylic acid (250 mg), which was used in the next step directly without further purification. MS obsd. (ESI+) [(M+H)+]:516.2.

[2264] Step g: Preparation of N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]-2-[(3-nitrophenyl)methoxy]ethyl]indole-3-carboxamideDocket No. P60153

[2265]

[2266] Example 42

[2267] To a mixture of 4-fluoro-l-[l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]-2-[(3-nitrophenyl)methoxy]ethyl]indole-3-carboxylic acid (220 mg, 0.430 mmol) in DMAc (6 mL) were added HATU (221 mg, 0.580 mmol), 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride (120 mg, 0.390 mmol) and DIPEA (250 mg, 1.94 mmol). The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (40 mL) three times. The combined organic layer was washed with brine (100 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified prep-HPLC (FA) to afford N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]-2-[(3-nitrophenyl)methoxy]ethyl]indole-3-carboxamide (78.6 mg). 'HNMR (400 MHz, DMSO-6) 8 = 10.97 (s, 1H), 8.79 (d, J= 2.0 Hz, 1H), 8.39 (d, J= 5.2 Hz, 1H), 8.24 (s, 1H), 8.20 (s, 1H), 8.11 - 8.06 (m, 1H), 8.01 (t, J= 2.0 Hz, 1H), 7.95 - 7.90 (m, 2H), 7.69 (d,.7= 8.0 Hz, 1H), 7.63 - 7.46 (m, 5H), 7.39 (d, = 8.0 Hz, 1H), 7.20 - 7.11 (m, 1H), 6.91 (dd, J= 11.6, 8.0 Hz, 1H), 6.16 (dd, J= 8.4, 4.8 Hz, 1H), 5.11 (dd, J = 13.2, 5.2 Hz, 1H), 4.77 - 4.66 (m, 2H), 4.60 (d, J= 5.6 Hz, 2H), 4.49 - 4.39 (m, 2H), 4.37 - 4.25 (m, 2H), 3.86 (s, 3H), 2.97 - 2.84 (m, 1H), 2.69 -2.53 (m, 1H), 2.45 - 2.30 (m, 1H), 2.05 - 1.94 (m, 1H). MS obsd. (ESI+) [(M+H)+]:771.2.

[2268] Example 43

[2269] l-[2-[(3-aminophenyl)methoxy]-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethyl]-7V-[[2-(2,6-dioxo- 3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide

[2270]

[2271] Docket No. P60153

[2272] Example 43

[2273] To a stirred solution of N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro- l-[l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]-2-[(3-nitrophenyl)methoxy]ethyl]indole-3-carboxamide (150 mg, 0.19 mmol) and tetrahydroxydiboron (52.3 mg, 0.580 mmol) in DMF (2 mL) was added 4, 4'-dipyridine (15.2 mg, 0.1 mmol) at 0 °C. After being stirred at room temperature for 5 minutes, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (30 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by prep-HPLC (FA) to afford l-[2-[(3-aminophenyl)methoxy]-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethyl]-A-[[2-(2,6-dioxo-3-piperidyl)- l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide (74.4 mg).1H NMR (400 MHz, DMSO-6) 8 = 10.97 (s, 1H), 8.78 (d, J= 2.4 Hz, 1H), 8.43 (q, J= 5.4 Hz, 1H), 8.25 (s, 1H), 8.19 (s, 1H), 7.95 - 7.89 (m, 2H), 7.70 (d, J= 7.6 Hz, 1H), 7.59 (s, 1H), 7.55 - 7.45 (m, 2H), 7.37 (d, J= 8.0 Hz, 1H),7.2O - 7.12 (m, 1H), 6.97 - 6.86 (m, 2H), 6.45 - 6.42 (m, 2H), 6.36 - 6.32 (m, 1H), 6.09 (dd, J = 8.4, 4.8 Hz, 1H), 5.11 (dd, J = 13.2, 5.2 Hz, 1H), 5.05 - 4.92 (m, 2H), 4.61 (d, J = 6.0 Hz, 2H), 4.47 - 4.26 (m, 5H), 4.18 (dd, J= 10.4, 4.8 Hz, 1H), 3.85 (s, 3H), 2.97 - 2.85 (m, 1H), 2.69 - 2.55 (m, 1H), 2.46 - 2.30 (m, 1H), 2.06 - 1.92 (m, 1H). MS obsd. (ESI+) [(M+H)+]:741.3.

[2274] Example 44

[2275] 4-chloro-V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3- (methylamino)-4-(l-methylpyrazol-3-yl)phenyl]methyl]indole-3-carboxamide

[2276]

[2277] Example 44

[2278] The title compound was prepared according to the following synthetic route.Docket No. P60153

[2279]

[2280] Step b: Preparation of methyl 3-[bis(tert-butoxycarbonyl)amino]-4-bromo-benzoate

[2281]

[2282] Compound 44a

[2283] To a solution of 3-amino-4-bromobenzoic acid methyl ester (25.0 g, 109 mmol), di-t-butyl di carb onate (23.7 g, 109 mmol) in THF (500 mL) was added DMAP (1.33 g, 10.9 mmol). The mixture was stirred at 70 °C for 16 hours. After cooling to room temperature, the reaction mixture was poured into water (100 mL) and extracted with EtOAc (300 mL) three times. The combined organic layer was washed with brine (200 mL) three times, dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 50% EtOAc in PE) to give methyl 3-[bis(tert-butoxycarbonyl)amino]-4-bromo-benzoate (36.0 g). MS obsd. (ESI+) [(M-C5H9O2-CH3+H)+]:317.9.

[2284] Step b: Preparation of ethyl 4-bromo-3-(tert-butoxycarbonylamino)benzoate and 4-bromo-3-((tert-butoxycarbonyl)amino)benzoic acidDocket No. P60153

[2285]

[2286] Compound 44b-l and Compound 44b-2

[2287] To a solution of methyl 3-[bis(tert-butoxycarbonyl)amino]-4-bromo-benzoate (36.0 g, 83.7 mmol) in EtOH (200 mL) was added K2CO3(23.1 g, 167 mmol) and the mixture was stirred at 25 °C for 16 hours. The reaction mixture was poured into water (300 mL) and extracted with EtOAc (300 mL) three times. The combined organic layer was washed with brine (100 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 100% EtOAc in PE) to give ethyl 4-bromo-3-(tert-butoxycarbonylamino)benzoate (15.0 g, MS obsd. (ESI+) [(M-C4H9+H)+]:288.0.) and 4-bromo-3-((tert-butoxycarbonyl)amino)benzoic acid (8.0 g, MS obsd. (ESI+) [(M-C4H9+H)+]: 260.0.

[2288] Step c: Preparation of ethyl 4-bromo-3-[tert-butoxycarbonyl(methyl)amino]benzoate

[2289]

[2290] Compound 44c

[2291] To a solution of ethyl 4-bromo-3-(tert-butoxycarbonylamino)benzoate (14.0 g, 42.4 mmol), Cs2CO3(27.6 g, 84.8 mmol) in DMF (100 mL) was added iodomethane (7.20 g, 50.8 mmol). After being stirred at 25 °C for 16 hours, the reaction mixture was poured into water (100 mL) and extracted with EtOAc (200 mL) three times. The combined organic layer was washed with brine (200 mL), Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 100% EtOAc in PE) to give ethyl 4-bromo-3-[tert-butoxycarbonyl(methyl)amino]benzoate (15.0 g). MS obsd. (ESI+) [(M-C4H9+H)+]:304.0.

[2292] Step d: Preparation of 4-bromo-3-[tert-butoxycarbonyl(methyl)amino]benzoic acid

[2293]

[2294] Compound 44dDocket No. P60153

[2295] To a solution of ethyl 4-bromo-3-[tert-butoxycarbonyl(methyl)amino]benzoate (12.0 g, 34.9 mmol,) in MeOH (50.0 mL) and water (20.0 mL) was added NaOH (6.97 g, 174 mmol). After being stirred at 25 °C for 16 hours, the reaction mixture was poured into water (50 mL), and pH was adjusted to about 5 by adding 1M HCl. The resulting mixture was extracted with EtOAc (300 mL) three times. The combined organic layer was washed with brine (200 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 100% EtOAc in PE) to give 4-bromo-3-[tert-butoxycarbonyl(methyl)amino]benzoic acid (10.5 g) as a yellow solid. MS obsd. (ESI+) [(M-C4H9+H)+]:275.9

[2296] Step e: Preparation of tert-butyl N-[2-bromo-5-(hydroxymethyl)phenyl]-7V-methyl-carbamate

[2297]

[2298] Compound 44e

[2299] To a solution of 4-bromo-3-[tert-butoxycarbonyl(methyl)amino]benzoic acid (10.0 g, 30.3 mmol) in THF (50.0 mL) cooled at 0 °C, was added borane dimethyl sulfide complex (18.2 mL, 182 mmol, 10 M) dropwise. After being stirred at 25 °C for 16 hours, the reaction was quenched with aq. HC1 (100 mL, 0.5 N) at °C and extracted with EtOAc (250 mL) three times. The combined organic layer was washed with brine (100 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 80% EtOAc in PE) to give tert-butyl N-[2-bromo-5-(hydroxymethyl)phenyl]-A-methyl-carbamate (9.50 g). MS obsd. (ESI+) [(M-C4H9+H)+]: 338.0.

[2300] Step f: Preparation of methyl l-[[4-bromo-3-[tert-butoxycarbonyl(methyl)amino]phenyl]methyl]-4-chloro-indole-3-carboxylate

[2301]

[2302] Compound 44f

[2303] To a solution of tert-butyl N-[2-bromo-5-(hydroxymethyl)phenyl]--methyl-carbamate (1.0 g, 1.98 mmol), methyl 4-chloro-1-indole-3-carboxylate (415 mg, 1.98 mmol) in toluene (10 mL) was added CMBP (1.1 g, 3.96 mmol), the mixture was stirred at 90 °C for 15 hours. After cooling to roomDocket No. P60153

[2304] temperature, the mixture was concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 50% EtOAc in PE) to afford methyl l-[[4-bromo-3-[tert-butoxycarbonyl(methyl)amino]phenyl]methyl]-4-chloro-indole-3-carboxylate (800 mg). MS obsd. (ESI+) [{35C1} (M-C4H9+H)+]: 507.1.

[2305] Step g: Preparation of methyl l-[[3-[tert-butoxycarbonyl(methyl)amino]-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-indole-3-carboxylate

[2306]

[2307] Compound 44g

[2308] To a solution of methyl 1-[[4-bromo-3-[tert-butoxycarbonyl(methyl)amino]phenyl]methyl]-4-chloro-indole-3-carboxylate (800 mg, 1.58 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-pyrazole (393 mg, 1.89 mmol) in 1,4-dioxane (5.0 mL), water (1.0 mL) were added K3PO4(1.00 g, 4.73 mmol) and Pd(dppf)Cl2(172 mg, 0.24 mmol). The reaction was stirred at 80 °C for 3 hours under N2. After cooling to room temperature, the mixture was concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (0 - 50% EtOAc in PE) to afford methyl l-[[3-[tert-butoxycarbonyl(methyl)amino]-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-indole-3 -carboxylate (800 mg). MS obsd. (ESI+) [{35C1} (M+H)+]: 509.2.

[2309] Step h: Preparation of l-[[3-[tert-butoxycarbonyl(methyl)amino]-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-indole-3-carboxylic acid

[2310]

[2311] Compound 44h

[2312] To a solution of methyl 1-[[3-[tert-butoxycarbonyl(methyl)amino]-4-(1-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-indole-3-carboxylate (800 mg, 1.58 mmol) in MeOH (10.0 mL), water (1 mL) was added NaOH (444 mg, 11.1 mmol), the solution was stirred at 50 °C for 16 hours. After cooling to room temperature, the mixture was poured into water (50 mL) and pH was adjusted to about 2 by adding aqueous HC1 (1 N). The solution was extracted with DCM (50 mL) three times. The combined organic layer was washed with brine (50 mL), dried over Na2SO4and concentrated underDocket No. P60153

[2313] reduced pressure. The residue was purified by prep-HPLC (FA as additive) to give l-[[3-[tert-butoxycarbonyl(methyl)amino]-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-indole-3-carboxylic acid (250 mg). MS obsd. (ESI+) [{35C1} (M+H)+]: 495.1.

[2314] Step i: Preparation of tert-butyl N-[5-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]-2-(l-methylpyrazol-3-yl)phenyl]-7V-methyl-carbamate

[2315]

[2316] Compound 44i

[2317] To a solution of 1-[[3-[tert-butoxycarbonyl(methyl)amino]-4-(1-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-indole-3-carboxylic acid (150 mg, 0.300 mmol), DIPEA (117 mg, 0.910 mmol), 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2, 6-dione hydrochloride (112 mg, 0.360 mmol) in DMF (1.0 mL) was added HATU (172 mg, 0.450 mmol). The mixture was stirred at 25 °C for 3 hours and the reaction mixture was purified by prep-HPLC (FA as additive) to afford tert-butyl N-[5-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methylcarbamoyl]indol-1-yl]methyl]-2-(1-methylpyrazol-3-yl)phenyl]--methyl-carbamate (90.0 mg, 40.0%). MS obsd. (ESI+) [{35C1} (M+H)+]: 750.2.

[2318] Step j: Preparation of 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl]methyl]indole-3-carboxamide

[2319]

[2320] Example 44

[2321] To a solution of tert-butyl N-[5-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methylcarbamoyl]indol-1-yl]methyl]-2-(1-methylpyrazol-3-yl)phenyl]--methyl-carbamate (70.0 mg, 0.090 mmol) in DCM (1.0 mL) was added TFA (0.5 mL) and stirred at 25 °C for 1 hour. The reaction mixture was purified by prep-HPLC (FA as additive) to afford 4-chloro--[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-[[3-(methylamino)-4-(1-methylpyrazol-3-yl)phenyl]methyl]indole-3-carboxamide (47.0 mg, 80.3%).Docket No. P60153

[2322] 1H NMR (400 MHz, DMSO-6) 6 = 10.98 (s, 1H), 8.73 (t, J= 6.0 Hz, 1H), 7.97 (s, 1H), 7.74 -7.67 (m, 2H), 7.59 (s, 1H), 7.56 (dd, J= 1.2, 7.6 Hz, 1H), 7.52 (br d, J= 7.6 Hz, 1H), 7.45 (d, J= 7.9 Hz, 1H), 7.16 (q, J= 7.6 Hz, 2H), 6.67 (s, 1H), 6.62 (d, J= 2.4 Hz, 1H), 6.41 (d, J= 8.0 Hz, 1H), 5.40 (s, 2H), 5.11 (dd, J= 5.2, 13.2 Hz, 1H), 4.57 (br d, J= 6.0 Hz, 2H), 4.49 - 4.41 (m, 1H), 4.33 (s, 1H), 3.87 (s, 3H), 2.96 - 2.86 (m, 1H), 2.83 (s, 3H), 2.60 (br d, J= 17.2 Hz, 1H), 2.40 (br d, J= 13.1 Hz, 1H), 2.05 - 1.95 (m, 1H). MS obsd. (ESI+) [{35C1} (M+H)+]: 650.2.

[2323] Example 45

[2324] 4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(methylamino)-4-(l- methyl pyr azol-4-yl)phenyl] methyl] indole-3-carboxamide

[2325]

[2326] The title compound (74.8 mg) was prepared in analogy to the preparation of Example 44. By using 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-pyrazole instead of 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-pyrazole in step g. *...

Claims

1. Docket No. P601531 CLAIMS1. A compound of formula (I),whereinR1is H or deuterium;each R2is independently H, halogen, hydroxy, amino or C1-6alkyl;each R3is independently H, halogen, hydroxy or C1-6alkyl;R4is R4aor R4acarbonyl, wherein R4ais a 6-10 membered aryl, 5-10 membered heteroaryl or 3-12 membered heterocyclyl, any one of which is unsubstituted or substituted by one to three substituents independently selected from the group consisting of(C1-6alkyl)2amino,(hydroxyC1-6alkoxy)C1-6alkoxy,amino,C1-6alkoxy,C1-6alkoxycarbonyl,C1-6alkyl,C1-6alkylamino,C1-6alkylsulfanyl,haloC1-6alkyl,halogen,hydroxy,hydroxyC1-6alkoxy,hydroxyC1-6alkyl,hydroxyC1-6alkyl(C1-6alkyl)amino,hydroxyC1-6alkylsulfanyl,hydroxyhaloC1-6alkoxy,Docket No. P601536-10 membered aryl unsubstituted or substituted by one to three substituents independently selected from the group consisting of (((hydroxyCi-6alkyl)carbonyl)(C1-6alkyl)amino)Ci- ealkyl, ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((C1-6alkyl)2amino)Ci-6alkyl, ((hydroxyCi- 6alkyl)carbonylamino)Ci-6alkyl, (C1-6alkoxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkoxy)Ci- ealkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyhaloC1-6alkyl)C1-6alkyl, amino, aminoCi- ealkyl, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(Ci- 6alkoxy)Ci-6alkyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl, hydroxyhaloC1-6alkyl, Ci- ealkylsulfinyl, C1-6alkyl sulfanyl and carbamoyl,5-10 membered heteroaryl unsubstituted or substituted by one to three substituents independently selected from the group consisting of (((hydroxyC1-6alkyl)carbonyl)(Ci- 6alkyl)amino)Ci-6alkyl, ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((C1-6alkyl)2amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (C1-6alkoxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyhaloC1-6alkyl)Ci- ealkyl, amino, aminoC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl, hydroxyhaloC1-6alkyl, C1-6alkylsulfinyl, C1-6alkylsulfanyl and carbamoyl, and 3-12 membered heterocyclyl unsubstituted or substituted by one to three substituents independently selected from the group consisting of (((hydroxyC1-6alkyl)carbonyl)(Ci- 6alkyl)amino)Ci-6alkyl, ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((C1-6alkyl)2amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (C1-6alkoxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyhaloC1-6alkyl)Ci- ealkyl, amino, aminoC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl, hydroxyhaloC1-6alkyl, C1-6alkylsulfinyl, C1-6alkylsulfanyl and carbamoyl,R5is H, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or (R5aCi-6alkoxy)C1-6alkyl, wherein R5ais H or phenyl unsubstituted or substituted by amino or nitro;R6is H or C1-6alkyl;L1is C1-6alkylene;L2is a bond or C1-6alkylene;m is 0, 1, 2 or 3;n is 0, 1, 2, 3 or 4;or a pharmaceutically acceptable salt thereof.Docket No. P601532. The compound of claim 1, whereinR1is H or deuterium;each R2is independently H, halogen, hydroxy, amino or C1-6alkyl;each R3is independently H, halogen, hydroxy or C1-6alkyl;R4is R4aor R4acarbonyl,wherein R4ais 1,2-benzoxazolyl, 1,3-benzodioxolyl, 1,3 -benzothiazolyl, 2, 3 -dihydro- 1,4- benzodioxinyl, benzimidazolyl, benzothiophenyl, imidazo[1,2-a]pyridinyl, indazolyl, indolyl, isoindolinyl, phenyl, pyrazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[4,3-b]pyridinyl, pyridyl or pyrimidinyl, any one of which is unsubstituted or substituted by one to three substituents independently selected from the group consisting of (C1-6alkyl)2amino,(hydroxyC1-6alkoxy)C1-6alkoxy,1.2.4-triazolyl substituted by C1-6alkyl,1.3.4-oxadiazolyl substituted by C1-6alkyl,1.3.4-thiadiazolyl unsubstituted or substituted by C1-6alkyl,2,3-dihydropyrazolo[5,l-b]oxazolyl,5.7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi-6alkyl)carbonyl, 5,7-dihydrothieno[3,4-d]pyrimidinyl,6,6-dioxo-5,7-dihydrothieno[3,4-d]pyrimidinyl,6.7-dihydro-4H-pyrazolo[1,5-a]pyrazinyl substituted by C1-6alkyl,6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl,6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazinyl,6-oxo-5,7-dihydrothieno[3,4-d]pyrimidinyl,amino,C1-6alkoxy,C1-6alkoxycarbonyl,C1-6alkyl,C1-6alkylamino,C1-6alkylsulfanyl,haloC1-6alkyl,halogen,hydroxy,hydroxyC1-6alkoxy,Docket No. P60153hydroxyC1-6alkyl,hydroxyC1-6alkyl(C1-6alkyl)amino,hydroxyC1-6alkylsulfanyl,hydroxyhaloC1-6alkoxy,imidazolyl substituted by C1-6alkyl,isoxazolyl,oxazolyl unsubstituted or substituted by C1-6alkyl,phenyl unsubstituted or substituted by aminoC1-6alkyl or ((Ci-6alkoxycarbonyl)amino)Ci- ealkyl,piperidyl disubstituted with C1-6alkyl and hydroxyC1-6alkyl,pyrazinyl,pyrazolyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of(((hydroxyC1-6alkyl)carbonyl)(C1-6alkyl)amino)C1-6alkyl,((C1-6alkoxycarbonyl)amino)C1-6alkyl,((C1-6alkyl)2amino)Ci-6alkyl,((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl,(C1-6alkoxyC1-6alkoxy)C1-6alkyl,(hydroxyC1-6alkoxy)C1-6alkyl,(hydroxyC1-6alkyl)C1-6alkyl,(hydroxyhaloC1-6alkyl)C1-6alkyl,amino,C1-6alkoxyC1-6alkyl,C1-6alkoxycarbonyl,C1-6alkyl,cyanoC1-6alkyl,halogen,hydroxy(C1-6alkoxy)C1-6alkyl,hydroxyC1-6alkyl,hydroxyhaloC1-6alkyl, andtetrahydrothiophenyl,pyridazinyl,pyridyl,Docket No. P60153pyrimidinyl unsubstituted or substituted by C1-6alkylsulfinyl, C1-6alkylsulfanyl, carbamoyl or C1-6alkoxycarbonyl,pyrrolidinyl unsubstituted or substituted by hydroxy,pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,tetrazolyl unsubstituted or substituted by C1-6alkyl,thiazolyl,thieno[3,4-d]pyrimidinyl, andtriazolyl unsubstituted or substituted by C1-6alkyl,R5is H, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or (R5aCi-6alkoxy)Ci-6alkyl, wherein R5ais H or phenyl unsubstituted or substituted by amino or nitro;R6is H or C1-6alkyl;L1is C1-6alkylene;L2is a bond or C1-6alkylene;m is 0 or 1;n is 1 or 2;or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R1is H.

4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein each R2is independently H, halogen, amino or hydroxy.

5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein each R2is independently H, fluoro, amino or hydroxy.

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein each R2is independently H or hydroxy.

7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein each R3is independently H, fluoro, chloro, hydroxy, methyl or ethyl.Docket No. P601538. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein each R3is independently H, halogen or C1-6alkyl.

9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein each R3is independently H, fluoro, chloro or ethyl.

10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, whereinR4is 1,2-benzoxazolyl,1,3-benzodioxolyl,1,3-benzothiazolyl,2,3-dihydro-1,4-benzodioxinyl,benzimidazolyl substituted by C1-6alkyl,benzothiophenyl,benzoyl,imidazo[1,2-a]pyridinyl,indazolyl unsubstituted or substituted by halogen or C1-6alkyl,indolyl substituted by C1-6alkyl,isoindolinyl substituted by C1-6alkoxycarbonyl,phenyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of(hydroxyC1-6alkoxy)C1-6alkoxy,1,2,4-triazolyl,2,3-dihydropyrazolo[5,l-b]oxazolyl,5,7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi- ealkyl)carbonyl,amino,C1-6alkoxy,C1-6alkoxycarbonyl,C1-6alkyl,C1-6alkylamino,C1-6alkylsulfanyl,halogen,Docket No. P60153hydroxy,hydroxyC1-6alkoxy,hydroxyC1-6alkyl,hydroxyC1-6alkyl(C1-6alkyl)amino,hydroxyC1-6alkylsulfanyl,hydroxyhaloC1-6alkoxy,imidazolyl substituted by C1-6alkyl,pyrazolyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of (((hydroxyCi-6alkyl)carbonyl)(Ci-6alkyl)amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (Ci-6alkoxyCi-6alkoxy)Ci- ealkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyhaloCi- 6alkyl)Ci-6alkyl, amino, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, cyanoC1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl and hydroxyhaloC1-6alkyl,pyrimidinyl unsubstituted or substituted by carbamoyl or C1-6alkoxycarbonyl, pyrrolidinyl substituted by hydroxy,pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,tetrazolyl,thieno[3,4-d]pyrimidinyl, andtriazolyl unsubstituted or substituted by C1-6alkyl,pyrazinyl disubstituted with amino and C1-6alkylpyrazolyl,pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino or C1-6alkylamino, pyrazolo[4,3-b]pyridinyl substituted by C1-6alkyl,pyridyl substituted by one or two substituents independently selected from the group consisting of(C1-6alkyl)2amino,1.2.4-triazolyl substituted by C1-6alkyl,1.3.4-oxadiazolyl substituted by C1-6alkyl,1.3.4-thiadiazolyl unsubstituted or substituted by C1-6alkyl,2,3-dihydropyrazolo[5,l-b]oxazolyl,5.7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,5,7-dihydrothieno[3,4-d]pyrimidinyl,6,6-dioxo-5,7-dihydrothieno[3,4-d]pyrimidinyl,Docket No. P601536.7-dihydro-4H-pyrazolo[1,5-a]pyrazinyl substituted by C1-6alkyl,6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl,6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazinyl,6-oxo-5,7-dihydrothieno[3,4-d]pyrimidinyl,amino,C1-6alkoxy,C1-6alkoxycarbonyl,C1-6alkyl,C1-6alkylamino,haloC1-6alkyl,hydroxyC1-6alkoxy,isoxazolyl,oxazolyl unsubstituted or substituted by C1-6alkyl,phenyl substituted by aminoC1-6alkyl or ((C1-6alkoxycarbonyl)amino)C1-6alkyl, piperidyl disubstituted with C1-6alkyl and hydroxyC1-6alkyl,pyrazinyl,pyrazolyl unsubstituted or substituted by ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((Ci- 6alkyl)2amino)Ci-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, amino, C1-6alkyl or tetrahydrothiophenyl,pyridazinyl,pyridyl,pyrimidinyl unsubstituted or substituted by C1-6alkyl sulfinyl or C1-6alkylsulfanyl, pyrrolidinyl,tetrazolyl unsubstituted or substituted by C1-6alkyl,thiazolyl,thieno[3,4-d]pyrimidinyl, andtriazolyl,or pyrimidinyl substituted by one or two substituents independently selected from the group consisting of amino, C1-6alkylpyrazolyl and pyrimidinyl.

11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, whereinR4is 1,3-benzodioxolyl,Docket No. P60153phenyl substituted by one or two substituents independently selected from the group consisting of2,3-dihydropyrazolo[5,l-b]oxazolyl,5.7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi- ealkyl)carbonyl,amino,C1-6alkoxycarbonyl,C1-6alkylamino,C1-6alkylsulfanyl,hydroxy,hydroxyC1-6alkoxy,pyrazolyl substituted by (hydroxyC1-6alkoxy)C1-6alkyl, C1-6alkyl or hydroxyC1-6alkyl, pyrimidinyl,pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,thieno[3,4-d]pyrimidinyl, andtriazolyl,pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,pyridyl substituted by one or two substituents independently selected from the group consisting of1,3,4-thiadiazolyl,2,3-dihydropyrazolo[5,l-b]oxazolyl,5,7-dihydrothieno[3,4-d]pyrimidinyl,amino,C1-6alkoxy,C1-6alkoxycarbonyl,phenyl substituted by aminoC1-6alkyl,pyrazolyl substituted by amino or C1-6alkyl,pyrimidinyl, andthieno[3,4-d]pyrimidinyl,or pyrimidinyl substituted by C1-6alkylpyrazolyl.

12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, whereinDocket No. P60153R4is l,3-benzodioxol-5-yl,phenyl substituted by one or two substituents independently selected from the group consisting of2,3-dihydropyrazolo[5,1-b]oxazol-7-yl,5,7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by methyl or 2-hydroxyacetyl, amino,methoxycarbonyl,methylamino,methylsulfanyl,hydroxy,2-hydroxyethoxy,pyrazolyl substituted by 2-(2-hydroxyethoxy)ethyl, methyl or 2-hydroxyethyl, pyrimidinyl,pyrrolo[3,4-d]pyrimidinyl substituted by methyl,thieno[3,4-d]pyrimidinyl, andtriazolyl,pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,pyridyl substituted by one or two substituents independently selected from the group consisting of1,3,4-thiadiazolyl,2,3-dihydropyrazolo[5,1-b]oxazolyl,5,7-dihydrothieno[3,4-d]pyrimidinyl,amino,C1-6alkoxy,C1-6alkoxycarbonyl,phenyl substituted by aminomethyl,pyrazolyl substituted by amino or methyl,pyrimidinyl, andthieno[3,4-d]pyrimidinyl,or pyrimidinyl substituted by 1-methylpyrazol-4-yl.

13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2-amino-4-(l-Docket No. P60153methylpyrazol-3-yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol- 3-yl)phenyl, 3 -amino-4-( 1 -methylpyrazol-3 -yl)phenyl, 3 -amino-4-( 1 -methylpyrazol-4-yl)phenyl, 3-amino-4-(6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl)phenyl, 3-amino-4-(triazol-2-yl)phenyl, 3-amino-4-[6-(2-hydroxyacetyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]phenyl, 3-amino-4-methoxycarbonyl-phenyl, 3-amino-4-methylsulfanyl-phenyl, 3-amino-4-pyrimidin-2-yl-phenyl, 3-amino-4-thieno[3,4-d]pyrimidin-2-yl-phenyl, 3-hydroxy-4-(l-methylpyrazol-3-yl)phenyl, 3-hydroxy-4-(6-methylpyrrolo[3,4-d]pyrimidin-2-yl)phenyl, 3-hydroxy-4-methoxycarbonyl-phenyl, 3-hydroxy-4-pyrimidin-2-yl-phenyl, 4-(l-methylpyrazol- 4-yl)phenyl, 4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl, 4-[l-(2-hydroxyethyl)pyrazol- 4-yl]phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2-pyridyl, 5-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl, 5-(3-aminopyrazol-l-yl)-6-methoxy-2-pyridyl, 5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl, 6-amino-5-(l,3,4-thiadiazol-2-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-amino-5-(5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl, 6-amino-5-pyrimidin-2-yl-2-pyridyl, 6-amino- 5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl, 6-methoxy-5-methoxycarbonyl-2-pyridyl, 7-aminopyrazolo[l,5-a]pyridin-6-yl or pyrazolo[l,5-a]pyridin-6-yl.

14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein R5is H, (3-aminophenyl)methoxymethyl, (3-nitrophenyl)methoxymethyl, 2-hydroxyethyl, benzyloxymethyl, ethyl, hydroxy, hydroxymethyl, methyl or propyl.

15. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein R5is H, C1-6alkyl, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl.

16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R5is H, benzyloxymethyl, ethyl, hydroxymethyl or methyl.

17. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R6is H.

18. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, wherein L1is methylene or ethane- 1,1 -diyl.Docket No. P6015319. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein L2is a bond or methylene.

20. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein m is 1.

21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2.

22. The compound of claim 1 or 2, whereinR1is H;each R2is independently H or hydroxy;each R3is independently H, halogen or C1-6alkyl;R4is 1,3-benzodioxolyl,phenyl substituted by one or two substituents independently selected from the group consisting of2,3-dihydropyrazolo[5,l-b]oxazolyl,5,7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi- ealkyl)carbonyl,amino,C1-6alkoxycarbonyl,C1-6alkylamino,C1-6alkylsulfanyl,hydroxy,hydroxyC1-6alkoxy,pyrazolyl substituted by (hydroxyC1-6alkoxy)C1-6alkyl, C1-6alkyl or hydroxyC1-6alkyl, pyrimidinyl,pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,thieno[3,4-d]pyrimidinyl, andtriazolyl,pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,Docket No. P60153pyridyl substituted by one or two substituents independently selected from the group consisting of1,3,4-thiadiazolyl,2,3-dihydropyrazolo[5,l-b]oxazolyl,5,7-dihydrothieno[3,4-d]pyrimidinyl,amino,C1-6alkoxy,C1-6alkoxycarbonyl,phenyl substituted by aminoC1-6alkyl,pyrazolyl substituted by amino or C1-6alkyl,pyrimidinyl, andthieno[3,4-d]pyrimidinyl,or pyrimidinyl substituted by C1-6alkylpyrazolyl;R5is H, C1-6alkyl, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl;R6is H;L1is C1-6alkylene;L2is a bond or C1-6alkylene;m is 1;n is 1 or 2;or a pharmaceutically acceptable salt thereof.

23. The compound of claim 22, whereinR1is H;each R2is independently H or hydroxy;each R3is independently H, fluoro, chloro or ethyl;R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2-amino-4-(l-methylpyrazol-3- yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 3- amino-4-( 1 -methylpyrazol-3 -yl)phenyl, 3 -amino-4-( 1 -methylpyrazol-4-yl)phenyl, 3 -amino-4- (6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimi din-2 -yl)phenyl, 3-amino-4-(triazol-2-yl)phenyl, 3- amino-4-[6-(2-hydroxyacetyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]phenyl, 3-amino-4- methoxycarbonyl-phenyl, 3-amino-4-methylsulfanyl-phenyl, 3-amino-4-pyrimidin-2-yl- phenyl, 3-amino-4-thieno[3,4-d]pyrimidin-2-yl-phenyl, 3-hydroxy-4-(l-methylpyrazol-3- yl)phenyl, 3-hydroxy-4-(6-methylpyrrolo[3,4-d]pyrimidin-2-yl)phenyl, 3-hydroxy-4-Docket No. P60153methoxycarbonyl-phenyl, 3-hydroxy-4-pyrimidin-2-yl-phenyl, 4-(l-methylpyrazol-4- yl)phenyl, 4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl, 4-[l-(2-hydroxyethyl)pyrazol-4- yl]phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2- pyridyl, 5-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl, 5-(3-aminopyrazol- l-yl)-6-methoxy-2-pyridyl, 5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl, 6-amino-5- (l,3,4-thiadiazol-2-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-amino-5- (5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl, 6-amino-5-pyrimidin-2-yl-2-pyridyl, 6- amino-5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2- pyridyl, 6-methoxy-5-methoxycarbonyl-2-pyridyl, 7-aminopyrazolo[l,5-a]pyridin-6-yl or pyrazolo[l,5-a]pyridin-6-yl;R5is H, benzyloxymethyl, ethyl, hydroxymethyl or methyl;R6is H;L1is methylene or ethane- 1,1 -diyl;L2is a bond or methylene;m is 1;n is 1 or 2;or a pharmaceutically acceptable salt thereof.

24. A compound of formula (la),whereinR1is H;R2ais H, halogen, amino or hydroxy;R2bis H or halogen;R2cis H;Docket No. P60153R3ais halogen, hydroxy or C1-6alkyl;R3bis H;R3cis H or halogen;R3dis H, halogen or C1-6alkyl;R4is 1,2-benzoxazolyl,1,3-benzodioxolyl,1,3-benzothiazolyl,2,3-dihydro-1,4-benzodioxinyl,benzimidazolyl substituted by C1-6alkyl,benzothiophenyl,benzoyl,imidazo[1,2-a]pyridinyl,indazolyl unsubstituted or substituted by halogen or C1-6alkyl,indolyl substituted by C1-6alkyl,isoindolinyl substituted by C1-6alkoxycarbonyl,phenyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of(hydroxyC1-6alkoxy)C1-6alkoxy,1,2,4-triazolyl,2,3-dihydropyrazolo[5,l-b]oxazolyl,5,7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi- ealkyl)carbonyl,amino,C1-6alkoxy,C1-6alkoxycarbonyl,C1-6alkyl,C1-6alkylamino,C1-6alkylsulfanyl,halogen,hydroxy,hydroxyC1-6alkoxy,hydroxyC1-6alkyl,hydroxyC1-6alkyl(C1-6alkyl)amino,Docket No. P60153hydroxyC1-6alkylsulfanyl,hydroxyhaloC1-6alkoxy,imidazolyl substituted by C1-6alkyl,pyrazolyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of (((hydroxyCi-6alkyl)carbonyl)(Ci-6alkyl)amino)Ci- ealkyl, ((hydroxyC1-6alkyl)carbonylamino)C1-6alkyl, (Ci-6alkoxyCi-6alkoxy)Ci- ealkyl, (hydroxyC1-6alkyl)C1-6alkyl, (hydroxyC1-6alkoxy)C1-6alkyl, (hydroxyhaloCi- 6alkyl)Ci-6alkyl, amino, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, cyanoC1-6alkyl, halogen, hydroxy(C1-6alkoxy)C1-6alkyl, hydroxyC1-6alkyl and hydroxyhaloC1-6alkyl,pyrimidinyl unsubstituted or substituted by carbamoyl or C1-6alkoxycarbonyl, pyrrolidinyl substituted by hydroxy,pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,tetrazolyl,thieno[3,4-d]pyrimidinyl, andtriazolyl unsubstituted or substituted by C1-6alkyl,pyrazinyl disubstituted with amino and C1-6alkylpyrazolyl,pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino or C1-6alkylamino, pyrazolo[4,3-b]pyridinyl substituted by C1-6alkyl,pyridyl substituted by one or two substituents independently selected from the group consisting of(C1-6alkyl)2amino,1.2.4-triazolyl substituted by C1-6alkyl,1.3.4-oxadiazolyl substituted by C1-6alkyl,1.3.4-thiadiazolyl unsubstituted or substituted by C1-6alkyl,2,3-dihydropyrazolo[5,l-b]oxazolyl,5.7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,5,7-dihydrothieno[3,4-d]pyrimidinyl,6,6-dioxo-5,7-dihydrothieno[3,4-d]pyrimidinyl,6.7-dihydro-4H-pyrazolo[1,5-a]pyrazinyl substituted by C1-6alkyl,6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl,6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazinyl,6-oxo-5,7-dihydrothieno[3,4-d]pyrimidinyl,Docket No. P60153amino,C1-6alkoxy,C1-6alkoxycarbonyl,C1-6alkyl,C1-6alkylamino,haloC1-6alkyl,hydroxyC1-6alkoxy,isoxazolyl,oxazolyl unsubstituted or substituted by C1-6alkyl,phenyl substituted by aminoC1-6alkyl or ((C1-6alkoxycarbonyl)amino)C1-6alkyl, piperidyl disubstituted with C1-6alkyl and hydroxyC1-6alkyl,pyrazinyl,pyrazolyl unsubstituted or substituted by ((C1-6alkoxycarbonyl)amino)C1-6alkyl, ((Ci- 6alkyl)2amino)Ci-6alkyl, (hydroxyC1-6alkyl)C1-6alkyl, amino, C1-6alkyl or tetrahydrothiophenyl,pyridazinyl,pyridyl,pyrimidinyl unsubstituted or substituted by C1-6alkyl sulfinyl or C1-6alkylsulfanyl, pyrrolidinyl,tetrazolyl unsubstituted or substituted by C1-6alkyl,thiazolyl,thieno[3,4-d]pyrimidinyl, andtriazolyl,or pyrimidinyl substituted by one or two substituents independently selected from the group consisting of amino, C1-6alkylpyrazolyl and pyrimidinyl;R5is H, (aminophenyl)Ci-6alkoxyCi-6alkyl, (nitrophenyl)Ci-6alkoxyCi-6alkyl, C1-6alkyl, hydroxy, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl;R6is H;L1is C1-6alkylene;L2is a bond or C1-6alkylene;or a pharmaceutically acceptable salt thereof.Docket No. P6015325. The compound of claim 24, or a pharmaceutically acceptable salt thereof, wherein R2ais H or hydroxy.

26. The compound of claim 24 or 25, or a pharmaceutically acceptable salt thereof, wherein R2bis H.

27. The compound of any one of claims 24-26, or a pharmaceutically acceptable salt thereof, wherein R3ais halogen.

28. The compound of any one of claims 24-27, or a pharmaceutically acceptable salt thereof, wherein R3ais fluoro or chloro.

29. The compound of any one of claims 24-28, or a pharmaceutically acceptable salt thereof, wherein R3cis H.

30. The compound of any one of claims 24-29, or a pharmaceutically acceptable salt thereof, wherein R3dis H or C1-6alkyl.

31. The compound of any one of claims 24-31, or a pharmaceutically acceptable salt thereof, wherein R3dis H or ethyl.

32. The compound of any one of claims 24-31, or a pharmaceutically acceptable salt thereof, whereinR4is 1,3-benzodioxolyl,phenyl substituted by one or two substituents independently selected from the group consisting of2,3-dihydropyrazolo[5,l-b]oxazolyl,5,7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi- ealkyl)carbonyl,amino,C1-6alkoxycarbonyl,C1-6alkylamino,C1-6alkylsulfanyl,Docket No. P60153hydroxy,hydroxyC1-6alkoxy,pyrazolyl substituted by (hydroxyC1-6alkoxy)C1-6alkyl, C1-6alkyl or hydroxyC1-6alkyl, pyrimidinyl,pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,thieno[3,4-d]pyrimidinyl, andtriazolyl,pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,pyridyl substituted by one or two substituents independently selected from the group consisting of1,3,4-thiadiazolyl,2,3-dihydropyrazolo[5,1-b]oxazolyl,5,7-dihydrothieno[3,4-d]pyrimidinyl,amino,C1-6alkoxy,C1-6alkoxycarbonyl,phenyl substituted by aminoC1-6alkyl,pyrazolyl substituted by amino or C1-6alkyl,pyrimidinyl, andthieno[3,4-d]pyrimidinyl,or pyrimidinyl substituted by C1-6alkylpyrazolyl.

33. The compound of any one of claims 24-32, or a pharmaceutically acceptable salt thereof, whereinR4is l,3-benzodioxol-5-yl,phenyl substituted by one or two substituents independently selected from the group consisting of2,3-dihydropyrazolo[5,1-b]oxazol-7-yl,5,7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by methyl or 2-hydroxyacetyl, amino,methoxycarbonyl,methylamino,methylsulfanyl,Docket No. P60153hydroxy,2-hydroxyethoxy,pyrazolyl substituted by 2-(2-hydroxyethoxy)ethyl, methyl or 2-hydroxyethyl, pyrimidinyl,pyrrolo[3,4-d]pyrimidinyl substituted by methyl,thieno[3,4-d]pyrimidinyl, andtriazolyl,pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,pyridyl substituted by one or two substituents independently selected from the group consisting of1,3,4-thiadiazolyl,2,3-dihydropyrazolo[5,l-b]oxazolyl,5,7-dihydrothieno[3,4-d]pyrimidinyl,amino,C1-6alkoxy,C1-6alkoxycarbonyl,phenyl substituted by aminomethyl,pyrazolyl substituted by amino or methyl,pyrimidinyl, andthieno[3,4-d]pyrimidinyl,or pyrimidinyl substituted by 1-methylpyrazol-4-yl.

34. The compound of any one of claims 24-31, or a pharmaceutically acceptable salt thereof, wherein R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2-amino-4-(l-methylpyrazol-3-yl)phenyl, 3 -(2-hydroxy ethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol- 3-yl)phenyl, 3 -amino-4-( 1 -methylpyrazol-3 -yl)phenyl, 3 -amino-4-( 1 -methylpyrazol-4-yl)phenyl, 3-amino-4-(6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl)phenyl, 3-amino-4-(triazol-2-yl)phenyl, 3-amino-4-[6-(2-hydroxyacetyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]phenyl, 3-amino-4-methoxycarbonyl-phenyl, 3-amino-4-methylsulfanyl-phenyl, 3-amino-4-pyrimidin-2-yl-phenyl, 3-amino-4-thieno[3,4-d]pyrimidin-2-yl-phenyl, 3-hydroxy-4-(l-methylpyrazol-3-yl)phenyl, 3-hydroxy-4-(6-methylpyrrolo[3,4-d]pyrimidin-2-yl)phenyl, 3-hydroxy-4-methoxycarbonyl-phenyl, 3-hydroxy-4-pyrimidin-2-yl-phenyl, 4-(l-methylpyrazol- 4-yl)phenyl, 4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl, 4-[ 1 -(2-hydroxy ethyl)pyrazol-Docket No. P601534-yl]phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2-pyridyl, 5-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl, 5-(3-aminopyrazol-l-yl)-6-methoxy-2-pyridyl, 5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl, 6-amino-5-(l,3,4-thiadiazol-2-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-amino-5-(5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl, 6-amino-5-pyrimidin-2-yl-2-pyridyl, 6-amino- 5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl, 6-methoxy-5-methoxycarbonyl-2-pyridyl, 7-aminopyrazolo[l,5-a]pyridin-6-yl or pyrazolo[l,5-a]pyridin-6-yl.

35. The compound of any one of claims 24-34, or a pharmaceutically acceptable salt thereof, wherein R5is H, (3-aminophenyl)methoxymethyl, (3-nitrophenyl)methoxymethyl, 2-hydroxyethyl, benzyloxymethyl, ethyl, hydroxy, hydroxymethyl, methyl or propyl.

36. The compound of any one of claims 24-35, or a pharmaceutically acceptable salt thereof, wherein R5is H, C1-6alkyl, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl.

37. The compound of any one of claims 24-36, or a pharmaceutically acceptable salt thereof, wherein R5is H, benzyloxymethyl, ethyl, hydroxymethyl or methyl.

38. The compound of any one of claims 24-37, or a pharmaceutically acceptable salt thereof, wherein R6is H.

39. The compound of any one of claims 24-38, or a pharmaceutically acceptable salt thereof, wherein L1is methylene or ethane- 1,1 -diyl.

40. The compound of any one of claims 24-37, or a pharmaceutically acceptable salt thereof, wherein L2is a bond or methylene.

41. The compound of claim 24, whereinR1is H;R2ais H or hydroxy;R2bis H;R2cis H;Docket No. P60153R3ais halogen;R3bis H;R3cis H;R3dis H or C1-6alkyl;R4is 1,3-benzodioxolyl,phenyl substituted by one or two substituents independently selected from the group consisting of2,3-dihydropyrazolo[5,l-b]oxazolyl,5.7-dihydropyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl or (hydroxyCi- ealkyl)carbonyl,amino,C1-6alkoxycarbonyl,C1-6alkylamino,C1-6alkylsulfanyl,hydroxy,hydroxyC1-6alkoxy,pyrazolyl substituted by (hydroxyC1-6alkoxy)C1-6alkyl, C1-6alkyl or hydroxyC1-6alkyl, pyrimidinyl,pyrrolo[3,4-d]pyrimidinyl substituted by C1-6alkyl,thieno[3,4-d]pyrimidinyl, andtriazolyl,pyrazolo[1,5-a]pyridinyl unsubstituted or substituted by amino,pyridyl substituted by one or two substituents independently selected from the group consisting of1,3,4-thiadiazolyl,2,3-dihydropyrazolo[5,l-b]oxazolyl,5,7-dihydrothieno[3,4-d]pyrimidinyl,amino,C1-6alkoxy,C1-6alkoxycarbonyl,phenyl substituted by aminoC1-6alkyl,pyrazolyl substituted by amino or C1-6alkyl,pyrimidinyl, andDocket No. P60153thieno[3,4-d]pyrimidinyl,or pyrimidinyl substituted by C1-6alkylpyrazolyl;R5is H, C1-6alkyl, hydroxyC1-6alkyl or phenylC1-6alkoxyC1-6alkyl;R6is H;L1is C1-6alkylene;L2is a bond or C1-6alkylene;or a pharmaceutically acceptable salt thereof.

42. The compound of claim 40, whereinR1is H;R2ais H or hydroxy;R2bis H;R2cis H;R3ais fluoro or chloro;R3bis H;R3cis H;R3dis H or ethyl;R4is l,3-benzodioxol-5-yl, 2-(l-methylpyrazol-4-yl)pyrimidin-5-yl, 2-amino-4-(l-methylpyrazol-3- yl)phenyl, 3-(2-hydroxyethoxy)phenyl, 3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl, 3- amino-4-( 1 -methylpyrazol-3 -yl)phenyl, 3 -amino-4-( 1 -methylpyrazol-4-yl)phenyl, 3 -amino-4- (6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimi din-2 -yl)phenyl, 3-amino-4-(triazol-2-yl)phenyl, 3- amino-4-[6-(2-hydroxyacetyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]phenyl, 3-amino-4- methoxycarbonyl-phenyl, 3-amino-4-methylsulfanyl-phenyl, 3-amino-4-pyrimidin-2-yl- phenyl, 3-amino-4-thieno[3,4-d]pyrimidin-2-yl-phenyl, 3-hydroxy-4-(l-methylpyrazol-3- yl)phenyl, 3-hydroxy-4-(6-methylpyrrolo[3,4-d]pyrimidin-2-yl)phenyl, 3-hydroxy-4- methoxycarbonyl-phenyl, 3-hydroxy-4-pyrimidin-2-yl-phenyl, 4-(l-methylpyrazol-4- yl)phenyl, 4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl, 4-[l-(2-hydroxyethyl)pyrazol-4- yl]phenyl, 4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl, 5-(l-methylpyrazol-4-yl)-2- pyridyl, 5-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl, 5-(3-aminopyrazol- l-yl)-6-methoxy-2-pyridyl, 5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl, 6-amino-5- (l,3,4-thiadiazol-2-yl)-2-pyridyl, 6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl, 6-amino-5- (5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl, 6-amino-5-pyrimidin-2-yl-2-pyridyl, 6- amino-5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl, 6-methoxy-5-(l-methylpyrazol-4-yl)-2-Docket No. P60153pyridyl, 6-methoxy-5-methoxycarbonyl-2-pyridyl, 7-aminopyrazolo[l,5-a]pyridin-6-yl or pyrazolo[l,5-a]pyridin-6-yl;R5is H, benzyloxymethyl, ethyl, hydroxymethyl or methyl;R6is H;L1is methylene or ethane- 1,1 -diyl;L2is a bond or methylene;or a pharmaceutically acceptable salt thereof.

43. A compound selected from:4-chl oro-7V-[[2-(2,6-di oxo-3 -piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(2-phenylethyl) indole-3 -carboxamide;4-chl oro-7V-[[2-(2,6-di oxo-3 -piperidyl)- 1 -oxo-isoindolin-5-yl]methyl]- 1 -[( 1 -methylindazol-3-yl)methyl]indole-3-carboxamide;4-chl oro-7V-[[2-(2,6-di oxo-3 -piperidyl)- 1 -oxo-isoindolin-5-yl]methyl]- 1 -phenacyl-indole- 3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-(2-hydroxy-2-phenyl-ethyl)indole-3-carboxamide;4-chl oro-l-[2-(2, 3 -dihydro-l,4-benzodioxin-6-yl)-2-hydroxy-ethyl]-7V-[[2-(2,6-di oxo-3 -piperidyl)- l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-[(1-methylbenzimidazol-2-yl)methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3 -piperidyl)- l-oxo-isoindolin-5-yl]methyl]-4-hydroxy-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl]indole-3-carboxamide;1-(1,2-benzoxazol-3-ylmethyl)-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-benzyl-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chl oro-7V-[[2-(2,6-di oxo-3 -piperidyl)- 1 -oxo-isoindolin-5-yl]methyl]- 1 -[( 1 -methylindol- 4-yl)methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-(imidazo[1,2-a]pyridin-6-ylmethyl)indole-3-carboxamide;Docket No. P601531-benzyl-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide;4-chloro-7V-[[2-(2,6-di oxo-3 -piperidyl)- 1 -oxo-isoindolin-5-yl]methyl]- 1 - [ [4 - ( 1 -methylpyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-(l-methylpyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;l-benzyl-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-fluoro-1-[[4-(1H-pyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;Ethyl 4-[4-[[3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]-4-fluoro-indol- 1 -yl]methyl]phenyl]pyrazole- 1 -carboxylate;1-[2-benzyloxy-1-[5-(1-methylpyrazol-4-yl)-2-pyridyl]ethyl]-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[2-hydroxy-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethoxy)phenyl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethoxy)-4-methyl-phenyl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-4-fluoro-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethoxy)-4-methyl-phenyl]methyl]indole-3-carboxamide;l-[[4-chloro-3-(2-hydroxy ethoxy )phenyl]methyl]-7V-[[2-(2, 6-di oxo-3 -piperidyl)- 1-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide;l-[[4-chl oro-3 -(2-hydroxy ethoxy )phenyl]methyl]-7V-[[2-(2, 6-di oxo-3-piperi dyl)-4-fluoro-l -oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-[[3-(2-hydroxyethoxy)-4-methyl-phenyl]methyl]-4-methyl-indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-fluoro-3-(2-hydroxyethoxy)phenyl]methyl]indole-3-carboxamide;Docket No. P60153N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2 -hydroxy ethyl)-4-methyl-phenyl]methyl]-4-methyl-indole-3-carboxamide;l-[[4-chloro-3-(2 -hydroxy ethyl)phenyl]methyl]-7V-[[2-(2, 6-dioxo-3 -piperidyl)- 1-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(2 -hydroxy ethoxy)-5-methyl-2-pyridyl]methyl]-4-methyl-indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-[2-(2-hydroxyethoxy)ethoxy]phenyl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(l-phenylbutyl)indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(lR)-l-[3-(2-hydroxyethoxy)phenyl]ethyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(lS)-l-[3-(2-hydroxyethoxy)phenyl]ethyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethylsulfanyl)phenyl]methyl]-4-methyl-indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(2-hydroxy-l -phenyl-ethyl)indole-3 -carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-(3-hydroxy-l -phenyl-propyl)indole-3 -carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[2-hydroxy-l-[4-(l-methylpyrazol-4-yl)phenyl]ethyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]-2-[(3-nitrophenyl)methoxy]ethyl]indole-3-carboxamide;l-[2-[(3-aminophenyl)methoxy]-l-[5-(l-methylpyrazol-4-yl)-2-pyridyl]ethyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(methylamino)-4-(l-methylpyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;Docket No. P601534-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-(5-fluoro-l-methyl-pyrazol-4-yl)-3-(methylamino)phenyl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(methylamino)-4-(l-methylimidazol-4-yl)phenyl]methyl]indole-3-carboxamide;l-[[3-amino-4-(l-methylpyrazol-4-yl)phenyl]methyl]-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[2-(methylamino)-4-(l-methylpyrazol-3-yl)phenyl]methyl]indole-3-carboxamide;l-[[2-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[2-(methylamino)-4-(l-methylimidazol-4-yl)phenyl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[2-(methylamino)-5-(l-methylimidazol-4-yl)phenyl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(methylamino)-5-(l-methylimidazol-4-yl)phenyl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(methylamino)-5-(l-methylpyrazol-3-yl)phenyl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[7-(methylamino)pyrazolo[l,5-a]pyridin-6-yl]methyl]indole-3-carboxamide;l-[(7-aminopyrazolo[l,5-a]pyridin-6-yl)methyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;l-[(4-aminopyrazolo[l,5-a]pyridin-6-yl)methyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-(methylamino)pyrazolo[l,5-a]pyridin-6-yl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[5-(methylamino)-3-pyridyl]methyl]indole-3-carboxamide;l-[(3-amino-4-chloro-phenyl)methyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide;l-[[4-chloro-3-(methylamino)phenyl]methyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3-carboxamide;Docket No. P60153l-[(3-amino-4-fluoro-phenyl)methyl]-4-chloro-7V-[[2-(2,6-di oxo-3-piperi dyl)- 1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-fluoro-3-(methylamino)phenyl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(3-hydroxyphenyl)methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(4-fluoro-3-hydroxy-phenyl)methyl]-4-methyl-indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-(1H-indazol-5-ylmethyl)indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-1-(1H-indazol-4-ylmethyl)indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-1-[(7-fluoro-1H-indazol-4-yl)methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-1-[(7-fluoro-1H-indazol-5-yl)methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[6-(l-methylpyrazol-4-yl)-3-pyridyl]methyl]indole-3 -carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-(l-methylimidazol-4-yl)phenyl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[2-(l-methylpyrazol-4-yl)pyrimidin-5-yl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(4-pyrazol-l-ylphenyl)methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-7-ethyl-4-fluoro-l-[[4-(l-methylpyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[2-fluoro-4-(l-methylpyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;l-[(4-chlorophenyl)methyl]-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3 -carboxamide;Docket No. P60153l-(benzothiophen-2-ylmethyl)-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3 -carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(tri fluoromethyl)-3 -pyridyl]methyl]indole-3 -carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-methyl-l-[(l-methylindazol-5-yl)methyl]indole-3 -carboxamide;l-(l,3-benzothiazol-5-ylmethyl)-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-methyl-indole-3 -carboxamide;l-[2-(l,3-benzodioxol-5-yl)-3-hydroxy-propyl]-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(6-pyrrolidin-l-yl-3-pyridyl)methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[(l-methylpyrazolo[4,3-b]pyridin-5-yl)methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[(l-methylindazol-5-yl)methyl]indole-3 -carboxamide;tert-butyl 5-[[3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]-4-fluoro-indol-l-yl]methyl]isoindoline-2-carboxylate;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[2-methoxy-6-(l-methylpyrazol-4-yl)-3-pyridyl]methyl]indole-3 -carboxamide;4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-(methylamino)-3-(l-methylimidazol-4-yl)phenyl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(lS)-l-[3-(2-hydroxyethoxy)phenyl]propyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4,6-difluoro-l-[[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;4-chloro-l-[[3-(l,l-difluoro-2-hydroxy-ethoxy)phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;Docket No. P601534-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[2-(2-hydroxyethoxy)-4-(l-methylpyrazol-4-yl)phenyl]methyl]indole-3 -carboxamide;l-[[3-amino-4-[l-(2-methoxyethyl)pyrazol-3-yl]phenyl]methyl]-4-chloro-N-[[2-(2,6-di oxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[(3-amino-4-pyrimidin-2-yl-phenyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-[2-[(2-hydroxyacetyl)-methyl-amino]ethyl]pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;l-[2-(l,3-benzodioxol-5-yl)ethyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy- 1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[(lS)-l-[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]propyl]indole-3-carboxamide;1-[[6-amino-5-(1-methylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;1-[[3-amino-4-(1-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[[2-[(3R)-2,6-dioxo-3-piperidyl]-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;1-[[3-amino-4-(1-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[[2-[(3S)-2,6-dioxo-3-piperidyl]-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]-3-methoxy-phenyl]methyl]indole-3-carboxamide;N-[[4-amino-2-(2,6-di oxo-3-piperi dyl)-l-oxo-isoindolin-5-yl]methyl]-4-chl oro-1 -(pyrazolo[l,5-a]pyridin-6-ylmethyl)indole-3-carboxamide;l-[[3-amino-4-(l -methyltri azol-4-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-di oxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;1 -[(3 -amino-4-pyrazol- 1 -yl-phenyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3 -piperidyl)- 1 -oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(6-methoxy-5-pyrazol-l-yl-2-pyridyl)methyl]indole-3 -carboxamide;l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-4-fluoro-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;1-[[6-amino-5-(triazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;Docket No. P601531-[[6-amino-5-(1-methylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-6-fluoro-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]-l-[[6-methoxy-5-(l-methylpyrazol-4-yl)-2-pyridyl]methyl]indole-3-carboxamide;1-[1-[6-amino-5-(1-methylpyrazol-3-yl)-2-pyridyl]ethyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[(6-amino-5-pyridazin-3-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]-l-(pyrazolo[l,5-a]pyridin-6-ylmethyl)indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4,7-difluoro-l-[[4-[l-(2-hydroxy ethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[2-[2-(2-hydroxyethoxy)-4-(l-methylpyrazol-3-yl)phenyl]ethyl]indole-3-carboxamide;1-[[3-amino-4-[1-(2-methoxyethyl)pyrazol-3-yl]phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-[2-[(2-hydroxyacetyl)amino]ethyl]pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-4-fluoro-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[5-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]-6-methoxy-2-pyridyl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]-2-methoxy-phenyl]methyl]indole-3-carboxamide;l-[[3-amino-4-(triazol-2-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[3-amino-4-(tetrazol-2-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[4-(3-aminopyrazol-l-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;1-[[3-amino-4-[1-(2-hydroxyethyl)pyrazol-3-yl]phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;Docket No. P60153l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;1-[[5-(3-aminopyrazol-1-yl)-6-methoxy-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;tert-butyl N-[[l-[6-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]-2-methoxy-3-pyridyl]pyrazol-4-yl]methyl]carbamate; 1-[[6-amino-5-(1-methylpyrazol-3-yl)pyrazin-2-yl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;1-[(6-amino-5-pyrazol-1-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[(4-amino-5-pyrimidin-2-yl-pyrimidin-2-yl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[6-amino-5-(tetrazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[4-[l-(2,2-difluoro-3-hydroxy-propyl)pyrazol-4-yl]phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[3-hydroxy-l-[4-(l-methylpyrazol-4-yl)phenyl]propyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[2-(2-hydroxyethoxy)-4-(l-methylpyrazol-3-yl)phenyl]methyl]indole-3 -carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[2-[4-(2-hydroxyethoxy)phenyl]ethyl]indole-3-carboxamide;4-chloro-N-[l-[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]ethyl]-l-[[3-(2-hydroxyethoxy)phenyl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[2-(2-hydroxyethoxy)-6-(l-methylpyrazol-3-yl)-3-pyridyl]methyl]indole-3 -carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[2-[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[2-[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;Docket No. P601534-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-hydroxy-4-(l-methylpyrazol-3-yl)phenyl]methyl]indole-3 -carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(3-hydroxy-4-pyrimidin-2-yl-phenyl)methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(lS)-l-[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[2-[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[(lS)-l-[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-(3-hydroxypyrrolidin-l-yl)phenyl]methyl]indole-3 -carboxamide;l-(l,3-benzodioxol-4-ylmethyl)-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3 -carboxamide;l-(l,3-benzodioxol-5-ylmethyl)-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3 -carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-fluoro-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-(2-hydroxyethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-[4-(hydroxymethyl)-4-methyl-l-piperidyl]-3-pyridyl]methyl]indole-3 -carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(lS)-l-[3-[2-hydroxyethyl(methyl)amino]phenyl]ethyl]indole-3-carboxamide;N-[[2-(2,6-di oxo-3 -piperidyl)-4-fluoro- 1 -oxo-isoindolin-5-yl]methyl]-4-fluoro- 1 - [ [4- [ 1 -(2-hydroxyethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-4-fluoro-l-oxo-isoindolin-5-yl]methyl]-l-[[3-(2-hydroxyethoxy)phenyl]methyl]-2,4-dimethyl-indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[3-fluoro-l-(2-hydroxy ethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[l-(2-hydroxyethyl)pyrazol-4-yl]-3-methyl-phenyl]methyl]indole-3-carboxamide;Docket No. P60153l-[[4-[l-[2-(l,l-difluoro-2-hydroxy-ethoxy)ethyl]pyrazol-4-yl]phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[5-fluoro-l-(2-hydroxy ethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-(2-methoxyethyl)pyrazol-3-yl]-3-(methylamino)phenyl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]-l-[[4-(l-methylpyrazol-4-yl)phenyl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[l-(2-methoxy ethyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]-l-[2-[4-[l-[2-(2-methoxyethoxy)ethyl]pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[(lR)-l-[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]propyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(methylamino)-5-(l-methylpyrazol-3-yl)-2-pyridyl]methyl]indole-3-carboxamide;l-[2-[3-amino-4-(l-methylpyrazol-3-yl)phenyl]ethyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[[4-[3-fluoro-l-[2-(2-hydroxy ethoxy)ethyl]pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[4-[l-(3-hydroxy-2-methoxy-propyl)pyrazol-4-yl]phenyl]methyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4-fluoro-l-[(lS)-l-[4-[l-[2-(2-hydroxyethoxy)ethyl]pyrazol-4-yl]phenyl]ethyl]indole-3-carboxamide;l-[[6-amino-5-(l,3,4-thiadiazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[5-[4-(aminomethyl)phenyl]-6-methoxy-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-di oxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;tert-butyl N-[[4-[6-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]-2-methoxy-3-pyridyl]phenyl]methyl]carbamate;4-chloro-l-[[4-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)phenyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;Docket No. P601534-chloro-l-[[5-(2,3-dihydropyrazolo[5,l-b]oxazol-7-yl)-6-methoxy-2-pyridyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chloro-l-[[6-(dimethylamino)-3-pyridyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chloro-l-[[5-[l-[2-(dimethylamino)ethyl]pyrazol-4-yl]-6-methoxy-2-pyridyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[(lR)-l-[3-(2-hydroxyethoxy)phenyl]propyl]indole-3-carboxamide;N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(2 -hydroxy ethoxy)-5-methyl-2-pyridyl]methyl]-4,7-dimethyl-indole-3-carboxamide;l-[(3-amino-4-chloro-phenyl)methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-4,7-dimethyl-indole-3-carboxamide;l-[(3-amino-4-methylsulfanyl-phenyl)methyl]-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[6-amino-5-(5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl]methyl]-4-chloro-7V-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[(6-amino-5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-7V-[[2-(2,6-di oxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;methyl 6-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]-2-methoxy-pyridine-3-carboxylate;l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-7V-[l-[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[6-(methylamino)-5-pyrimidin-2-yl-2-pyridyl]methyl]indole-3-carboxamide;l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-N-[(lR)-l-[2-[(3R)-2,6-di oxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-N-[(lR)-l-[2-[(3S)-2,6-di oxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-N-[(lS)-l-[2-[(3R)-2,6-di oxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-N-[(lS)-l-[2-[(3S)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;Docket No. P60153l-[[6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[(lR)-l-[2-[(3R)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[[6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[(lR)-l-[2-[(3S)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[[6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[(lS)-l-[2-[(3R)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamidel;l-[[6-amino-5-(l-methylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[(lS)-l-[2-[(3 S)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[(3-amino-4-pyrimidin-2-yl-phenyl)methyl]-4-chloro-N-[(lR)-l-[2-[(3R)-2,6-di oxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[(3-amino-4-pyrimidin-2-yl-phenyl)methyl]-4-chloro-N-[(lR)-l-[2-[(3 S)-2, 6-di oxo-3 -piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[(3-amino-4-pyrimidin-2-yl-phenyl)methyl]-4-chloro-N-[(lS)-l-[2-[(3R)-2,6-di oxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[(3-amino-4-pyrimidin-2-yl-phenyl)methyl]-4-chloro-N-[(lS)-l-[2-[(3S)-2,6-di oxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[(lR)-l-[2-[(3R)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[(lR)-l-[2-[(3 S)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-~{N}-[(l~{S})-l-[2-[(3~{R})-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[(lS)-l-[2-[(3S)-2,6-dioxo-3-piperidyl]-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[[6-amino-5-(5-methylsulfinylpyrimidin-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[6-amino-5-(l-methylpyrazol -3-yl)-2-pyridyl]methyl]-4-chloro-N-[l-[2-(2,6-di oxo-3-piperidyl)-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[[6-amino-5-(l-methylpyrazol -3-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-di oxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[6-amino-5-(5-methylsulfanylpyrimidin-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;Docket No. P60153l-[[6-amino-5-(5-methyl-l,3,4-oxadiazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[6-amino-5-(5-methyloxazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-di oxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[6-amino-5-(6,7-dihydro-4H-pyrazolo[5,l-c][l,4]oxazin-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[6-amino-5-(5-methyl-l,3,4-thiadiazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo- 3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[6-amino-5-(6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[(6-amino-5-oxazol-2-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[6-amino-5-(l-methyl-l,2,4-triazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[(6-amino-5-pyrimidin-4-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[(6-amino-5-thiazol-2-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-di oxo-3-piperi dyl)- 1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[6-amino-5-(2-pyridyl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;1 -[(6-amino-5-pyrazin-2-yl-2-pyridyl)methyl]-4-chl oro-N-[[2-(2,6-di oxo-3 -piperidyl)- 1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[6-amino-5-(5-methyl-6,7-dihydro-4H-pyrazolo[l,5-a]pyrazin-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-7-fluoro-indole-3-carboxamide;l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)- 4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[3-amino-4-(6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide; l-[[3-amino-4-(6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;Docket No. P60153l-[[3-amino-4-(l-methyl-l,2,4-triazol-3-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[(3-amino-4-pyrimidin-4-yl-phenyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)- 1-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[(3-amino-4-thieno[3,4-d]pyrimidin-2-yl-phenyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[(6-amino-5-thieno[3,4-d]pyrimidin-2-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[3-amino-4-[6-(2-hydroxyacetyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;methyl 4-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]-2-hydroxy -benzoate;methyl 4-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]-2-hydroxy -benzoate;l-[[3-amino-4-(5-carbamoylpyrimidin-2-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[3-amino-4-(4-carbamoylpyrimidin-2-yl)phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;methyl 2-[2-amino-4-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]phenyl]pyrimidine-5-carboxylate;methyl 2-amino-4-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol- 1 -yl]methyl]benzoate;methyl 2-amino-4-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol- 1 -yl]methyl]benzoate;l-[(6-amino-5-isoxazol-3-yl-2-pyridyl)methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;methyl 2-amino-6-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]pyridine-3 -carboxylate;methyl 2-amino-6-[[4-chloro-3-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methylcarbamoyl]indol-l-yl]methyl]pyridine-3 -carboxylate;l-[[6-amino-5-(6-oxo-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;Docket No. P60153l-[[6-amino-5-(6,6-dioxo-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chl oro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-hydroxy-4-(6-methyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl)phenyl]methyl]indole-3-carboxamide;4-chl oro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]-l-[[3-hydroxy-4-(6-methylpyrrolo[3,4-d]pyrimidin-2-yl)phenyl]methyl]indole-3-carboxamide;l-[[6-amino-5-(5-methyltetrazol-2-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[[6-amino-5-(l-tetrahydrothiophen-3-ylpyrazol-3-yl)-2-pyridyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[(lS)-l-(6-amino-5-pyrimidin-2-yl-2-pyridyl)ethyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;l-[(lR)-l-(6-amino-5-pyrimidin-2-yl-2-pyridyl)ethyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide;4-chl oro-1 -[[5-(6,7-dihy dro-5H-pyrazolo[5,l-b][ 1, 3] oxazin-3 -yl)-6-methoxy-2-pyridyl]methyl]-N-[[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]methyl]indole-3-carb oxami de;l-[(6-amino-5-pyrimidin-2-yl-2-pyridyl)methyl]-N-[[2-(2,6-di oxo-3-piperi dyl)- 1-oxo-isoindolin-5-yl]methyl]-4,6-difluoro-indole-3-carboxamide;4-chl oro-1 -[[5-(2,3-dihy dropyrazolo[5,l -b]oxazol-7-yl)-6-methoxy-2-pyridyl]methyl]-N-[l -[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[[3-amino-4-(l-methylpyrazol-3-yl)phenyl]methyl]-4-chloro-N-[l-[2-(2,6-dioxo-3-piperidyl)-4-hydroxy-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide;l-[[3-amino-4-[l-(cyanomethyl)pyrazol-3-yl]phenyl]methyl]-4-chloro-N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]indole-3-carboxamide; andl-[[3-amino-4-[6-(2-hydroxyacetyl)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]phenyl]methyl]-4-chloro-N-[l-[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]ethyl]indole-3-carboxamide; or a pharmaceutically acceptable salt thereof.

44. A process for the preparation of a compound according to any one of claims 1 to 43 comprising the following step:Docket No. P60153a) coupling of compound (VI),(VI), with compound (VII),the presence of a suitable coupling reagent and a suitable base;whereinin step a), the coupling reagent is T3P, HATU, PyBOP or EDCI / HOBt; the base is TEA, DIEPA or DMAP;R1, R4, R5, R6, R2a, R2b, R2c, R3a, R3b, R3c, R3d, L1and L2are defined as in any one of claims 1-42.

45. A compound according to any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, when manufactured according to a process of claim 44.

46. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 43 and a pharmaceutically acceptable excipient.

47. A compound or pharmaceutically acceptable salt according to any one of claims 1 to 43 for use as therapeutically active substance.

48. The use of a compound according to any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, for the treatment or prophylaxis of cancer, wherein the cancer is hematological malignancies, gastric cancer, esophageal cancer, colorectal cancer, pancreatic ductal adenocarcinoma, lung cancer, ovarian cancer, breast cancer, prostate cancer, liver cancer or glioblastoma.Docket No. P6015349. The use of a compound according to any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prophylaxis of cancer, wherein the cancer is hematological malignancies, gastric cancer, esophageal cancer, colorectal cancer, pancreatic ductal adenocarcinoma, lung cancer, ovarian cancer, breast cancer, prostate cancer, liver cancer or glioblastoma.

50. The use according to claim 48 or 49, wherein the cancer is lung cancer, hematological malignancies, prostate cancer or breast cancer.

51. The use according to any one of claims 48-50, wherein the lung cancer is non-small cell lung cancer or small cell lung cancer.

52. The use according to any one of claims 48-51, wherein the hematological malignancies is multiple myeloma or acute myeloid leukemia.

53. A compound according to any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancer, wherein the cancer is lung cancer, hematological malignancies, prostate cancer or breast cancer.

54. A method of treating cancer in a subject in need thereof, wherein the cancer is lung cancer, hematological malignancies, prostate cancer or breast cancer, and wherein the method comprises administering a therapeutically effective amount of a compound according to any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, to the subject.